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Abstract 
 
A fundamental modification called ubiquitination controls the fate of many proteins. The 
third enzyme in the ubiquitination pathway, the E3 ubiquitin ligase, has been implicated 
in a variety of cancers. WWP2 is a HECT E3 ligase associated with the progression of 
prostate cancer, alongside its closest relative WWP1. WWP2 selectively targets 
substrates via the interaction of WW domains with PPxY motifs. Ubiquitin is 
consequently added to the substrate using the catalytic cysteine in the HECT domain. 
The three isoforms of WWP2 with different WW domain compositions have shown 
selective preferences towards substrates of the TGF-b signalling pathway and PTEN, 
a negative regulator of AKT signalling. Understanding more about the WW domain 
interactions and the activity of the HECT domain can lead to the discovery and 
development of novel therapeutics.  
The aim of this thesis is to find novel inhibitors of WWP2 by utilising different 
approaches. The initial approach was to structurally solve WWP2 WW domains that 
reside within different isoforms and investigate substrate-based peptide interactions. 
Using structural analysis by NMR spectroscopy, the solved structure of WW4 is 
reported here. NMR titrations were used for interaction analysis of WW1 and WW1-2 
domains, with substrate-based peptides, to aid peptide-based inhibitor design and 
characterise the selectivity of the WW domains. The other strategy involved small 
molecule screening to find inhibitors of WWP2-FL activity. Results presented here 
identify potential inhibitors with IC50 values below 3 µM. Counter screening against 
other enzymes in the ubiquitination cascade was also carried out to investigate the 
selectivity of the hit compounds. A total of 5 final compounds were successfully 
identified as selective, making them attractive for further investigations. Overall, the 
data collected in this thesis can be used in further understanding WWP2 interactions 
and for structure-based/hit-to-lead development for novel inhibitory molecules as 
potential prostate cancer therapeutics. 
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1. Introduction  
 2 
Proteins are one of the basic building blocks of cells. They have both structural and 
functional roles in many cellular processes which can vary across cell types. Regulation 
of proteins is a requirement for maintaining the correct environment for cells to function 
both internally and externally. Many mechanisms are employed in the regulation of 
protein activity from transcriptional regulation at the DNA level, to post-translational 
regulation at the protein level. This affects the localisation, activity and even the 
turnover of proteins. One such method of post-translational modification, which controls 
protein activity and ultimately the fate of the cell, is ubiquitination. This process can 
result in both proteolytic and non-proteolytic events downstream in signalling pathways. 
The addition of ubiquitin to the final substrate is carried out by the E3 ligase. The HECT 
E3 ligase called WWP2 (WW domain containing protein 2) is a member of the Nedd4 
E3 ligase family. WWP2 acts by ligating ubiquitin monomers and polymers to 
substrates via intrinsic catalytic activity. This labels the target substrates for 
degradation by the proteasome, although other consequences may occur via WWP2 
activity that have yet to be uncovered. Dysfunction and aberrant regulation of this ligase 
has been associated with disease. One of the most common diseases today is cancer 
which can develop either by genetic mutation or dysregulation at the protein level 
changing the cellular environment. This leads to cellular transformation and damaging 
effects in the body. The overexpression of WWP2 increases the targeting of tumour 
suppressor proteins which protect the cells from transformation. Known substrates of 
WWP2 are Smad proteins in the TGF-b signalling pathway, and PTEN, a negative 
regulator of PI3K/AKT signalling. Understanding more about how this ligase interacts 
and targets substrates in both the TGF-b and PI3K/AKT pathways will be explored 
further in this thesis with regards to prostate cancer development, which has been 
linked to WWP2 overexpression. This thesis aims to uncover the structural basis of the 
WW domains which interact with substrates as a method for progressing the design of 
short peptides that can potentially interfere with these protein-protein contacts. Another 
approach will also be explored using small molecules in the discovery of compounds 
which can inhibit WWP2 activity. This will be taken one step further to begin looking at 
the potential effects these compounds could have as possible treatments of advanced 
prostate cancer.    
 3 
1.1. Ubiquitination 
Many eukaryotic processes are regulated using modifications at the protein level. One 
such modification is ubiquitination, initially identified by the work of Ciechanover, 
Hershko and Rose (Ciechanover et al., 1978; Hershko et al., 1979; Hershko et al., 
1980) to play a role in protein stability and turnover. Ubiquitin addition has later been 
found to regulate other cellular processes as well such as signal transduction, 
transcriptional control and DNA repair (Boase and Kumar, 2015; Chantry, 2011). 
Ubiquitin (Ub) is a 76-amino acid protein which is highly conserved across eukaryotes, 
reflected in the sequence difference of only 3 amino acids between yeast and humans, 
supporting its function in cellular survival. Ubiquitin is covalently attached to the target 
substrate by three specialised enzymes: E1-activating, E2-conjugating and E3 ligase 
enzymes. Initially ubiquitin is attached to E1-activating enzyme in an ATP dependent 
manner forming E1~Ub thioester (Pickart and Eddins, 2004). The charged ubiquitin is 
then transferred to E2-conjugating enzyme (Berndsen and Wolberger, 2014), which 
consequently interacts with substrate bound E3 ubiquitin ligase, enabling the formation 
of an isopeptide bond between the ubiquitin molecule and a substrate lysine residue 
(Chantry, 2011; Kamadurai et al., 2013; Soond et al., 2013). Once complete, the E2 
enzyme and substrate are released. This cascade can result in mono-, multi-mono- 
and poly-ubiquitination, each with specific biological functions related to the substrate. 
A simplified representation of this cascade can be seen in Figure 1.1.1. 
 
Substrates can undergo different types of ubiquitination. The specific E2 and E3 
enzymes involved in the cascade, timing, localisation and cellular context in addition to 
chain type and length can directly determine the fate of the substrate protein (Kirkin 
and Dikic, 2007; Nathan et al., 2013). The presence of seven lysine (K) residues in 
ubiquitin at positions K6, K11, K27, K29, K33, K48 and K63 enables seven different 
inter-ubiquitin chain types (Schlesinger et al., 1975; Komander and Rape, 2012). 
Additionally, evidence has been found for N-terminal linear ubiquitin chain formation 
creating a total of eight different linkage-types for the formation of poly-ubiquitin chains 
(Komander and Rape, 2012; Rieser et al., 2013). The simplest type is 
mono-ubiquitination with the addition of a single ubiquitin monomer. This can also occur 
more than once across the target substrate referred to as multi-mono-ubiquitination. 
The role of mono-ubiquitination is not as well established as that of poly-ubiquitin 
chains, however Kaiser and colleagues (2011) discovered that the overall levels of 
mono-ubiquitination were higher than poly-ubiquitination supporting this modification 
type as an important regulator of cellular functions. This is also observed in the role of 
 4 
mono-ubiquitination in non-proteolytic events (Nakagawa and Nakayama, 2015). For 
example, mono-ubiquitination of the histone protein H2B is required for transcriptional 
elongation, whereas the same modification to another histone protein H2A results in 
transcriptional repression by blocking H3K4 methylation (Nakagawa et al., 2008). 
Another example is the tightly controlled localisation of the tumour suppressor protein 
p53, in which mono-ubiquitination results in conformational changes that expose the 
nuclear export signal inducing exclusion of p53 to the cytoplasm (Kruse and Gu, 2009). 
As for poly-ubiquitination, the length and type of chain seems to determine whether 
proteolytic or non-proteolytic events follow. K48 chains are the main chain type to target 
proteins for degradation by the 26S proteasome (Thrower et al., 2000). A chain with a 
minimum of four ubiquitin molecules is required for sufficient proteasomal recognition 
by 19S subunit receptors leading to protein unfolding. Ubiquitin molecules are then 
recycled by deubiquitination (DUB) enzymes also associated with the 19S complex and 
the protein is then degraded. Complicating our understanding of the functions of 
ubiquitination types in cellular processes, however, is the emerging evidence of 
mono-ubiquitination also resulting in proteasomal degradation. This backs up the 
likelihood that it is more than just the ubiquitination type that determines proteolytic 
consequences (Livneh et al., 2017). Support for the complexity of target substrate fate 
towards degradation also comes from evidence showing K63-Ub chains, historically 
said to mediate non-proteolytic activity, can trigger the internalisation of membrane 
proteins such as the receptor tyrosine kinase EGFR (epidermal growth factor receptor) 
for lysosomal degradation. Cytokine signal transduction is also regulated by K63 
poly-ub chains, as observed for TRAF6-Ubc13-mediated K63 polyubiquitination 
resulting in the activation of IKK in the NF-kB pathway (Deng et al., 2000). Furthermore, 
K63-linked chains have been shown to stabilise histones at regions of DNA damage 
for the recruitment of DNA repair enzymes (Komander and Rape, 2012). Collectively, 
this shows the diverse and complex nature of ubiquitination and shows the requirement 
for further understanding of the mechanisms and the substrates that undergo this 
modification, both in normal and aberrant cellular conditions. 
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Figure 1.1.1 - Step by step pathway diagram of ubiquitination 
Ubiquitin (Ub) is activated by the E1-activating enzyme (E1) and hydrolysis of ATP (adenosine 
triphosphate) to AMP (adenosine monophosphate) and pyrophosphate. Ubiquitin is then 
transferred to E2-conjugating enzyme (E2).  Ubiquitin is then transferred in either a one-step 
(left pathway) or two-step reaction (right pathway) to the substrate via interaction of E2~Ub with 
an E3 ligase which also binds the substrate. Purple hexagon represents the substrate; green 
semi-circle denotes a RING E3 ligase; blue shape symbolises a HECT E3 ligase. C and K 
indicate the catalytic cysteine residue and target lysine residue, respectively. 
Mono-ubiquitination (bottom centre), multi-mono-ubiquitination (bottom left) and 
poly-ubiquitination (bottom right) are also shown.  
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1.2. E1-activating and E2-conjugating enzymes 
As mentioned, there are three enzymes in the pathway that are required to ligate 
ubiquitin to specific targets. To date, only two E1 enzymes that interact with ubiquitin 
have been discovered (Schulman and Harper, 2009), each presenting slightly different 
roles in protein regulation. Uba1 (also known as UBE1), identified in 1979 (Hershko et 
al., 1979), interacts directly with ATP and the ubiquitin molecule is adenylated before 
transfer to the thiol site on the E1 enzyme. Uba1 in humans is homologous to Uba1 in 
yeast which is composed of two adenylation domains, where one is active (AAD) and 
binds ATP and ubiquitin whilst the other is inactive (IAD) (Lee and Schindelin, 2008; 
Schafer et al., 2014). Initially, ATP is hydrolysed, and the ubiquitin C-terminus 
adenylated. This then reacts with the catalytic cysteine residue to form a thioester bond 
between the ubiquitin carboxy terminal and the Uba1 cysteine side chain (Schulman 
and Harper, 2009). A second ubiquitin molecule then attaches to the initial adenylation 
site after the first has been attached to the catalytic cysteine residue (Haas et al., 1982; 
Schafer et al., 2014). This intermediate adenylated form is then maintained until 
transfer to the thiol site can occur. Purification of Uba1 led to the isolation of 2 isoforms 
(Cook and Chock, 1992) called Uba1a and Uba1b, generated from a secondary 
initiation codon in the gene locus. Each isoform has shown different localisation 
patterns. Uba1a localises to the nucleus whereas Uba1b, which lacks the first 40 amino 
acids where a nuclear localisation signal resides, mainly exists in the cytoplasm 
(Stephen et al., 1997). This enables Uba1a interaction with specific E2 enzymes, which 
also localise to the nucleus, facilitating a nuclear ubiquitin-proteasome system for 
secondary messengers within the nucleus. As for Uba1b, this isoform acts outside of 
this organelle in the cytoplasmic proteasomal system. The other E1-activiating enzyme, 
Uba6, is capable of activating both ubiquitin and the ubiquitin-like modifier FAT10. The 
ability of both of these E1 enzymes to bind to ubiquitin was thought to confer 
redundancy, however analysis of the E2 binding partners indicated this was only 
partially true. Knockout of Uba6 was embryonic lethal in mice via a defect in ubiquitin 
processing rather than FAT10 (Groetrupp et al., 2008), suggesting a fundamental Uba6 
function in cellular processes involving ubiquitin that works alongside Uba1 isoforms. 
The implication this second E1-activating enzyme has on cellular regulation, and any 
potential overlap with Uba1 isoform activity, should be investigated to develop further 
understanding of the mechanisms and functions of ubiquitination, given the increasing 
evidence of protein turnover in disease development.  
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In contrast to the E1-activating enzymes, ~40 E2-conjugating enzymes exist in humans 
which further increases the selectivity of ubiquitination towards particular E3 ligases 
and substrate types (Stewart et al., 2016). E2-conjugating enzymes have a central 
ubiquitin-conjugating (UBC) domain that contains all the essential binding sites and the 
catalytic cysteine residue required for function. A number of E2s also have additional 
regions, often disordered in nature. These extensions are thought to act as regulators 
of the E2 in aspects such as the intrinsic cysteine activity and ubiquitin chain 
generation, E3 interactions or even substrate selection (Pickart, 2001; Stewart et al., 
2016; Wenzel et al., 2011). The noncovalent interaction of activated E1~Ub complex 
with E2 enables the transfer of ubiquitin to the E2 cysteine via a transthiolation reaction. 
The activity of an E2 enzyme can be limited to a particular E3 ligase or a few, for 
example, some will only react with the catalytic cysteine of a HECT E3 ligase, but not 
a lysine residue as presented by RING ligases via the substrate molecule (Stewart et 
al., 2016). This selectivity in the E2 activation mechanism refines the activities of the 
ubiquitination cascade to particular E3 ligases and their substrates. In turn, only the 
selective E3 ligases which interact with the given E2 enzyme are able to transfer the 
ubiquitin molecule to their substrate. This ultimately supports the role of E2-conjuating 
enzymes as regulators of E3 ligase activity and subsequent substrate modification 
consequences. A further regulatory mechanism of E2-conjugating enzymes is their 
inability to interact with both E1 and E3 enzymes at the same time due to an overlap in 
interaction sites (Wenzel et al., 2011). This means that the E3 ligase has to be released 
before E2 can be charged with ubiquitin again and continue ubiquitin addition. While 
this may limit the processivity of the ubiquitination cascade, it provides a further stage 
of regulation to the pathway.  
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1.3. E3 ligases 
The final step in the ubiquitination pathway is controlled by the activity of the E3 
ubiquitin ligase. These enzymes are able to interact with both the E2 conjugating 
enzyme and the substrate, and therefore determine the target specificity of the 
activated pathway. Over 600 E3s have been identified in the human genome so far 
(Scheffner and Kumar, 2014). These are grouped into three main families based on 
structure and mechanism of action: RING/U-box E3 ligases, HECT E3 ligases and the 
smaller group of RING-between-RING (RBR) E3 ligases; although only the first two 
groups will be discussed in this introduction as RBR ligases have not yet been 
investigated to the same degree as RING and HECT ligases. 
 
1.3.1. RING E3 ligases 
The RING (Really Interesting New Gene)/U-box E3 ligase group (RING-type) is the 
largest of the three groups to exist in humans. RING E3 ligases adopt a ‘cross-brace’ 
configuration by interacting with two zinc ions via coordination bonds with 
~8 cysteine/histidine residues (Figure 1.3.1A). U-box RING-types, however, assume 
the same conformation but without the presence of zinc, by utilising non-covalent 
interactions within the centre of the protein (Metzger et al., 2014). The absence of 
intrinsic activity in RING-type E3 ligases means that they rely on the interaction and 
ubiquitin-binding capacity of the E2-conjugating enzyme to both facilitate ubiquitin 
transfer as well as determine the type of ubiquitination. While these enzymes are 
capable of acting as individual monomers, quite often they form active homo-/hetero-
dimers. Dimerization can be mediated either via interaction of the RING domains and 
C-terminus or by the interaction of both N- and C-terminal regions between monomers. 
Homodimers tend to have two active RING-type ligases where both are capable of 
binding to E2~Ub. Whereas heterodimers often have one active E2~Ub binding 
monomer and one inactive non-E2~Ub binding monomer. The E2 binding site is 
created by two loops which form a groove with a central helix. This structure correctly 
orientates the E2~Ub conjugate and the recipient substrate to enable direct transfer of 
ubiquitin in one step (Berndsen and Wolberger, 2014). The first time the RING-E2~Ub 
intermediate was structurally solved, using an RNF4 homodimer bound to UbcH5a, 
revealed the structural and mechanistic basis for the E2~Ub-E3 interaction step 
(Plechanovova et al., 2012). Binding of UbcH5a~Ub to the RNF4 homodimer caused 
rigidity of the E2 conformational sampling into a position where the ubiquitin C-terminus 
was primed for attack within an active site on the E2, and enabled interaction with the 
substrate lysine leading to ubiquitin transfer. This was also observed in experiments 
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involving the RING heterodimer BRCA1-BARD1 (Pruneda et al., 2012). This activation 
of the E2~Ub conjugate by initiating a closed conformation ready for ubiquitin transfer 
to the substrate, suggests that these ligases act as more than just scaffolds and are 
maybe more like activators/repressors of ubiquitination. As for substrate interactions, 
this seems to be more complex, especially since many ligases are able to interact with 
the same substrate and that the recognition of substrates occurs by different means 
(Metzger et al., 2014). Some RING-type ligases contain localisation signals to direct 
them towards their substrates or are embedded in the plasma membranes of organelle. 
Others recognise substrates based on post-translational modification such as 
phosphorylation or acetylation, or even require the presence of an adaptor protein. 
Examples include the RING E3 ligase Cbl (Figure 1.3.1B) which acts individually and 
binds to phosphorylated substrates via an SH2 (Src homology 2) domain. Whereas 
SCF complexes (Figure 1.3.1B) and the APC ligase are formed from different proteins 
coming together to facilitate ubiquitination (Jackson et al., 2000). This diversity in 
RING-type E3 ligases enables the ubiquitination of a plethora of protein types and 
investigation of these proteins advances the understanding of ubiquitination and its role 
in cellular control. 
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Figure 1.3.1 - Schematic diagrams of the RING domain and example ligases  
A) RING domain layout where 6 cysteine residues (blue circles), a histidine residue (purple 
circle) and another which can be either cysteine or histidine (orange circle) form coordination 
bonds to create a cross-brace conformation with zinc ions (yellow circles). N and C refer to the 
amino and carboxyl termini B) Representations of a single component RING ligase, Cbl (Casitas 
B-lineage lymphoma) (left), and the multicomponent RING ligase SCF (Skp, Cullin-1, F-box) 
complex (right) interacting with an E2 enzyme and substrate. A key is provided underneath the 
diagrams.  
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1.3.2. HECT E3 Ligases 
In contrast to RING-type E3 ligases, HECT (Homologous to E6AP C-Terminus) E3 
ligases contain intrinsic catalytic activity. There is a total of 28 HECT family E3 ligases 
currently known to be expressed in humans (Lorenz, 2018). These E3 ligases contain 
a catalytic cysteine residue within the HECT domain which creates an intermediate 
cysteine-ubiquitin complex making the final ubiquitin transfer a two-step reaction 
(Huibregtse et al., 1995). The characteristic HECT domain was originally described in 
the protein E6AP (E6-associated protein) (Huang et al., 1999). Deletion analysis 
identified the last 84 amino acids of E6AP as essential for p53 and E6 protein 
ubiquitination by E6AP. This functional region was also identified in Nedd4 establishing 
this region as a common trait in proteins related to ubiquitination (Huibregtse et al., 
1993). Structural analysis by Huang and colleagues revealed the HECT domain as 
bilobal in nature. Mutagenesis of the interface between the lobes interfered with 
catalysis (Huang et al., 1999), which was similar to the mutations identified in Angelman 
syndrome, highlighting the region between the lobes as important to function. The 
catalytic cysteine residue resides in the smaller C-lobe and the E2 docking site in the 
larger N-lobe with a flexible hinge region connecting the two lobes. The E6AP HECT 
domain structure bound to UbcH7 can been seen in Figure 1.3.2A, where the HECT 
domain has an L-shaped conformation. The flexible hinge enables rotation of the lobes 
upon E2 and ubiquitin binding bringing the cysteine residues closer together (Verdecia 
et al., 2003). The E2 binding site on the N-lobe consists of a hydrophobic region which 
contacts a specific phenylalanine residue in the E2 enzyme as shown by E6AP~UbcH7 
(Huang et al., 1999). Further analysis involving ubiquitin-charged UbcH5B interacting 
with Nedd4L-HECT domain construct showed that, while the contacts between 
UbcH5B and the N-lobe were comparable to those for the already published 
E6AP~UbcH7 complex, the rotation of the C-lobe closer towards the ubiquitin molecule 
resulted in a much more compact HECT structure as seen in Figure 1.3.2B (Kamadurai 
et al., 2009). A distance of only ~8 Å was observed between the UbcH5B cysteine site 
and Nedd4L catalytic cysteine site (mutated to Ser/Ala in the experiment), although 
these active sites were still not close enough to facilitate ubiquitin transfer. The 
reorientation of the C-lobe is further supported by the many arrangements published 
for other HECT E3 ligases such as Smurf 2 at ~50 Å between cysteine positions 
(Ogunjimi et al., 2005) and WWP1(WW domain containing E3 ubiquitin protein ligase 
1) at 16 Å away (Verdecia et al., 2003). The distance observed for Nedd4L is much 
smaller than those observed for other modelled HECT~E2 complexes, showing the 
structural conformation just before ubiquitin transfer. Collectively, these structures at 
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various stages of C-lobe reorientation show that rearrangement of the HECT lobes is 
essential for the generation of the HECT~Ub intermediate.  
 
 
 
 
Figure 1.3.2 - HECT domain structures for E6AP and Nedd4L when bound to E2/E2~Ub 
A) Surface structure of the E6AP HECT domain (gold) bound to UbcH7 (blue). B) Structure of 
Nedd4L HECT domain (gold) bound to UbcH5B (blue) and ubiquitin (yellow). The catalytic 
cysteine residue is highlighted in red. Structures solved by Huang et al. (1999) and Kamadurai 
et al. (2009) using X-ray diffraction. Images generated using Chimera.  
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While all HECT E3 ligases share the presence of the HECT domain for catalysis and 
E2 interactions, the domains in the N-terminal region from HECT are responsible for 
substrate specificity. There are three subgroups: the HERC family, the ‘other HECT’ 
family and the Nedd4 family (Lorenz, 2018). The HERC family has 6 members and all 
contain at least one RCC1 (regulator of chromatin condensation 1) domain and range 
from ~1000 to ~5000 amino acids in length. While HERC3-6 only contain the HECT 
domain and RCC1, HERC1 and 2 have additional domains in the N-terminal regions 
linked to substrate interactions. In contrast, the ‘other HECT’ family only share similarity 
via the HECT domain and can contain varying lengths and domains outside of HECT. 
Lastly, the Nedd4 family of HECT E3 ligases, of which there are nine family members, 
all contain very similar domain architecture but with varying sequences and linker 
lengths. This Nedd4 sub-family of ubiquitin ligases is the centre of this work and will be 
discussed further in the next section. 
 
Errors in ubiquitination as a result of aberrant regulation of E3 ligases have been 
identified in many diseases, such as neurological, inflammatory and cardiac disease. 
For example, mutations in the gene encoding the RBR ligase parkin have been linked 
to the development of Parkinson’s disease (Charan and LaVoie, 2015). Loss of 
function, a decrease in solubility and aggregation of parkin results in reduced 
ubiquitination of downstream substrates such as mitochondrial surface proteins. The 
lack of parkin enzymatic activity on the mitochondrial surface prevents recognition and 
clearance of mitochondria via the autophagosomal degradation pathway. In turn, this 
results in the toxic build-up of dysfunctional mitochondria and neurone death 
(Karbowski and Youle, 2011). The role of parkin in neurodegeneration is further 
supported by parkin’s ability to protect neurones during times of apoptotic stress, ER 
stress and dopamine stress. Since the structural solution of parkin (Riley et al., 2013; 
Wauer and Komander, 2013), further understanding of the molecular mechanisms and 
functions of parkin has pushed forward the idea of this E3 ligase being a potential target 
for agonistic or allosteric activator design in disease treatment. Additionally, parkin has 
also been shown to play a role in cardiac injury after myocardial infarction (Willis et al., 
2015). The recruitment of parkin by the ubiquitin ligase Mfn2 (mitofusin-2) in 
cardiomyocytes is required for the removal of damaged mitochondria in order to control 
cellular homeostasis during reperfusion and tissue recovery. Parkin also displays a 
protective element in cardiac tissue to help minimise damage should a second event 
occur. Thus, reduced levels of functional parkin can result in heart disease and failure 
to develop a protective response upon a following heart attack. 
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Another neurological disease called Angelman syndrome has been linked to deletion 
or point mutation of the gene UBE3A. UBE3A encodes the HECT E3 ligase E6AP with 
substrates identified in many different regulatory pathways, such as the kinases CDK1 
and CDK4 involved in cell cycle regulation, and MAPK1 in cell proliferation (Cooper et 
al., 2004). The abnormal regulation of these proteins, along with ~120 other substrates, 
due to loss of E6AP enzymatic activity, results in symptoms such as seizures, loss of 
speech and mental deficiencies. In contrast to E6AP, the loss of another HECT E3 
ligase called Itch, leads to chronic lung inflammation, enlarged liver and spleen as well 
as autoimmune disease (Venuprasad et al., 2015).  The loss of Itch results in 
stabilisation of the protein JunB, leading to an imbalance in T helper cell differentiation 
towards Th2 type cells. The increase in Th2 cells results in significantly increased 
allergic responses in Itch deficient mice, further supporting the role of Itch in the 
regulation of inflammatory response. Collectively, these examples show the importance 
of having functional E3 ligases and the implications mutation and/or loss of regulated 
ubiquitin ligase activity can have in the development of disease. 
 
In addition to the above diseases, E3 ubiquitin ligases have also been identified as 
drivers of oncogenesis, by either being a proto-oncogene themselves or by 
overexpression leading to a decrease in tumour suppressor proteins. Further 
understanding of the structure-activity relationship of E3 ligases and their substrates 
has led to the development of novel cancer therapies. For example, RING E3 ligase 
overexpression has previously been associated with cancer growth. One of the most 
studied RING E3 ligases is Mdm2. Mdm2 overexpression has been found in many 
cancer types, including prostate cancer (Leite et al., 2001). This E3 ligase interacts with 
and regulates the activity of the tumour suppressor protein p53 via three methods – 
ubiquitination of p53 leading to degradation; binding and blocking of the p53 activation 
domain; and induction of nuclear export preventing DNA interaction of p53. These all 
result in a reduction of apoptosis and cancer cell survival (Zhao et al., 2015). Successful 
development of inhibitors of Mdm2 has shown increasing capabilities in disruption of 
the protein-protein interaction restoring tumour suppressive protein activity, in turn 
reducing tumorigenesis. This wouldn’t have been possible without the knowledge of 
the structure, interaction and function of these enzymes and substrates. This is not the 
only the case as there is an accumulating body of evidence supporting the association 
of HECT E3 ligase overexpression as well in the development and progression of 
cancer (Bernassola et al., 2008). The focus of the work in this thesis will be on the 
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Nedd4 superfamily of HECT E3 ligases with most interest focused on the E3 ligase 
WWP2. 
 
1.4. Nedd4 family of HECT E3 ligases 
The human genome is known to encode 9 HECT E3 ligases that make up the Nedd4 
(neural precursor cells-expressed developmentally down-regulated 4) superfamily, 
including HECW1, HECW2, Nedd4, Nedd4-2 (Nedd4L), Smurf 1, Smurf 2, Itch, WWP1 
and WWP2. The Nedd4 family members differ in size from 748 residues up to 1606 but 
have a well-characterised structure consisting of three main regions. Situated at the 
N-terminus is the C2 domain, in the middle resides up to four double tryptophan (WW) 
domains, and at the C-terminal end sits the HECT domain (Scheffner and Kumar, 2014; 
Soond and Chantry, 2011; Yang and Kumar, 2010). The domain organisation can be 
seen in Figure 1.4.1 outlining all nine members of the Nedd4 family. 
 
 
 
 
Figure 1.4.1 - Members and domain arrangements of the Nedd4 E3 ligase family 
Schematic representations of the domain architecture of Nedd4 family E3 ligases as 
described by uniprot. N-terminal C2 domain is shown by the orange box, WW domains 
are represented as blue boxes and the purple box at the C-terminus is the catalytic 
HECT domain.  
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intracellular calcium via conserved aspartic acid side chains in the b2/3 and b6/7 loop 
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proteins using the fluctuations in calcium as a mediator of protein translocation. Plant 
and co-workers (1997) showed that removal of the C2 domain from Nedd4 abolished 
its localisation to the plasma membrane and phospholipid interaction. The presence of 
the C2 domain in Nedd4 is, therefore, required for directing the activity of this ligase at 
cellular membranes and may help the targeting of these ligases towards particular 
substrates as implied by its conservation in all 9 members. More recently, solution 
structure of the Smurf 2 C2 domain highlighted that this domain adopts the same 
folding pattern common to C2 domains. However, there was an upside-down 
orientation with the N- and C-termini at the ‘bottom’ of the structure (class II), unlike the 
C2 domain of PKC with these termini at the ‘top’ (class I) (Wiesner et al., 2007). Based 
on sequence similarity across the Nedd4 family, this suggested a conserved class II 
C2 domain in this group. Further investigations into the Smurf 2 C2 domain to 
understand more about its role in Smurf 2 activity uncovered interactions with the HECT 
domain. The presence of the C2 domain led to steady-state levels of Smurf 2 with no 
ubiquitination activity however removal of the C2 domain resulted in auto-ubiquitination 
activity of the ligase. This supports the function of the C2 domain in regulating Smurf 2 
activity and provides a possible mechanism employed by other Nedd4 E3 ligases. On 
this note, the same role of C2 has been reported for Nedd4 (Wang et al., 2010), 
highlighting this region as important in the control of ubiquitination and 
auto-ubiquitination for these members.  
 
Alternatively, both WW domains and linker regions have shown auto-inhibitory 
functions in Nedd4 family proteins. Itch showed autoinhibition could be relieved by the 
addition of NDFIPs (Nedd4 family interacting proteins) which bind to WW domains 
(Riling et al., 2015). Further study revealed intramolecular interactions of the WW2-3 
region with the HECT domain as the mechanism of autoinhibition in which mutation of 
the 2nd tryptophan, important for PPxY recognition, resulted in Itch activity similar to 
NDFIP interaction. While this was also thought to apply to the closely related WWP2 
enzyme, evidence by Chen and co-workers (2017) showed that it is the linker between 
WW2 and WW3 which is involved in WWP2 inhibition. The linker forms a helix that 
interacts with both the N- and C-lobes of the HECT domain with the last 6 residues of 
WW2 also contacting the HECT domain (Chen et al., 2017). This region of WW2 and 
the N-terminal residues of the 2-3 linker are proposed to interact with a ubiquitin 
‘exosite’ in the HECT domain, previously identified in Nedd4 and Smurf 2 (Maspero et 
al., 2011; Zhang et al., 2016), but yet to be formally located in WWP2. These 
mechanisms employed by Nedd4 E3 ligases result in tight regulation of their activity as 
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well as providing insight into possible ways to limit the activity of these proteins when 
they are over-active.  
 
WW domains within the central region of the proteins vary in number within the Nedd4 
family of proteins with only 2 residing in HECW1, HECW2 and Smurf 1, three within 
Smurf 2 and the rest containing four WW domains. WW domains are usually 30-40 
amino acids in length with two distinctive tryptophan residues towards either end of the 
domain interspaced by ~20 residues. The second tryptophan residue, however, is 
sometimes replaced by tyrosine/phenylalanine, as seen for example in WW4 of WWP2 
and Smurf 1 WW2 domain. The Nedd4 family of ligases are typical class I WW domains 
with a binding preference for the proline-rich PPxY residue sequence. There are, 
however, a further 3 classes of WW domain. These other classes can interact with 
PPLP motifs (class II), proline-arginine (class III) and phospho-serine-proline (class IV) 
(Bedford et al., 2000; Espanel and Sudol, 1999). WW domains both within the same 
protein and between different proteins can share the same interaction partner, yet also 
show a selective preference towards particular targets. As the motif is the same, this 
shows that the sequence outside of the proline motif is key for determining the binding 
profile of the individual WW domains.  
 
Several WW domains within Nedd4 E3 ligases have been structurally solved. This has 
helped to uncover atomic aspects of WW domain folding and the interactions with target 
substrates (Aragon et al., 2011; Aragon et al., 2012; Chen et al., 2017; Chong et al., 
2006; Chong et al., 2010; Kanelis et al., 2001; Panwalker et al., 2016; Qi et al., 2014). 
WW domains all share a 3 stranded anti-parallel b-sheet conformation with disordered 
N and C terminals situated either under or heading away from the secondary structures. 
Curvature of the strands creates a central groove where substrates can interact. Within 
this twisted region resides a group of conserved residues that form a hydrophobic 
patch. Two key residues are a tyrosine/phenylalanine on the second strand and the 
C-terminal tryptophan residue that make up the XP pocket. The XP pocket specifically 
orientates the first two prolines of the PPxY motif in the substrate, promoting interaction 
between the two proteins (Marcias et al., 1996). A second specificity pocket is formed 
by another two residues - a hydrophobic amino acid often leucine, valine or isoleucine 
located in the second strand and a histidine residue in loop II. These are involved in 
contacting the tyrosine residue of the PPxY motif. Mutagenesis highlighted the 
hydrophobic residue as the major contributor towards interactions of class I WW 
domains, as mutation of this residue abolished tyrosine binding and changed the WW 
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domain recognition towards the class II PPLP substrate type. Histidine showed more 
diversity in which 5 substitutions were possible that retained PPxY binding (Espansel 
and Sudol, 1999). As the XP pocket, 2nd specificity pocket and PPxY motif are shared 
across the Nedd4 family, the specific orientations, residue type and other contacts must 
relay the specificity shown by WW domains towards substrates. Uncovering this 
information in a variety of WW domains with similar and unique interaction partners 
should reveal information about the specific interface between Nedd4 E3 ligases and 
their specific target proteins. 
 
Comparison of the XP residues in the bound structures for Smurf 1 WW2 (PDB: 2LTX) 
Smurf 2 WW3 (PDB:2LTZ) and Nedd4-2 WW2 (PDB: 2LTY) (Aragon et al., 2012) in 
the presence of the same substrate Smad 7 peptide is shown in Figure 1.4.2. While the 
first XP residue is a tyrosine in all three domains, only Nedd4-2 contains a canonical 
2nd tryptophan residue, whereas both Smurf 1 WW2 and Smurf 2 WW3 have a 
phenylalanine residue at this position. Nevertheless, similar orientations of the XP 
residue side chains are observed when in contact with the first and second proline 
residues of Smad 7. Variation is present, however, in the structural interfaces between 
these domains. A tight hairpin fold is observed when the peptide interacted with 
Nedd4-2, whereas for Smurf 1 and Smurf 2 WW2 and WW3 domains, respectively, this 
turn is not nearly as tight. Other residues in Nedd4-2 WW2 that contact the Smad 7 
peptide are situated across the whole domain. R389 and T391 on the third strand, along 
with V384 and H386 on the second strand interact with the conserved tyrosine residue 
in the PPPY motif, and the additional residue T391 in the WW domain also contacts 
the PPPY prolines. Further away from the proline motif in the Smad 7 peptide, 
additional contacts are made with L378 and R380 in loop I-strand 2 of the WW domain. 
Mutation of these residues in Nedd4L WW2 resulted in a decrease in affinity towards 
the Smad 7 peptide. In contrast, no loop I contacts are present for Smurf domain 
interactions, but mutagenesis of the arginine residue at the equivalent Nedd4-2 WW2 
R380 position in Smurf 1 WW2 (R295) and Smurf 2 WW3 (R312) had the same 
decrease in affinity, showing the role of this residue in Smad 7 peptide interaction. The 
conformation of the substrate and the contacts differ between domains highlighting the 
complexity in understanding the preferences and interactions between WW domains 
and substrates. Analysis of Nedd4-2 domains interacting with Smad 2 and Smad 3 
showed that interactions were dependent on the activation of the Smad protein via 
phosphorylation of a threonine residue upstream of the PPxY motif and involved more 
than one WW domain (Gao et al., 2009). This brings in the idea that both modifications 
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and tandem domain functionality can also control WW domain interactions with target 
substrates, and that particular substrate sequences outside of the PPxY motif may 
determine individual WW domain: substrate preferences, as shown by the constitutive 
Smad 7 binding to Nedd4-2 in contrast to Smad 2/3 interactions.  
 
 
 
Figure 1.4.2 - Comparison of the XP residues of Smad 7 bound WW domains in Nedd4 
family members  
The structures of Smurf 1 WW2 (gold) (PDB: 2LTX), Smurf 2 WW3 (purple) (PDB:2LTZ) and 
Nedd4-2 WW2 (green) (PDB: 2LTY) when bound by Smad 7 peptide (Aragon et al., 2012). The 
equivalent first XP pocket tyrosine residues on the second strand and the 
tryptophan/phenylalanine that constitutes the second residue of the XP pocket are shown for all 
three domains. Comparison and image generation carried out using Chimera.  
 
Another example where WW domains show selective preferences for substrates can 
be seen in the founding family member, Nedd4.  Staub and colleagues (1996) identified 
Nedd4 as an ENaC (epithelial sodium channel) binding partner via two PY motifs 
present in the C-tail of the membrane channel leading to internalisation of the channels 
and ubiquitin-dependent degradation. Other Nedd4 family members such as Nedd4-2 
and WWP2 also target ENaC (McDonald et al., 2002). The regulation of ENaC by these 
ligases is important as seen in Liddle’s syndrome, where loss or mutation of the PY 
motif leads to reduced ubiquitin-dependent degradation and the subsequent increase 
in ENaC protein levels leading to the development of hypertension (Goulet et al., 1998; 
Harvey et al., 1999). GST pull-downs using WW domains of WWP2 and Nedd4-2, and 
ENaC subunits showed all WW domains except WW1 of WWP2 could interact with 
ENaC. Similar to WWP2, all domains of human Nedd4 bound to ENaC, but not the first 
 20 
WW domain compared to rat and mouse homologues (Lott et al., 2002). Only a single 
amino change from an arginine to a threonine on the third strand was capable of 
enabling human Nedd4 WW1 to interact with ENaC. Analysis of the interface between 
the Nedd4 WW domains and ENaC found that WW3 had the highest affinity for ENaC, 
and the XP pocket residues phenylalanine 476 and tryptophan 487 displayed the same 
accommodation of the two prolines of the PPxY motif (Kanelis et al., 2001) as described 
for other WW domains. Unlike the Smad 7 motif which has another proline at the x 
amino acid site, the x residue of the ENaC motif is an asparagine but forms the same 
polyproline helical conformation. The contacts with the tyrosine are made by an 
isoleucine and histidine residue in WW3, with additional contacts to a leucine residue 
C-terminal of the tyrosine in ENaC (Kanelis et al., 2001). Investigations into the specific 
contacts in these interactions is showing that there are individual residues that are 
outside of the classic motifs that are dictating specificity and only by exploring these 
individual contacts can we begin to understand how these ligases function. 
 
mRNA screening showed wide distribution of HECT E3 ligases across cell types, yet 
certain ligases showed selective over expression in cancer cell lines (Komuro et al., 
2004). For example, Nedd4, WWP1 (Komuro et al., 2004) and WWP2 (Soond et al., 
2013) have shown over expression in melanoma, prostate and breast cancer. Komuro 
also showed higher levels of Smurf 2 in colon, breast and ovarian cancer, whereas 
WWP1 was over expressed in colon, stomach and an ovarian cancer cell line. 
Expression analysis by Kuratomi et al. (2005) also identified Nedd4-2 over expression 
in several cancer cell lines including colon, breast, ovarian and melanoma. More 
recently, analysis of WWP2 isoforms in patient samples of these cancers revealed 
potential stage specific and cancer type specific expression levels (Soond et al., 2013). 
This analysis, however, has only involved a small sample size thus further study is 
required to determine if this can be observed across more cases. This would be 
interesting to find out as it may provide another prognostic marker for these cancers, 
because, for example in prostate cancer, there are cases where the biomarker PSA is 
not sufficient in identifying cancer (PSA negative prostate cancer cases) unless other 
symptoms are present (Birtle et al., 2003). 
 
1.4.1. WWP2 and its isoforms 
WWP2 was first discovered in 1997 (Pirozzi et al., 1997; Harvey and Kumar, 1999) and 
was identified as a member of the Nedd4 family. The full-length protein consists of 870 
amino acids which form independent domains as shown in Figure 1.4.3. WWP2 has 
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not been studied as much as other Nedd4 family members, however research is 
starting to answer some of the unknown aspects of this protein. WWP2 has 3 main 
isoforms found in humans generated from alternative splicing and/or use of alternate 
promoters. WWP2-N is created from the retention of an intron between exon 9 and 10 
that contains an alternative stop codon resulting in a premature stop signal and 
translation truncation. This results in a shorter protein consisting of only amino acids 
1 – 335 of the N-terminal region and contains the C2 domain and the first WW domain. 
In contrast, another isoform WWP2-C consists of the C-terminal region from residue 
440 – 870 containing WW4 and the HECT domain. This is created from an internal 
putative promoter at the start of exon 13. Other isoforms have been found in human 
cells, however further identification and investigations are required to determine if these 
are true isoforms and have a functional role.  
 
 
 
 
 
Figure 1.4.3 - Diagrams defining the regions present in WWP2 isoforms  
A summary of the three well-known active isoforms of WWP2, and their individual domain 
architecture – N-terminal C2 domain important for calcium and phospholipid binding, central 
WW domains involved in substrate interactions and the characteristic HECT domain at the 
C-terminus. WWP2-N contains only the C2 domains and WW1 regions, whereas WWP2-C 
consists of WW4 and the HECT domain. Numbers are the start and end refer to the amino acid 
number in relation to full-length WWP2. 
 
Structural solution of the domains within WWP2 is currently limited to the HECT 
domain, WW2 and the WW2-3 linker region. Crystallisation of the HECT domain (Gong 
et al., 2015) showed the same bilobal T-shape conformation as other HECT domains 
such as WWP1 (Verdecia et al., 2003), Itch and Nedd4-2, which contrasts with the 
L-shape of Nedd4 (Maspero et al., 2011) and Smurf 2 (Ogunjima et al., 2015). These 
different conformations are due to the flexibility of the hinge region that connects the 
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two lobes, and most likely the differences in intra-molecular contacts of the two lobes. 
Nedd4 was suggested to convert to the more stable T-shape conformation when 
interacting with the E2~Ub complex (Maspero et al., 2013), however, evidence of the 
yeast HECT E3 ligase Rsp5 suggests that the L-shape conformation can be maintained 
even when bound by Ub and substrate Sna3 (Kim et al., 2011). E6AP also showed an 
L-shape conformation (Huang et al., 1999). Perhaps these conformations are one way 
in which the individual HECT domains separate their activity from other members of 
the same family, and it may be useful to untangle the specifics for ways to target 
selective HECT domains. The T-shape conformation of the WWP2 HECT domain was 
further confirmed by Chen et al. (2017) as its autoinhibited form by interaction of HECT 
with the WW2-2-3 linker region. Chen and co-workers also showed that WW2 of WWP2 
reflected the 3 stranded anti-parallel b-sheet previously identified for WW domains. 
Unbound structures for the other WW domains within WWP2 as well as 
substrate-bound structures however, have yet to be solved.  
 
1.4.2. WWP2, signaling pathways and their role in prostate cancer 
The most common cancer to affect men is prostate cancer (PCa), with around 47,000 
men being diagnosed each year in the UK (PCUK, 2017). The prostate is a gland that 
sits beneath the bladder. There are three main regions of the prostate – the central 
zone which surrounds the ejaculatory duct which connects the seminal vesicle to the 
urethra; the transitional zone that is located directly below the bladder and surrounds 
the urethra; and the peripheral zone which is at the posterior region of the gland 
(Hammerich et al., 2008; Packer and Maitland, 2016). The acinus of the prostate is 
lined with secretory luminal cells that are important for the release of seminal fluid into 
the duct. The luminal layer is surrounded by further layers of progenitor basal cells and 
stem cells additionally encased by a stromal cell environment (Packer and Maitland, 
2016). The stem cells divide into either more stem cells or cells that differentiate into 
basal cells in order to maintain the basal cell and luminal cell layers. To date, the 
heterogeneity of the prostate gland has restricted the identification of specific factors 
associated with PCa development, along with no obvious epidemiological factor.  
 
PCa is grouped into three main stages based on whether it has spread from the 
prostate or how far it has spread (NICE clinical guidelines, 2014). Localised PCa 
resides only in the prostate gland itself, whereas localised advanced has spread 
outside of the prostate to the nearby tissues such as the bladder and seminal vesicle. 
The last stage is metastatic PCa in which the cancerous cells have spread further into 
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the body, often through the lymphatic system to the bones. In addition to this, a further 
refined grading system called the Gleason score is used to describe the cellular 
histology of the prostate tissue rather than just location for the assessment of PCa, 
ranging from 1 to 5 (Hammerich et al., 2008; Packer and Maitland, 2016; PCUK, 2017). 
Due to the heterogeneity of PCa, two values are given in order represent the primary 
and secondary tissue grades present in patient samples. These resulting scores can 
therefore range from 2 (1 + 1) to 10 (5 + 5), where the individual grades of 1 and 2 refer 
to non-cancerous tissue while 3, 4 and 5 indicate a cancerous profile. Grades of 6-10 
(3+3 to 5+5) rank the cancer from slow growing and unlikely to differentiate further into 
aggressive disease, up to advanced metastatic disease that is aggressive in nature 
and spread outside of the localised region of the prostate. PCa can form several foci in 
the gland, meaning that increased samples are taken by biopsy of the prostate in order 
to determine the presence or absence of PCa. 
 
There are currently many treatment options based on the Gleason score and stage of 
the cancer. Both watchful waiting and active surveillance are used either when men do 
not want to undergo treatment or when PCa is localised and has a low or intermediate 
risk of future progression. The most well-known active treatment is androgen ablation 
therapy. These therapies act upon the androgen receptor signaling pathway by either 
chemical or surgical means in order to reduce serum hormone levels to that of 
castration conditions (Gomella et al., 2014). Other treatment options include 
radiotherapy and chemotherapy, however, each of these treatments can come with 
side effects which result in a poor quality of life. While there are many options, the major 
problem associated with hormone therapy and other current treatments in the long term 
is that, in most cases, the tumours return in ~18 months as hormone-independent PCa 
(also known as castrate-resistant PCa) which is more aggressive and quick growing 
(Gomella et al., 2014; Singh and Kim, 2016). Hence, therapies which target other 
molecular factors associated with AR-independent cancer for use in castrate-resistant 
PCa are required.  
 
Nan and colleagues (2003) showed PTEN as a negative regulator of the androgen 
receptor, a nuclear steroid receptor associated with PCa development, via AKT 
signaling suggesting PTEN as a target for PCa-associated therapeutics. The 
prevalence of PTEN loss in castrate-resistant cancer however is high suggesting a 
different drug target involved in PTEN regulation may be a better strategy for treating 
advanced PCa (Carver et al., 2011; Taylor et al., 2010). PTEN loss has been linked to 
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over expression of HECT E3 ligases in PCa, as well as increased loss of other tumour 
suppressor proteins such as Smad proteins in the canonical TGF-b signaling pathway. 
Hence the ubiquitination pathway presents an ideal target for further investigation, 
especially as members of the Nedd4 family of E3 ligases have substrate specific WW 
domains attractive for drug design, which will be explored further in this work.  
 
Over expression of WWP2 isoforms has been linked to the development and 
progression of prostate cancer. Expression profiling in patient samples found a stage 
specific expression pattern in prostate cancer (Soond et al., 2013). While this study 
used a small sample size, further investigation may reveal WWP2 as a potential 
biomarker for prostate cancer, particularly important in PSA negative and PTEN 
negative cases. Furthermore, the effect of WWP2 overexpression on tumour 
suppressors such as Smad proteins and PTEN has significant effects on cancer cell 
abilities to bypass usual control mechanisms such as growth inhibition and apoptosis 
(Chantry, 2011). This highlights the importance of regulation of this ligase in the 
suppression of tumour formation.  
 
Smad proteins in the TGF-β signalling pathway (more detail provided in section 1.6) 
and the lipid phosphatase PTEN (further described in section 1.7), are known binding 
partners of WWP2 isoforms and have been linked to cancer development (Chen and 
Matesic, 2007; Soond et al., 2013). WWP2 isoforms have been shown to respond 
differently in the presence of TGF-β. Levels of WWP2-FL increased with TGF-β 
stimulation with the highest level detected on day 2 which then became undetectable 
on day 4, whereas WWP2-N was only detectable at low levels for the first 3 days and 
WWP2-C undetectable throughout (Soond and Chantry, 2011). This suggests that the 
regulation of WWP2 isoform expression may be regulated in a context-specific manner, 
but the specifics have yet to be fully elucidated. Analysis of WWP2 isoform interactions 
showed that these differences may be mediated by the interaction and ubiquitination of 
Smad proteins that act as the secondary messengers in TGF-β signaling. Differential 
binding of WWP2-FL to both Smads 2 and 3 compared to Smad 7 was observed, 
although TGF-β stimulation increased interaction with Smad 7 resulting in greater 
Smad 7 degradation. On the other hand, WWP2-N bound preferentially to Smad 3 
under both TGF-β negative and positive conditions, with reduced binding to Smad 2 
only observed with TGF-β stimulation. Interaction with Smad 2 and 3 in TGF-β positive 
conditions is thought to stabilize the cellular concentrations of these transcription 
factors as WWP2-N lacks the catalytic HECT domain. The binding of Smad 2 by 
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WWP2-FL was also only observed under TGF-β stimulation. WWP2-C bound to Smad 
7 in TGF-β-dependent conditions to a greater degree than WWP2-FL. Due to the 
isoform architecture, it was inferred that WW1 targets R-smads 2 and 3, and WW4 
selectively binds inhibitory Smad 7. More recent NMR analysis highlighted WW4 as 
capable of binding to Smads 2 and 3 as well, although the highest affinity was towards 
phospho-Smad 7 followed by Smad 3 (Wahl, 2016).  
 
Soond and Chantry (2011) also found that the isoforms were capable of modulating 
WWP-FL activity. While auto-ubiquitination activity of WWP2-FL was observed in the 
presence of WWP2-N and WWP2-C, only WWP2-N was detected in pull-down 
analysis.  Binding of WWP2-N to WWP2-FL under TGF-β negative conditions resulted 
in a decrease in Smad 2/3 levels but no change in Smad 7. However, upon ligand 
stimulation, the WWP2-FL: WWP2-N isoform complex dissociated and WWP2-FL 
preferentially targeted Smad 7. WWP2-N therefore modulates WWP2-FL autoinhibition 
and isoform activity in a TGF-β mediated manner. 
 
Another interaction partner of WWP2 as mentioned above is PTEN (Maddika et al., 
2011), discussed later in section 1.7. The binding region in PTEN was isolated to within 
the phosphatase domain, suggesting WWP2 binding acts to physically prevent PTEN 
activity. Furthermore, the use of a catalytically inactive WWP2 abolished PTEN 
ubiquitination supporting WWP2 as a PTEN specific interaction, also supported by 
WWP2 knockdown affecting PTEN abundance. The binding site within WWP2 and its 
isoforms, however, have yet to be isolated as PTEN lacks the characteristic PPxY motif 
found in known substrates of WWP2. In order to specifically disrupt selective 
interactions between WWP2 and its substrates, further understanding of the 
protein-protein contacts involved is required. 
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1.5. TGF-β signalling 
TGF-β (transforming growth factor-β) signaling has many roles in both the embryo and 
in adult systems. Smad proteins are the secondary messengers in the TGF-β family of 
signaling pathways that relay the signal from the cellular membrane receptors to the 
DNA in the nucleus to control transcription. Cytokines including TGF-β, BMPs (bone 
morphogenetic proteins) and activins bind to kinase receptor complexes leading to 
downstream signaling events. Interactions of the type I and type II TGF-β receptors is 
triggered by the activation of cytokines in the extra-cellular matrix which binds to type 
II receptors which recruits type I receptors to oligomerize with the type II (Croxford et 
al., 2017; David and Massague, 2018). This results in phosphorylation of the type I 
receptor cytoplasmic GS (glycine-serine rich) domains. This activates the kinase 
activity of the type I receptors and induces phosphorylation of receptor-regulated smad 
proteins (R-smads) such as Smad 2 and 3 in canonical TGF-β signaling. Activation of 
these messengers by phosphorylation enables heterotrimeric complex formation with 
the common-mediator smad (co-smad), smad 4. This complex can then translocate 
into the nucleus and regulate transcriptional activity via interaction with co-activators 
(e.g. p300 and CBP), co-repressors (e.g. SnoN) (Soond and Chantry, 2011), or other 
transcription factors into a high-affinity DNA binding complex. A negative regulator of 
this pathway is called an inhibitory smad (I-Smads) protein, an example being Smad 7 
in canonical TGF-β signaling. I-Smads inhibit downstream activity of the TGF-β 
pathway via competitive binding to the type I receptors (Hayashi et al., 1997), by 
interaction with R-smads and the recruitment of specific E3 ligases to R-smads and cell 
surface receptors (Kavsak et al., 2000; Kuratomi et al., 2005; Yan et al., 2016). A 
simplified summary of canonical TGF-β signaling is shown in Figure 1.6.1. 
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Figure 1.6.1 - Schematic representation of canonical TGF-β signaling  
Activation and binding of TGF-β ligand (blue triangle) to TGF-β-RI (white rectangle) and 
TGF-β-RII (white circle) receptor pairs leads to phosphorylation (red ‘P’ circles) of the type I 
receptor and activation of the receptor kinase activity. TGF-β-RI recruits and phosphorylates 
R-smads 2 and 3 (green circles), which then oligomerise with co-Smad4 (purple circle) into a 
trimeric complex. The trimer then localises to the nucleus, binds to other transcription factors 
(pale blue circles) before DNA binding to either activate or repress transcription. I-smad 7 (blue 
circle) negatively regulates the TGF-β receptors and R-Smad interactions and phosphorylation. 
TGF- β – transforming growth factor beta; RI/II – receptor I/II; P – phosphate. 
 
Smad proteins have different domain compositions related to their role in the signaling 
pathway and can be split into three groups. A common domain across all three types 
of smad protein is the MH2 (Mad homology 2) domain. This domain is required for 
mediating protein-protein interactions with other transcription factors and receptors. At 
the very end of this domain in R-smads, the C-terminus contains a Ser-x-Ser motif that 
is recognized and phosphorylated by TGF-β-RI, in turn activating the protein and 
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facilitating MH2 domain interactions with other Smad proteins. Next to this MH2 domain 
is a flexible linker region. The linker region contains sequences that can both 
up-regulate and down-regulate activity. Phosphorylation sites such as those for 
CDK8/9 (cyclin-dependent kinases 8/9) increase the function of these smad proteins in 
mediating transcription (Alarcón et al., 2009), whereas when GSK3 (glycogen synthase 
kinase 3) phosphorylates the linker region, this recruits HECT E3 ligases to the 
transcription factor to mark it for degradation (Aragón et al., 2011; Gao et al., 2009). 
HECT E3 ligases are able to interact with these transcription factors via recognition of 
another motif in the linker region, a proline rich PPxY motif. This motif is conserved in 
all smad proteins indicating an important sequence for the regulation of these proteins. 
R-Smads and co-smads also contain another globular domain at the N-terminus, an 
MH1 domain. This domain functions as a DNA binding domain that recognizes the 
Smad binding element 5’-CAGAC-3’ and is highly conserved in these two types of 
Smad protein (Dennler et al., 1998). In contrast, inhibitory smads lack the MH1 domain 
and instead have an extended linker region that is more diverse but still retains the 
PPxY motif.  
 
 
 
Figure 1.6.2 - Schematic representations of Smad protein domains  
A summary of the characterizing domains pf the different types of Smad protein. The N-terminal 
MH1 domain (blue) is connected to an MH2 domain (yellow) in R-Smads and Co-Smad by a 
linker region (black). In contrast I-smads contain the MH2 domain but lack the MH1. The PPxY 
motif is shown in linker region of R-Smads and I-Smads that enables E3 ligase recognition. MH1 
and MH2 – Mad homology domains 1 and 2; R-smad – receptor-regulated smad; Co-smad – 
common-mediator smad; I-smad – inhibitory smad; PPxY – proline-proline-(any amino acid)-
tyrosine; SxS – serine-(any amino acid)-serine. 
 
Regulation of TGF-β signaling is essential as this pathway controls the activity of many 
genes associated with cell growth and differentiation. One mechanism employed 
includes self-regulation via intra-molecular contacts between the MH1 and MH2 
R-Smad
Co-Smad
I-Smad
MH1 MH2linker
PPxY
PPxY
SxS
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domains of R-smad 2 and co-smad 4 (Hata et al., 1997). This prevents early 
oligomerization and activation of these transcription factors when the pathway 
receptors are inactive. Phosphorylation of the C-terminal tail relieves the autoinhibited 
conformation between the N and C terminal regions and activates these smad proteins 
for downstream signaling.  
 
As briefly mentioned earlier, Smad 7 acts as a negative regulator of TGF-β signaling. 
Smad 7 can down-regulate activity by many different mechanisms. Hayashi et al. 
(1997) showed that Smad 7 transiently interacts with the type I TGF-β receptors via the 
MH2 domain at the C-terminus of Smad 7, thereby blocking R-smad access to undergo 
phosphorylation by the receptor which antagonizes downstream events by R-Smads. 
Additional activity as a consequence of Smad 7 association with TGF-β-RI includes the 
recruitment of both phosphatases and E3 ligases (Ebisawa et al., 2001; Kavsak et al., 
2000; Komuro et al., 2004; Kuratomi et al., 2005). This often results in silencing of the 
kinase domain activity of the receptors and/or internalization and degradation. More 
recently, evidence of direct interaction between I-Smad 7 and R-smads via the Smad 
7 MH2 domain shows competitive inhibition by preventing co-Smad 4 binding. In turn, 
recruitment of E3 ligases such as Nedd4-2 to this complex results in ubiquitination and 
degradation of the R-smad proteins (Yan et al., 2016). Mutation of the PPxY motif in 
Smad 7 did not prevent binding between Smad 7 and R-smads but did affect the 
recruitment of E3 ligases for R-smad turnover. Therefore, not only does Smad 7 act on 
the membrane receptors to inhibit TGF-β signaling but also on the R-smads themselves 
in turn leading to the turnover of both the receptor and activated messengers.  
 
While Smad 7 is one regulator of the pathway via the recruitment of E3 ligases, the 
degradation of Smad proteins by Nedd4 E3 ligases also regulates TGF-β signaling by 
removing them from the cellular environment. Smurf 2 (Smad ubiquitin regulatory factor 
2) has a high affinity for the I-smad Smad 7 but is still capable of binding Smad 2 and 
3 at a reduced degree (Kavsak et al., 2000; Lin et al., 2000). Deletion constructs of 
Smurf 2 identified WW2 as the binding region for Smads 2 and 3, as deletion abolished 
binding between these partners (Lin et al., 2000). Interaction of Smurf 2 with Smad 2 
resulted in ubiquitination and degradation of the smad protein during TGF-β activation. 
In contrast, Smad 3 expression levels were unaffected, suggesting another E3 ligase 
could be responsible for the majority of Smad 3 turnover. Based on the preference for 
Smad 3 by WWP2 isoforms regardless of TGF-β status mentioned previously, WWP2 
may be the preferential controller of Smad 3 levels. This was further supported by 
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luciferase reporter assay where, upon TGF-β stimulation, expression of Smurf 2 
resulted in a greater decrease in Smad 2 activity compared to Smad 3. Smurf 2: Smad 
7 binding was found to have a slightly different outcome. Kavsak et al. (2000) presented 
evidence to support direct binding of Smurf 2 and Smad 7 and later discovered this 
complex was recruited to the TGF-β type I and II receptors located at the cellular 
membrane, rather than immediate ubiquitination of Smad 7 upon binding. The complex 
formation enabled Smurf 2 translocation out of the nucleus leading to down-regulation 
of TGF-β receptor availability, thus lowering the activity of the pathway.  
 
Further screening assays also identified WWP1 and Nedd4-2 as Smad 7 interaction 
partners (Komuro et al., 2004; Kuratomi et al., 2005). Both WWP1 and Nedd4-2 
showed a similar function as Smurf 2 in effectively binding to Smads 2, 3 and 7 as well 
as mediating receptor degradation using Smad 7 as an adaptor (Komuro et al., 2004). 
However, WWP1 failed to ubiquitinate the R-smads, unlike Smurf 2, suggesting a 
different role for WWP1 associate in R-Smad regulation than ubiquitination for 
degradation. These ligases also appeared to have Smad 4 interaction capabilities via 
Smad 7, leading to proteasomal degradation of Smad 4, similar to the Smurf E3 ligases 
(Morén et al., 2005). These overlapping yet individual functions suggest partial 
redundancy in E3 ligase activity in regulating the TGF-β pathway.  
 
1.5.1. TGF-β signaling in prostate cancer 
TGF-β signaling is known to be both tumour suppressive and tumour promoting 
dependent on the context of the cell. The tight regulation of this pathway is important 
as it has various roles in development, differentiation and cell maintenance. 
Understanding the deviations from controlled signaling present in non-cancerous cells 
is important in uncovering novel aspects of the disease which could potentially lead to 
better therapeutics.  
 
The three isoforms of TGF-b (TGF-b1, TGF-b2 and TGF-b3) can all bind to the same 
receptors and seem to share biological activities in cells. In early stages of PCa, all 
three TGF-b proteins are suppressive in nature by inducing cell cycle arrest and 
apoptosis, however as the disease progresses cells become resistant and increased 
TGF-b promotes angiogenesis and tumour growth (Croxford et al., 2017). Over 
expression of TGF-b1 in primary PCa patient samples was found to shorten survival, 
and increase angiogenesis and metastasis (Wikström et al., 1998). Likewise, higher 
than normal levels of TGF-b2 as a result of PI3K and p38 signaling also induces 
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tumourigenesis (Wan et al., 2010). However, TGF-b3 has shown the most potent effect 
by inducing invasive phenotypes by reducing cellular adhesion and increasing motility 
via Smad 3 signaling in PC3 cells (Walker et al., 2013). Expression analysis of both 
mRNA and protein levels of TGF-b signaling components in prostate cancer cell lines 
identified both metastatic cell lines PC3 and DU145 as having high expression of 
TGF-b3, potentially highlighting the role of this isoform in prostate metastasis. In 
contrast, TGF-b1 was ubiquitous across all cell lines investigated, suggesting a minor 
role for this isoform in metastatic changes. Further investigation revealed differences 
in proliferation, migration and invasion between the PCa cell lines in response to TGF-b 
isoforms. While DU145 proliferation was inhibited by TGF-b, PC-3 cells showed no 
response. On the other hand, migration and invasion was increased in PC-3 cells but 
remained unchanged in DU145 cells. These differences may be due to the context of 
the cells and the use of both Smad-dependent and -independent signaling pathways.  
 
Several reports have linked TGF-b in the induction of EMT (epithelial-to-mesenchymal 
transition) associated with cancer development, progression and therapeutic 
resistance (Khan et al., 2015; Montanari et al., 2017). Epithelial cells are known for their 
tight and adherent junctions that restrict them to a defined organization with a basement 
membrane. In contrast, mesenchymal cells are less rigid in structure and more 
migratory (Khan et al., 2015).  The molecular programming that controls this process 
relies on the cooperative action of many pathways and transcription factors. Key 
components are often used as markers to determine whether the morphological and 
cellular changes observed are related to EMT initiation. For example, E-cadherin 
involved in cell junctions is often down-regulated during EMT due to repression of 
transcription and protein phosphorylation and degradation (Tsai and Yang, 2013). 
Another marker is vimentin, an intermediate filament type, which increases in 
expression levels during EMT and PCa metastasis, as shown in the advanced 
metastatic PCa cell lines PC3 and DU145 (Singh et al., 2003). Other proteins which 
are regulators of EMT are Snail and Twist, also used as markers. These proteins are 
known to function directly and indirectly as repressors of E-cadherin expression (Tsai 
and Yang, 2013), in turn inducing a more mesenchymal phenotype. TGF-b signaling 
has been shown to directly alter the transcription of these factors highlighting it as one 
of the main mechanisms for the induction of EMT, and consequently, the transition 
towards metastatic PCa.  
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The overexpression of Nedd4 E3 ligases has been identified as a major mechanism of 
EMT up-regulation in cancer (Soond and Chantry, 2011; Soond et al., 2013). shRNA 
knockdown of WWP2-N appeared to redirect WWP2-FL to target Smad 7 over the 
R-smads 2 and 3 resulting in greater expression of the EMT marker vimentin, 
suggesting greater capacity for differentiation into migratory cancer cells. This was 
supported by analysis of other EMT markers in which the same effects were seen. 
Furthermore, individual WW domain expression of WW1 and WW4, present in all 
isoforms, resulted in inhibited Smad 3-mediated transcription. WW1 alone also reduced 
EMT, observed by decreased vimentin under TGF-β stimulated conditions. This 
indicates the potent effects these individual WW domains of WWP2 can have and why 
they make good targets for drug design. Similar work was carried out by Chong et al. 
(2010), using Smurf 2 WW domains and Smad 7 PY-based peptide. Further work is 
needed into the structural effects and the role these domains could play as biomarkers 
and/or therapeutic agents in PCa and potentially other cancers such as breast and 
melanoma, which also present with dysregulation of TGF-b and Nedd4 E3 ligases. 
 
1.6. PTEN and PI3K/AKT signaling 
Phosphoinositide 3 kinase (PI3K)-AKT signaling is an important pathway for the control 
of many cellular processes such as cell proliferation, differentiation, cellular metabolism 
and apoptosis (Vara et al., 2004; Song et al., 2012). Growth factor binding to its 
respective receptor tyrosine kinase triggers internal phosphorylation of the receptor and 
recruitment of phosphoinositide 3-kinase (PI3K) (Figure 1.7.1). Binding of ligand to G-
protein coupled receptors can also trigger PI3K localization to the plasma membrane. 
PI3K converts phosphatidylinositol-4,5-biphosphate (PI-4,5-P2, also known as PIP2) to 
the triphosphate PI-3,4,5-P3 (PIP3) mediating further signaling via serine/threonine 
protein kinases PDK1 (phosphoinositide-dependent kinase 1) and AKT/PKB 
(previously called protein kinase B). These kinases are essential to the 
activation/inhibition of other proteins leading to growth and apoptosis and are often 
involved in cellular transformation into cancer phenotypes. Hence, understanding the 
regulation of these pathways is important for gaining knowledge of cancerous 
conditions and triggers of cancer formation, as well as for the development of novel 
therapeutics which are greatly required. 
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Figure 1.7.1 - Schematic representation of PI3K/AKT signaling activation  
A simplified diagram showing the PI3K/AKT pathway. Binding of ligand/growth factor (blue 
triangle) to a receptor tyrosine kinase (RTK) or G-protein couple receptor (GPCR) (white 
rectangles) activates the receptors and phosphoinositide 3-kinase (PI3K) (green circle) is 
recruited. PI3K then converts phosphatidylinositol-4,5-biphosphate (PIP2) into 
phosphatidylinositol-3,4,5-triphosphate (PIP3) (purple circles) which then activates the kinases 
phosphoinositide-dependent kinase 1 (PDK1) (orange circle) and protein kinase B (AKT) (red 
circle) for downstream phosphorylation events that control many cellular processes such as 
cellular growth and survival. PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) negatively regulates PI3K activity.  
 
One protein known to regulate PI3K/AKT signaling is PTEN, a phosphatase and tensin 
homologue deleted on chromosome 10. PTEN is 403 residues in length and consists 
of an N-terminal PIP2 binding domain followed by a catalytic phosphatase domain (Brito 
et al., 2015). Next to this resides a phospholipid binding C2 domain, a C-terminal tail 
and finally a PDZ domain. PTEN negatively regulates PI3K/AKT signaling by catalyzing 
the removal of a phosphate group from PIP3 converting it back to PIP2. This results in 
reduced levels of substrate for AKT activation and a decrease in signaling activity (Song 
et al., 2012). The role of PTEN as a negative regulator of AKT signaling has been 
associated with tumour suppressor activity as PTEN loss, often seen in many types of 
cancer (Chen and Matesic, 2007; Fang et al., 2007; Guldberg et al., 1997; Taylor et al., 
2010), leads to constitutive activation of the pathway and uncontrolled cellular growth 
and survival. This is further supported by diseases like Cowden’s syndrome where 
PTEN mutation results in patients developing multiple tumours such as breast, 
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colorectal, kidney, prostate and melanoma (Carnero and Paramio, 2014; He et al., 
2012). Therefore, maintaining levels of PTEN appears to be critical for the regulation 
of normal cellular function.  
 
PTEN is regulated at several stages of its production and activities. Post-translational 
modifications and protein-protein interactions are used to regulate localisation, 
interactions, enzymatic activity and turnover of this phosphatase (Brito et al., 2015; 
Gericke et al., 2006). One key modification is phosphorylation. The C-tail contains 
serine/threonine clusters which are targeted for phosphorylation by kinases such as 
casein kinase 2 (CK2) (Miller et al., 2002) and GSK3 β (Al-Khouri et al., 2005). The 
addition of phosphate groups to the tail results in a more compact conformation 
restricting the access of interaction partners, and also prevents membrane association. 
PTEN activity is predominantly associated with its lipid phosphatase domain so by 
preventing interaction with the plasma membrane or proteins within the membrane, this 
effectively inactivates PTEN. This has also been shown to occur by mutation of the 
PIP2 binding domain (Walker et al., 2004).  
 
PTEN expression levels, cellular localization and activity are also regulated by 
ubiquitination. Both mono- and poly-ubiquitination have been reported to control PTEN 
activity. Wang and colleagues (2007) identified Nedd4 as a PTEN specific E3 ligase. 
In the presence of Nedd4, an increase in PTEN poly-ubiquitination and degradation 
was observed, implicating Nedd4 in PTEN turnover. Furthermore, knockdown of Nedd4 
resulted in increased PTEN levels and decreased phospho-AKT signaling. However, 
further research contradicted Nedd4 as the major regulator of PTEN function and 
degradation (Chen et al., 2016; Chen et al., 2017; Fouladkou et al., 2008). Purification 
of PTEN and its endogenous interaction partners failed to identify Nedd4 but did reveal 
WWP2, another E3 ligase in same family as Nedd4 (Maddika et al., 2011). This may 
be a result of the cellular context; however, it has later been shown that WWP2 is a 
biological interaction partner capable of ubiquitinating PTEN in mouse models (Li et al., 
2018). Increased PTEN levels and decreased PI3K/AKT signaling was observed in 
mouse embryonic fibroblasts derived from WWP2 knockout mice, although PTEN 
mRNA was unaffected. This supports WWP2 as a physiological regulator of PTEN 
activity at the protein level. Further investigations into the activity of WWP2 and Nedd4 
on the function of PTEN revealed that the phosphorylation status of PTEN can control 
the interaction and ubiquitination mediated by Nedd4 E3 ligases (Chen et al., 2016). 
While poly-ubiquitination by Nedd4 on PTEN was unaffected by C-tail phosphorylation, 
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WWP2 mediated poly-ubiquitination was abolished. The phosphorylation of PTEN 
protects the phosphatase from ubiquitination and degradation thereby regulating 
steady state levels of PTEN. The targeting of the active unphosphorylated PTEN by 
WWP2 adds another level of tight control on the system. As for mono-ubiquitination, 
the addition of a single ubiquitin molecule by Nedd4 to PTEN has been shown to 
facilitate transport of PTEN into the nucleus (Trotman et al., 2007). The localization of 
PTEN into the nucleus protects it from cytoplasmic targeting for degradation. 
Additionally, the presence of PTEN in the nucleus has been shown to antagonize AKT 
signaling and in turn trigger apoptosis. However, the localization of Nedd4 in the 
nucleus has also been shown in some cell lines, therefore PTEN mono-ubiquitination 
by Nedd4 may not be an entirely protective mechanism.  
 
1.6.1. PTEN in prostate cancer 
The study of PTEN loss in mouse models has demonstrated that homozygous deletion 
results in an embryonic lethal phenotype. However, mice with a heterozygous genotype 
for the PTEN allele develop several tumours in areas such as the breast and prostate 
(Cristofano et al., 1998). This supports the identity of PTEN as a true tumour 
suppressor protein. With the use of conditional knockout of PTEN, Wang and 
colleagues (2003) showed that complete loss of PTEN not only resulted in prostate 
cancer development, but also significantly increased the invasion capabilities of the 
cancer in turn decreasing the time-frame for metastatic cancer to develop. Additionally, 
the combined inactivation of PTEN and Smad4 in TGF-b signaling, further enhances 
tumourigenesis and drives invasion towards metastatic PCa (Ding et al., 2011). The 
loss of PTEN is also associated with reoccurrence under androgen-independent 
conditions and the resistance to androgen signaling based treatments such as 
abiraterone, an androgen synthesis inhibitor, and enzalutamide, an androgen receptor 
inhibitor (Bitting and Armstrong, 2013). Therefore, understanding the molecular 
regulation of PTEN could prove vital to cancer research into new therapies.  
 
The regulation of PTEN by E3 ligases has been implicated in exacerbating the loss of 
PTEN in the progression of prostate cancer towards metastasis. The incidence of 
WWP2 overexpression, in particular WWP2-N, has been established in primary tumour 
samples of the prostate (Soond et al., 2013). In addition to the identification of WWP2 
as a major regulator of PTEN turnover, and that a reduction in WWP2 leads to 
increased PTEN levels and decreased AKT-mediated cellular survival, this implies that 
WWP2 is an oncoprotein that stimulates the progression of prostate cancer. 
 36 
Additionally, cross-talk between PTEN function and the TGF-b pathway further 
suggests a role of WWP2 in mediating oncogenesis.  
 
1.7. Inhibitors of ubiquitination  
The ubiquitin-proteasome pathway has been of interest in drug discovery for many 
years as it is essential for the regulation of many cellular processes, and dysfunction of 
key members of this pathway have been linked to cancer development (Zhang and 
Sidhu, 2014). Targeting of the proteasome by the small molecule inhibitor Bortezomib 
showed some success in the treatment of myeloma and other cancers and was found 
to be fairly selective to cancerous over non-cancerous cells (Orlowski et al., 2002; 
Richardson et al., 2005; Zhang and Sidhu, 2014). However, by inhibiting the 
proteasome which acts to degrade many different cellular components, there is little 
specificity in the pathways affected and this results in many non-specific side effects. 
To this end, focus was directed towards other components of the ubiquitination cascade 
with the aim of increasing selectivity and effectiveness. Research into Uba1 activity 
revealed an inhibitor called PYR-41 that blocked the cysteine residue of Uba1 (Yang et 
al., 2007). In doing so, a decrease in the total ubiquitinated protein level was detected 
suggesting that perhaps E1 inhibition may not be an ideal target either on the basis that 
only two E1 enzymes function in humans in the activation and transfer of ubiquitin to 
many E2-conjugating enzymes. Similarly, the interaction of a single E2 enzyme with 
many E3 ligases further suggests that inhibitors of ubiquitination should be designed 
for the more selective E3 ligases in order to target particular pathways. 
 
The role of E3 ligases in cancer development and progression has led to increasing 
interest for drug discovery. The first group of active inhibitors against E3 ligases were 
the nutlins (Zhao et al., 2015). These compounds were shown to be very potent with 
IC50 values in the low micromolar and nanomolar range and specific to the RING E3 
ligase Mdm2 often over expressed in human cancers. Nutlins block the ubiquitination 
and degradation of the important tumour suppressor protein p53, in turn triggering cell 
cycle arrest and/or apoptosis. This opened up the field of inhibitor discovery against E3 
ligases due to the increasing evidence of over-expression in cancer. Nedd4 E3 ligases 
have also been promising targets in cancer therapy based on the selective binding by 
WW domains. This is supported by many HECT E3 ligases being over expressed in 
cancer cells (Komuro et al., 2004; Soond and Chantry, 2011; Soond et al., 2013). The 
high expression of these proteins promotes resistance to growth inhibition, increased 
proliferation and metastatic transition. However, few inhibitors of HECT E3 ligases have 
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currently been discovered. In 2014, the identification of bicyclic peptides and a small 
molecule inhibitor revealed that HECT E3 ligases could in fact be targets for novel 
therapeutics (Mund et al., 2014). The bicyclic peptides were found to interact with the 
HECT domains of Smurf 2, Nedd4 and WWP1 at the E2-binding site, thereby blocking 
E2~Ub access and inhibiting the ubiquitination activity of these ligases. This supports 
the idea that peptide design could be used for reducing the activity of these ligases, 
however further work into this aspect of therapy design is required. As for the small 
molecule inhibitor in this work, Heclin was found to inhibit the ubiquitination activity of 
several Nedd4 E3 ligases, including WWP2, at 100 µM, by altering the oxidation state 
of the cysteine residue in the HECT domain rather than blocking the E2~Ub binding 
site. Research by another group also identified an already established anti-depressant 
drug, clomipramine, as an inhibitor of the Nedd4 E3 ligase Itch (Rossi et al., 2014). This 
was also shown to inhibit the thiolation reaction with the cysteine residue of HECT. 
Alternative to the catalytic cysteine being the sole site of inhibition, work by Kathman 
and colleagues (2015) discovered a covalent inhibitor of Nedd4-1, which blocked a 
non-catalytic cysteine (C627) residue associated with ubiquitin chain formation located 
in the N-lobe previously identified by Maspero et al. (2011) as a non-covalent 
ubiquitin-binding exocite. Other HECT E3 ligases such as Itch, WWP1 and WWP2 
showed no inhibition by compound 3, thought to be due to the absence of this cysteine 
residue at the equivalent position, highlighting potential in generating selective Nedd4 
family member specific inhibitors. Interestingly, while they lack a non-catalytic cysteine 
at the same position, these three ligases contain a cysteine residue 10 amino acids 
upstream from this position, providing a potential site for an equivalent processive 
mechanism and potential inhibitor binding site, although this has yet to be uncovered. 
Another research group later identified other indole-based compounds as potent 
inhibitors of Nedd4 (Quirit et al., 2017). Indole-3-carbinol and analogues showed 
inhibition of Nedd4 polyubiquitination activity with IC50 values ranging from 10-100s in 
micromolar. These inhibitors were also identified as binders of the HECT domain, 
further highlighting this region as a predominant site for current inhibitory activity. The 
different methods of discovery and mechanisms of action by these inhibitory molecules 
highlights the different possible ways in which the activity of these ligases can be 
inhibited, and further investigations could reveal a whole new group of therapeutics. In 
particular, there is potential for the discovery of inhibitors which act outside of the 
catalytic HECT domain to potentially inhibit selective interactions with substrates, 
although such inhibitors have yet to be developed. 
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1.8. Thesis Aims 
Current knowledge of Nedd4 E3 ligase structure and function has been discussed in 
this chapter, with focus on TGF-b signaling and PTEN regulation of PI3K/AKT signaling. 
Both of these pathways undergo regulation by the E3 ligase WWP2. The 
overexpression of WWP2 has been associated with the initiation and progression of 
prostate cancer, thereby acting as an oncoprotein for the increased ubiquitination and 
degradation of Smad proteins and PTEN. Accumulating evidence is supporting this 
ligase as a potential target for novel therapeutics in prostate cancer. The presence of 
discrete binding modules within WWP2 presents an ideal drug design site, however 
information about the mechanisms of substrate binding and the selectivity of these 
domains is still lacking. Additionally, the catalytic activity located in the HECT domain 
provides another site of potential inhibition that could be manipulated in drug discovery 
to abolish the ubiquitination activity of this ligase.  
 
The overall aim of this project is to utilize both structural and screening-based 
approaches for the discovery of WWP2 inhibitors as potential novel therapeutics for 
future use in prostate cancer treatment. In order to design peptidomimetics to interfere 
in the selective WW domain interactions with substrates, NMR analysis will be used to 
uncover the structure of WW4 in WWP2 that is a key interaction site for the inhibitory 
Smad 7 protein. Furthermore, while Smad protein interactions with WW4 have been 
investigated, little is known about Smad binding to the other WW domains. In 
conjunction with the significant role WWP2 plays in Smad protein and PTEN turnover 
in prostate cancer, interaction analysis using pull-downs will attempt to look at WWP2 
isoform binding to PTEN, and NMR titrations using Smad peptides containing the PPxY 
motif will be carried out with WW1 and tandem domain WW1-2 with the aim of 
uncovering the atomic aspects of Smad protein interactions. The alternative approach 
of small molecule screening will also be used to identify drug-like compounds that are 
capable of inhibiting WWP2 enzymatic activity, with counter screening against other 
members of the ubiquitination pathway and Nedd4 family of E3 ligases to determine 
the selectivity of any hit compounds. Collectively, this work hopes to advance research 
into the structure-function relationship of WWP2 and to progress the development of 
novel treatments towards WWP2 in particular, of which inhibitors are currently lacking.  
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2. Material and Methods 
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2.1. DNA-based procedures 
2.1.1. Plasmids and primers 
Tables 2.1.1 and 2.1.2 list all the plasmids used throughout this project along with the 
source or method of synthesis. Primers used in this work are listed in Table 2.1.3. 
Plasmid Origin 
pRK5-FLAG-WWP2-FL 
pRK5-FLAG-WWP2-N 
pRK5-FLAG-WWP2-C 
pRK5-HA-WWP2-FL 
pRK5-HA-WWP2-WW1-2 
pRK5-HA-WWP2-WW3-4 
pRK5-HA-Smad 2 
pRK5-Smad 3-N-GFP 
pSKDuet01-GB1-WW1-2 
pOPINf-WWP1 
pGEX2T-PTEN 
 
pGEX2T-PTEN 1-274 
 
pGEX2T-PTEN ∆274-342 
 
pRK5-HA-Ubiquitin 
 
pET3a-hUBA1-CtermHis 
 
pET3a-UbcH7-CtermHis 
pGEX4T-1-UbcH7a 
pGEX4T-1-hE1 (Uba1) 
pGEX-5X3-Nedd4-FL 
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab  
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab 
Available in Dr Andrew Chantry’s lab 
Gifted by William Sellers (Addgene plasmid 
#10784 – 803) 
Gifted by William Sellers (Addgene plasmid 
#10741 – 821) 
Gifted by William Sellers (Addgene plasmid 
#10739 – 824) 
Gifted by Ted Dawson (Addgene plasmid 
#17608) 
Gifted by Titia Sixma (Addgene plasmid 
#63571) 
Gifted by Prof Martin Scheffner 
Gifted by Dr Arthur L Haas lab 
Gifted by Dr Arthur L Haas lab 
Gifted by Shiaw-Yih Lin (Addgene plasmid 
#45043) 
Table 2.1.1 - Summary of plasmid names and sources.  
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Plasmid Cloning technique 
pSKDuet01-GB1-WW1 
pGEX2T-PTEN 1-100  
pGEX2T-PTEN 1-185 
pGEX2T-PTEN 1-350 
pGEX2T-PTEN 1-400 
pET21d-SUMO-Smad 2 
pET21d-SUMO-Smad 3 
pGEX2T-WWP2-C 
pGEX2T-WWP2-FL 
pGEX2T-WWP2-CC399A 
pGEX2T-WWP2-FLC838A 
In-fusion  
QuikChange mutagenesis 
QuikChange mutagenesis 
QuikChange mutagenesis 
QuikChange mutagenesis 
In-fusion 
In-fusion 
In-fusion 
In-fusion 
QuikChange mutagenesis 
QuikChange mutagenesis 
Table 2.1.2 - Summary of plasmids cloned during this work and the method used. 
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PCR 
product 
Vector Primers 5’ – 3’ 
WW1 
 
PTEN  
1-100a/b 
PTEN  
1-185a/b 
 
PTEN  
1-350a/b 
PTEN  
1-400a/b 
Smad 2 
 
Sm2 p1 
 
Sm3 p1 
 
Sm2 p2 
Sm3 p2 
WWP2-C 
 
WWP2-
CC399Aa/b 
WWP2-
FL 
WWP2-
FLC838A 
a/b 
pSKDuet-
01(GB1) 
pGEX2T 
 
pGEX2T 
 
 
pGEX2T 
 
pGEX2T 
 
pGEX4T 
 
pET21d 
 
pET21d 
 
pET21d 
pET21d 
pGEX2T 
 
pGEX2T 
 
pGEX2T 
 
pGEX2T 
F - cgtaacggaaggatcccaggcccccgacgctct 
R - atgcggccgcaagcttttaccgctcccaggtggtggtctt 
caagatcttcacaaaagggtcagataagttctagctgtggtggg 
cccaccacagctagaacttatctgacccttttgtgaagatcttg 
gaaacaacagtgccactggtctataatctcaatgattctttaacaggtagctataa-
taa 
ttattatagctacctgttaaagaatcattgagattatagaccagtggcactgttgtttc 
tgacggctcctctcatgtttttgtgaagtacagcttcacc 
ggtgaagctgtacttcacaaaaacatgagaggagccgtca 
gatgaattctcagacttttcaaatttgtgtatgctgatcttcatcaaaaggttc 
gaaccttttgatgaagatcagcatacacaaatttgaaaagtct-gagaattcatc 
F - gctagcatgtcgtccatcttgcca 
R - gaattcaaatgcaggttctgagta 
F - gaacagattggaggtccacagagtaattatattcc 
R - gctcgaattcggatccttattctccatcttcactgatat 
F - gaacagattggaggtccccagagcaatattccaga 
R - gctcgaattcggatccttattctccatcttcactcaggt 
F - gaacagattggaggtattgagccacagagtaat 
F - gaacagattggaggtatcgagccccagagcaatatt 
F - gttccgcgtggatccatgatccaggaaccagct 
R - agtcacgatgaattcttactcctgtccaaagcc 
tccagacggttgaaggcggtgtggcttctggg 
cccagaagccacaccgccttcaaccgtctgga 
F - gttccgcgtggatccatggcatctgccagctct 
R - agtcacgatgaattcttactcctgtccaaagcc 
Same mutagenesis primers as WWP2-CC399Aa/b 
Table 2.1.3 - Summary of primers used in plasmid cloning and mutagenesis.  
Sm2 – Smad 2; Sm3 – Smad 3; p1 – peptide 1; p2 – peptide 2. 
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2.1.2. Phusion PCR  
Phusion polymerase reactions were set up as described in Table 2.1.4 per the 
manufacturer’s protocol (Thermo Fisher #F-530S). Cycling conditions used are 
described in Table 2.1.5. The reaction products were analysed by 1% agarose gel 
electrophoresis run at 100 V using SYBR safe (Invitrogen) for 1 hour (hr) or until the 
dye front was ~0.5 cm from the gel end. Gels were imaged using BIORAD Geldoc+ 
and Imagelab (BIORAD). 
Component 20 μL rxn 100 μL rxn Final conc. 
Sterile nuclease free H2O 
5X Phusion HF buffer 
10 mM dNTPs 
Forward primer (10 μM) 
Reverse primer (10 μM) 
Template DNA 
Phusion DNA polymerase 
Add to 20 μL 
4 μL 
0.4 μL 
1 μL 
1 μL 
0.25 μL 
0.2 μL 
Add to 100 μL 
20 μL 
2 μL 
5 μL 
5 μL 
1.25 μL 
1 μL 
- 
1 X 
200 μM of each 
0.5 μM 
0.5 μM 
- 
0.02 U/μL 
Table 2.1.4 - Components used for both small and large-scale phusion reactions (rxn). 
HF - high fidelity; dNTPs – deoxyribonucleic acid triphosphates; conc – concentration; U - units. 
Cycle step Temperature (°C) Time No. of cycles 
Initial denaturation 
Denaturation 
Annealing 
Extension 
Final extension 
98 
98 
Based on primer Tm 
72 
72 
4 
30 s 
7.5 s 
20 s 
15 s/kb 
7.5 min 
Hold 
1 
1 
30 
1 
1 
Table 2.1.5 - Cycling conditions used for phusion reactions.  
Tm – melting temperature; kb – kilobases; s - seconds; min - minutes. 
2.1.3. DNA gel extraction 
QIAgen QIAquick gel extraction kit was used according to the manufactures protocol. 
DNA was eluted in 50 μL elution buffer provided and stored on ice or at -20 °C until 
required. 
2.1.4. In-fusion  
In-fusion reactions were set up as described in Table 2.1.6 Reactions were mixed and 
incubated at 50 °C for 15 min, then placed on ice according to the In-fusion HD cloning 
kit manual (Takara Bio Clontech). 2.5 μL reaction mix was transformed into Stellar 
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competent cells using the protocol provided by the manufacturer with the cells 
(Clontech, Takara Bio). 
Component 10 μL rxn 
Sterile nuclease free H2O 
Purified PCR product 
Linear vector 
5x In-fusion HD enzyme premix 
Add to 10 μL 
50 – 100 ng 
50 – 100 ng 
2 μL 
Table 2.1.6 - Components used for a single reaction (rxn) mix. 
2.1.5. Restriction digest 
Under sterile conditions, all components described in Table 2.1.7 were mixed and 
incubated at 37 °C for 1-4 hrs. 6x agarose loading dye (Invitrogen) was added to each 
sample and analysed by 1 % agarose gel electrophoresis.  
Component 20 μL rxn 
Sterile nuclease free H2O 
10 x Enzyme buffer 
BSA (1 mg/mL) 
Plasmid DNA 
Enzyme(s) - total 
Add to 20 μL 
2 μL 
2 μL 
1-2 μL 
1 μL 
Table 2.1.7 - Restriction digest reaction components per 20 μL reaction (rxn). 
BSA – bovine serum albumin. 
2.1.6. QuikChange mutagenesis 
Samples were prepared according to the protocols provided with the QuikChange 
mutagenesis kit (Agilent Technologies). Table 2.1.8 summarizes the components used 
in each reaction, and primers are described in Table 2.1.3. The reaction mix was 
transformed into XL-10 Gold cells as described in the manufacturer’s protocol provided 
with the kit.  
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Component 50 μL rxn 
dH2O 
10 x reaction buffer 
Template DNA 
Oligo primer a 
Oligo primer b 
dNTP mix 
QuikSolution 
Add to 50 μL 
5 μL 
10 ng 
125 ng 
125 ng 
1 μL 
3 μL 
Table 2.1.8 - Component volumes used for a single mutagenesis reaction (rxn).  
2.1.7. Heat shock transformation 
Preparations of lysogeny broth (LB; per litre: 25 g high salt LB granules (Thermofisher; 
10g peptone, 5 g yeast extract and 10 g NaCl)) and LB-agar (LB with 3 % agar) were 
made and autoclaved in advance. 50-100 μL competent cells were aliquot into pre-
chilled micro-centrifuge tubes. 10 ng – 1 μg plasmid DNA/cloning reaction was added 
and gently mixed. After 30 min incubation on ice, samples were heat shocked for 45 
seconds at 42 °C using a water bath followed by 10 min incubation on ice. 0.3 mL LB 
was added and the tubes incubated for 45-60 min at 37 °C and 180 rpm. 100-200 μL 
transformation mixture was spread onto LB agar plates containing the appropriate 
antibiotics (final working concentrations: kanamycin – 50 µg/mL; ampicillin – 100 
µg/mL; chloramphenicol – 25 µg/mL). Plates were then incubated overnight at 37 °C.  
2.1.8. Plasmid purification 
Colonies were picked and used to inoculate antibiotic-containing LB and grown 
overnight at 37 °C. QIAgen spin miniprep kit, QIAgen plasmid plus midi kit and 
Nucleobond xtra maxi kit were used, dependent on DNA yield required, using the 
reagents and protocols provided in the kits. DNA was eluted in elution buffer provided 
in the kit or TE buffer (10 mM Tris-Cl pH 8, 1 mM EDTA pH 8). DNA concentration was 
determined using Thermo Scientific NanoDrop spectrophotometer. Sequencing was 
carried out to confirm plasmid DNA was correct, using Eurofins Genetics value read 
tube service. 
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2.2. Protein-based procedures 
2.2.1. Recombinant protein expression - unlabelled  
Plasmids were transformed into an E.coli BL21-derived cell line and spread onto LB 
agar plates, and grown overnight at 37 °C. Under aseptic conditions, a single colony 
was picked and used to inoculate 10 - 20 mL of antibiotic-containing LB, then incubated 
overnight at 37 °C and 180 rpm. Overnight cultures were used to inoculate 50 mL - 2 L 
antibiotic-containing LB at 1 in 50 dilutions and grown at 37 °C and 180 rpm until an 
OD600 of 0.6 - 0.8 was reached. 1M IPTG (isopropyl β-D-1-thiogalactopyranoside) stock 
was used to induce the cultures at the concentrations and growth conditions described 
in Table 2.2.1.  
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Plasmid Cell line  Antibiotic IPTG 
conc. 
(mM) 
Temp. 
(°C) 
Time 
pGEX2T-PTEN 
 
pGEX2T-PTEN 1-274 
pGEX2T-PTEN 
∆274-342 
pGEX2T-PTEN 1-100 
pGEX2T-PTEN1-185 
pGEX2T-PTEN1-350 
pET21d-SUMO- 
Smad 2 
pET21d-SUMO- 
Smad 3 
pGEX2T-WWP2-
C/CC399A 
pGEX2T-WWP2-
FL/FLC838A 
pET3a-UbcH7 
pET3a-hUBA1 
pGEX4T-1-UbcH7a 
pGEX4T-1-hE1 (Uba1) 
pOPINF-WWP1-FL 
BL21 (DE3)/ 
Rosetta2 pLysS 
Rosetta2 pLysS  
Rosetta2 pLysS  
 
Rosetta2 pLysS 
Rosetta2 pLysS 
Rosetta2 pLysS 
Codon Plus RP 
 
Codon Plus RP 
 
Rosetta2 pLysS 
  
Rosetta2 pLysS 
  
Codon Plus RP  
BL21 (DE3)  
BL21 (DE3)  
BL21 (DE3) 
Codon Plus RP 
Amp/Amp & 
Cam 
Amp & Cam 
Amp & Cam 
 
Amp & Cam 
Amp & Cam 
Amp & Cam 
Amp & Cam 
 
Amp & Cam 
 
Amp & Cam 
 
Amp & Cam 
 
Amp & Cam 
Amp 
Amp 
Amp 
Amp & Cam 
0.75 
 
0.75 
0.75 
 
0.75 
0.75 
0.75 
0.75 
 
0.75 
 
0.75 
 
0.75/0.5 
 
1.0 
1.0 
0.4 
1.0 
0.5 
30/16 
 
30 
30 
 
33 
30 
30 
33 
 
33 
 
33 
 
30/16 
 
25 
25 
20 
25 
16 
O/N 
 
O/N 
O/N 
 
O/N 
O/N 
O/N 
O/N 
 
O/N 
 
O/N 
 
O/N 
 
4hrs 
O/N 
O/N 
O/N 
O/N 
Table 2.2.1 - Protein expression conditions used for different plasmids.  
Amp – ampicillin; Cam – chloramphenicol; IPTG -isopropyl β-D-1-thiogalactopyranoside; O/N – 
overnight.  
2.2.2. Recombinant protein expression - labelled 
In advance, unlabelled M9 salts (per litre: 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g 
NH4Cl, pH7-7.4) and 15N-labelled M9 salts (per litre: 6 g Na2HPO4, 3 g KH2PO4, 0.5 g 
NaCl, 1 g 15N-NH4Cl, pH7-7.4) were made and autoclaved. Heat shock transformation 
of pSKDuet01-GB1-WW1 and pSKDuet01-GB1-WW1-2 into BL21 (DE3) Star was 
carried out as described in section 2.1.7. A single colony was picked from the 
LB-kanamycin agar plates to inoculate 10 mL LB-kanamycin. The starter culture was 
incubated overnight at 37 °C and 180 rpm. 8 mL of overnight culture was used to 
inoculate 100 mL of unlabelled minimal media plus supplements (final concentrations: 
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2 mM MgSO4, 10 μM CaCl2, 0.1 mM FeSO4 (from a stock made fresh), 0.2 % (w/v) 
glucose, 0.1 % vitamins solution (SIGMA M6895), 0.1 % micronutrients (1000 x stock: 
3 μM (NH4)2MoO4, 4 μM H3BO3, 30 μM CaCl2, 10 μM CuSO4, 80 μM MnCl2, 10 μM 
ZnSO4)) and left to grow at 37 °C, 180 rpm, until saturation. The starter culture was 
centrifuged at 4300 x g for 20 min at 22 °C and the supernatant discarded. The pellet 
was resuspended in 10 mL 15N-labelled minimal media, plus supplements at the same 
final concentrations as above, and added to each 500 mL 15N-labelled minimal media. 
Double-labelled 13C-15N media was made and used in the same way except 2 g/L 
13C-glucose was used.  Large-scale cultures were incubated at 37 °C until an OD600 
0.6—0.8 was reached. Cultures were induced with 1 M IPTG at a final concentration of 
0.75 mM and incubated at 30 °C and 180 rpm overnight. Cultures were centrifuged at 
4300 x g 4 °C for 20 min. The supernatants were discarded, and pellets stored at -80 °C 
until required. 
2.2.3. Cell lysate preparation 
Cell pellets were resuspended in appropriate buffers and sonicated on ice at 70-80 % 
amp for pulses of 2 sec on 1 sec off for a total of 2 min (Sonics Vibracell VCX 130). 
This was repeated 3-6 times with incubations on ice in between to prevent over-heating 
of the suspensions. Cell suspensions were then centrifuged either at 18 krpm 4 °C for 
45 min (Beckman, JA-20 rotor) or at 4300 x g 4 °C for 30 min (Heraeus Megafuge 
1.0R). Supernatants were decanted into a centrifuge tube for further purification and 
the pellet discarded. Samples were taken of the whole, insoluble and soluble fractions 
for SDS-PAGE analysis.  
2.2.4. Protein purification methods 
All buffers used in the following methods were filtered with either a 0.44 μm or 0.22 μm 
sterile filter.  
2.2.4.1. Nickel NTA  
Cell lysates were prepared as described in section 2.2.3 using Ni-NTA binding buffer 
(20 mM Na2HPO4, 0.5 M NaCl, 30 mM imidazole pH 7.4) and placed on ice until 
required. HisTrap FF 1mL and 5 mL columns (GE Healthcare) were used, according to 
the protocol provided with the columns, with 300 mM imidazole in the elution buffer 
(20 mM Na2HPO4, 0.5 M NaCl, 300 mM imidazole). The flow-through during sample 
loading, wash and manual elution were collected. Aliquots were taken for SDS-PAGE 
analysis. For the purification of His-GB1-WW1 and His-GB1-WW1-2, the ÄKTA-FPLC 
purification system was used for elution using a linear gradient of imidazole from 30 mM 
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to 300 mM at 1-5 mL/min flow-rate. 2-5 mL fractions were collected, and aliquots taken 
for SDS-PAGE analysis.  
2.2.4.2. Protein tag cleavage 
His-GB1-WW1 and His-GB1-WW1-2 were dialysed overnight at room temperature into 
Tris-Cl buffer (25 mM Tris-Cl pH 8, 0.5 M NaCl) using 7 kDa MWCO snakeskin dialysis 
tubing (Thermo Fisher). His(6x)-tag was cleaved off using thrombin (Thermo Fisher) at 
2 U/mg of protein, added to the dialysis sample. The samples were transferred to 
centrifuge tubes to continue digesting until 90-100 % digestion was achieved as 
determined by SDS-PAGE analysis. His-SUMO-Smad 2 and Smad 3 peptides were 
cleaved using His-SUMO protease (Invitrogen) at 1 U/mg or His-ULP-1 at 0.5:60 in 
Tris-Cl buffer as described above. Samples were analysed by SDS-PAGE. 
GST-tagged UbcH7 and GST-WWP2-FL were digested via on-column digestion 
overnight at 4 °C using a GSTrap FF 1 mL column (GE Healthcare) loaded with PBS 
(10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 137 mM NaCl pH 7.4) containing 10 
U/mL thrombin.  
2.2.4.3. Benzamidine 
Benzamidine resin (GE healthcare) was used for the removal of thrombin from 
GB1-WW1, GB1-WW1-2 and UbcH7 digestion samples. A gravity flow column was 
made with a 2 cm bed of resin. The column was washed with 5 column volumes dH2O 
and equilibrated with 5 column volumes PBS. The digest sample salt concentration was 
increased from 137 mM NaCl to 0.5 M then loaded onto the column. The flow-through 
was collected and the column washed with 5 column volumes high-salt PBS (10 mM 
Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 0.5 M NaCl pH 7.4). After the wash was 
collected, any bound proteins were eluted using elution buffer (50 mM glycine pH 3.0) 
into a centrifuge tube containing Tris-Cl pH 7.4 to prevent pH induced protein 
denaturation in case protein of interest was bound to the column. Samples were taken 
for SDS-PAGE analysis. 
2.2.4.4. Size exclusion chromatography 
A HiLoad 16/200 Sepharose S75 gel filtration column (GE Healthcare) was attached to 
the ÄKTA-FPLC system and washed with 2 column volumes of dH2O. The column was 
equilibrated with gel filtration buffer (50 mM Tris, 150 mM NaCl pH 7.5). After 
concentration of the protein sample to 2 mL, using a 5 kDa cut-off Vivaspin 20 
concentrator at 4300 xg 4 °C, the sample was loaded into the ÄKTA sample loop and 
loaded onto the column. A total of 120 mL buffer was run through the column at 
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1 mL/min and 2 mL fractions collected. Aliquots of alternate fractions were analysed by 
SDS-PADE to determine the cleanest fractions to be pooled and dialysed. 
2.2.4.5. Glutathione-GST  
Cell lysates were prepared as described in section 2.2.3 using PBS or PBS with 
protease inhibitors (Invitrogen). GST-tagged proteins were either purified using GSTrap 
FF 1 mL columns (GE healthcare) or by batch purification using glutathione sepharose 
4B resin (GE healthcare). Protocols provided by the manufacturer were followed. 
Samples were taken of the flow-through, wash and elution for the column method and 
an aliquot was taken of the beads from batch purification for SDS-PAGE analysis.  
2.2.5. GST-pull down assay 
PTEN coated beads were made as described in section 2.2.4.5 using 200 μL of 50 % 
glutathione bead slurry in PBS, with the PTEN proteins retained on the beads. 
~5-100 μL of the slurry was used per reaction, based on protein expression and binding 
as analysed by SDS-PAGE. 50 μL cell lysate containing HA-tagged WWP2-FL (full 
length), WWP2-N (N-terminal C2 and WW1), WWP2-C (C-terminal HECT and WW4), 
WW tandem domain 1-2 or WW 3-4 was added, and the mixture incubated for 1 hr at 
4 °C. Samples were centrifuged at 5000 rpm for 30 secs – 1min to pellet the beads. 
The supernatant was removed, and the beads washed 4-6 times with PBST (PBS 
containing 0.1 % Tween). 2x Laemmli (125 mM Tris, 4 % (w/v) SDS, 20 % (v/v) glycerol, 
0.01 % (w/v) bromophenol blue 100 mM DTT pH 6.8) was added and the samples 
heated at 100 °C for 3 min to elute and denature the proteins. Samples were analysed 
by SDS-PAGE and Western blot. 
2.2.6. SDS-PAGE  
2.2.6.1. Tris-glycine gels 
Tris-glycine resolving and stacking gels were made using the components described in 
Table 2.2.2. APS and TEMED were added last, gently mixed in and the solution poured 
between glass plates to produce a gel of 1.5 mm thickness with 8 or 15 wells. Gels 
were stored in SDS-PAGE running buffer (25 mM Tris base, 190 mM glycine, 0.1 % 
SDS, pH 8.3) at 4 °C until required, for a maximum of 2 weeks. Equal volume of 
2x Laemmli buffer was added to each sample and heated for 3 min at 100 °C. Samples 
were analysed by 10-15 % SDS-PAGE, set up as per manufacturer’s instructions for 
BIORAD mini-protean tetra system in SDS-PAGE running buffer for 60 min at 180 V or 
until the dye front reached the bottom. The gel was stained with Instant Blue 
(Expedeon) for a minimum of an hour and imaged using epiwhite light imager. Broad 
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range SDS-PAGE molecular weight standard (BIO-RAD, Catalogue no. 161-0317) was 
used for molecular weight analysis. 
Component Resolving gel Stacking gel 6 
% 10 % 15 %  
dH2O 
37.5:1 40 % (w/v) Acrylamide 
1.5 M Tris pH 8.8 
0.5 M Tris pH 6.8 
10 % (w/v) SDS 
10 % (w/v) APS 
TEMED 
7.7 mL 
4 mL 
4 mL 
- 
160 μL 
160 μL 
16 μL 
5.7 mL 
6 mL 
4 mL 
- 
160 μL 
160 μL 
16 μL 
5.8 mL 
1.5 mL 
- 
2.5 mL 
100 μL 
100 μL 
10 μL 
Table 2.2.2 - Gel components and volumes per 2 gels at 1.5 mm thickness. 
SDS – sodium dodecyl sulphate; APS – ammonium persulphate; TEMED -  
tetramethylethylenediamine. 
2.2.6.2. Tricine gels 
Tricine gels were used for resolution of low molecular weight proteins such as peptides. 
Gels were made using the same protocol as described in section 2.2.6.1 using the 
components described in Table 2.2.3 at both 1.5 mm and 0.75 mm thickness. Gels 
were run as described in the manufacturer’s instructions for BIO-RAD mini-protean 
tetra system (BIO-RAD) using upper cathode buffer (1 M Tris, 1 M Tricine and 1 % SDS 
pH 8.25) and lower anode buffer (2.1 M Tris pH 8.9). Gels were stained using silver 
staining. 
Component Resolving gel Stacking gel 6 % 
dH2O 
19:1 40 % (w/v) Bis-Acrylamide 
Gel buffer  
(3 M Tris-Cl pH 8.45, 0.3 % SDS) 
70 % Glycerol 
10 % (w/v) APS 
TEMED 
3.1 mL 
5 mL 
5 mL 
 
2 mL 
66.5 μL 
6.6 μL 
6.72 mL 
1.06 mL 
2.5 mL 
 
- 
80 μL 
8 μL 
Table 2.2.3 - Components and volumes used for making 2 tricine gels at 0.75 mm 
thickness. 
APS – ammonium persulphate; TEMED – tetramethylethylenediamine. 
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2.2.6.3. Silver staining 
Tricine gels were fixed for 30 min using a solution of 40 % methanol and 10 % acetic 
acid. The gels were then incubated for 10 min in 5 % methanol followed by 10 min in 
DTT solution (0.4 μM DTT in dH2O). Gels were then very briefly coated in dH2O and 
the water drained off. 0.1 % AgNO3 solution was added and incubated for 10 min. Gels 
were washed again in dH2O for 5-10 sec three times before developing solution wash 
added (7.5 g Na2CO3, 250 mL dH2O, 125 μL formaldehyde). The reaction was stopped 
using solid citric acid when the peptide bands appeared.  
2.2.7. Western blotting 
Samples were prepared and separated using a 10/15 % polyacrylamide gel as 
described above. The proteins were transferred onto 0.2 μm nitrocellulose membrane 
(BIORAD) using the Abcam protocol for a wet transfer. The transfer was run for 60 min 
at 100 V in transfer buffer (25 mM Tris base, 190 mM glycine, 20 % methanol). 0.1 % 
Ponceau S (0.1 % (w/v) in 5 % acetic acid) was used to check for protein presence and 
the blots then washed with TBST (Tris buffered saline-tween) (140 mM NaCl, 3 mM 
KCl, 25 mM Tris pH 7.4, 0.1 % Tween-20). The membranes were blocked with blocking 
buffer (3 % BSA (bovine serum albumin), 0.01 % sodium azide, TBST) for 1 hr at 4 °C 
with agitation before incubation in primary antibody solution, described in Table 2.2.4, 
overnight at 4 °C with agitation. After incubation and three TBST washes, secondary 
antibody diluted 1 in 10,000 in TBST was incubated with the blots for 1 hr at room 
temperature with agitation. After three TBST washes, the blot was developed by ECl 
chemiluminescence (Amersham ECl primer Western blotting detection reagent, GE 
Healthcare) according to the kit protocol. Amersham hyperfilm ECL high performance 
ECL film (GE Healthcare) was used and hand developed using Kodak film developer 
and fixer in a dark room. Conjugated primary antibodies were only incubated at room 
temperature for 1 hr before washing and development.  
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Antibody Dilution and buffer Source 
Anti-GST (mouse) 
Anti-HA (rat) 
Anti-Flag (mouse) 
Anti-6xHis-HRP 
Anti-streptavidin-HRP 
Anti-Flag-HRP 
Anti-mouse 
Anti-rat 
1 in 2000 
1 in 1000 
1 in 10,000 
1 in 20,000 
1 in 10,000 
1 in 10,000 
1 in 10,000 
1 in 10,000 
Thermo Fisher 8-326 
Sigma Clone3F10 
Sigma F3165 
Abcam Ab1187 
Thermo Fisher N100 
Sigma A8592 
Sigma A4416 
Sigma A5795 
Table 2.2.4 - Summary of antibodies, dilutions and source used. 
GST – glutathione S transferase; HA – human influenza hemagglutinin-derived tag; HRP – 
horse radish peroxidase. 
2.2.8. Glutathione plate coating 
Clear 96 well plates were incubated overnight at 4 °C with 50 µL of 2% (w/v) 
haemoglobin in 50 mM Na2CO3. Plates were then washed 4-6 times with PBS, 
incubated for 1 hr at room temperature in 50 µL 0.1 mM SSMPB (sulpho-succinimidyl 
4-(p-maleimidophenyl) butyrate) (Thermo Fisher) in PBS, washed a further 4 times with 
PBS then incubated overnight in 10 mM reduced glutathione solution (10 mM reduced 
glutathione, 10 mM Na2HPO4, 0.15 M NaCl, 1 mM EDTA pH 6.7). Plates were washed 
4 times and then stored in PBST at 4 °C. 
2.2.9. In vitro auto-ubiquitination assays 
All incubations were carried out at room temperature unless otherwise stated.  
2.2.9.1. Glutathione bead auto-ubiquitination assay 
100 μL 50 % glutathione sepharose 4B resin was washed with PBS to remove storage 
ethanol then incubated on a tube rotator (Labinco SH010) for 1 hr at 4 °C with 5 mL 
cell lysate containing either GST-WWP2-C or GST-WWP2-CC399A. Tubes were 
centrifuged at 600 x g 4 °C for 1 min to pellet the beads. The supernatant was 
discarded, and beads washed 3 times with PBST. 50 ng Uba1 (E1), 240 ng UbcH7 
(E2) and 5 μg biotinylated-ubiquitin was added to 10 μL bead samples to a total volume 
of 60 μL in ubiquitination buffer (50 mM Tris pH 7.5, 2 mM ATP, 5 mM MgCl2, 
2 mM DTT). For heclin samples, concentrations ranged from 6 – 100 μM with a total 
volume of 60 μL. Beads were incubated for 1 hr then washed using PBST. Samples 
were eluted from the beads using 2x Laemlli buffer and heating at 100 °C for 3 min. 
Samples were then analysed by SDS-PAGE and Western blotting using 
anti-streptavidin-HRP at a 1 in 10,000 dilution in TBST. 
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2.2.9.2. GST-WWP2 auto-ubiquitination assay 
Storage PBST buffer was removed and plates tapped dry prior to assay set up. After 
each incubation plates were washed 3 times with PBST and tapped dry. 50 μL cell 
lysate containing GST-tagged WWP2 was incubated on glutathione coated plates for 
1 hr. During plate incubation, 5-20 ng/well His-E1, 120-200 ng/well His-E2, 100 ng/well 
Flag-ubiquitin and 1.25 mM ATP were mixed together in ubiquitination buffer (25 mM 
Tris pH 8, 100 mM NaCl, 4 mM MgCl2, 50 μM DTT) and incubated for 45 min. 10 μM 
0.1 % DMSO (0.5-100 μM 1 % DMSO in the dose experiments) NCI diversity set 
V/natural products IV/oncology set VII compound (NIH/NCI DTP, http://dtp.cancer.gov) 
and 10/18 μL reaction mix to a total of 20 μL was added to each well. At least 3 wells 
per plate were left without reaction mix as 0 % activity controls (E3 only). 0.1/1 % DMSO 
was added to at least 3 wells per plate for 100 % activity control reactions. 3 wells of 
buffer were also used per plate to remove buffer effects. Plates were then incubated 
for 2 hrs and washed as above. 1 in 10,000 diluted anti-FLAG-HRP conjugate antibody 
solution (Sigma A8592) was added to all wells and incubated for 1 hr. Levels of anti-
FLAG antibody were quantified using TMB ELISA solution (Invitrogen) which was 
stopped using 1 M HCl and the OD at 450 nm measured using a Hidex Sense 
microplate reader. 
2.2.9.3. His-E2 assay 
Reaction mixes containing 2.2 μg/well GST-E1, 200 ng/well His-E2, 100 ng/well 
Flag-ubiquitin, 1.25 mM ATP, 10 μM compound or 1 % DMSO and ubiquitination buffer 
were set up. Mixes were incubated for 1 hr. Clear 96 well nickel-coated plates (Pierce, 
Thermo Fisher) were washed with PBST and tapped dry before 20 μL reaction mix was 
aliquoted into wells and incubated for 1 hr. Positive control wells contained DMSO-
reaction mix and negative control wells contained only His-E2 and buffer. After 
incubation, plates were washed 3 times with PBST and incubated with anti-Flag-HRP 
conjugate solution for 1 hr. Plates were washed 3 times with PBST and tapped dry. 
Quantification was carried as described in section 2.2.9.2.  
2.2.9.4. GST-E1 assays 
These assays were set up and run similar to that described in section 2.2.9.2 however, 
the cell lysate contained GST-E1 protein and reaction mixes consisted of 100 ng/well 
Flag-ubiquitin, 1.25 mM ATP and 10 μM 0.1% DMSO compounds. Reaction mix was 
incubated on the GST-E1-coated plates for 1 hr before washing with PBST. Plates were 
processed as described in section 2.2.9.2.  
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2.2.9.5. His-E1 ubiquitination assay 
Reactions were set up containing 0.9 μg His-E1, 1 μg ubiquitin, 2.5 mM ATP in 
ubiquitination buffer as described in section 2.2.9.2, with 0.1 % DMSO, 10 μM 
compound in 0.1 % DMSO, or 1 % b-mercaptoethanol as required to a total volume of 
20 μL. All reactions were incubated for 1 hr and analysed by SDS-PAGE and Instant 
Blue staining. 
2.2.9.6. GST-Nedd4 counter assay 
GST-Nedd4 auto-ubiquitination reactions were set up and run in the same manner as 
GST-WWP2 assays as described in section 2.2.9.2, using lysate from cells expressing 
GST-Nedd4 with compounds at 10 μM 0.1 % DMSO. All other components and steps 
were the same.  
2.2.9.7. His-WWP1 counter assay 
Cell lysate expressing His-WWP1 was incubated on clear 96 well plates nickel-coated 
(Pierce, Thermo Fisher) for 1 hr. Plates were washed 3 times with PBST containing 
15 mM imidazole. Plate blocking was carried out for 1 hr using 0.5 % BSA in PBST. 
After washing, 18 μL reaction mixes were added to the appropriate wells, containing 
2.7 μg/well GST-E1, 11 μg/well untagged UbcH7, 100 ng/well flag-ubiquitin and 
1.25 mM ATP as required after being incubated for 45 min prior to addition. 10 μM 
compound at 0.1 % DMSO were used. Plates were incubated for 2 hrs at room 
temperature and washed with PBST containing 15 mM imidazole. All other steps were 
the same as described in section 2.2.9.2.  
2.2.9.8. GST-PTEN substrate ubiquitination assay 
Reactions were set up containing the following components as required: 100 nM 
His-E1, 1 μM His-E2, 2 μM GST-WWP2-FL, 10 uM GST-PTEN, 250 μM Flag-ubiquitin 
and 5 mM ATP in ubiquitination buffer (40 mM Tris-Cl pH 7.5, 50 mM NaCl, 2 mM DTT, 
5 mM MgCl2) to a total volume of 60 μL. All samples were incubated for 1 hr at room 
temperature. Samples were analysed by SDS-PAGE and Western blotting against 
GST, Flag and His-tags.  
2.2.10. Statistical analysis  
All graphs and statistics were generated using GraphPad Prism 7.0c for Mac OS X 
(GraphPad Software, La Jolla California, USA; www.graphpad.com). For initial 
compound screening, Z score was used to determine the quality of the plate assays. 
For comparison to controls, a one-way or two-way ANOVA with Tukey’s, Dunnet’s or 
Sidek multiple comparisons were used.  
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2.3. Cell-based procedures 
All cells were grown at 37 °C and 5 % CO2 unless otherwise stated. 
2.3.1. Cell line preparation 
Cells were removed from the -80 °C freezer and immediately thawed using a 37 °C 
water bath with gentle swirling. When only a little ice was remaining, vials were 
transferred into the sterile lamina flow hood (Herasafe) and the cells added to 5 mL 
media, as described in Table 2.3.1. Cell suspensions were centrifuged at 600-1200 x g 
22 °C for 5 min to pellet the cells. The supernatant was discarded, and the pellet 
resuspended in 1 mL fresh media. Cells were transferred to a T25/T75 sterile cell 
culture flask (Nunclon Delta single vent tilt flasks, Thermo Fisher) and left to grow in an 
incubator.   
Cell line Cell Type Media composition 
HEK 293A 
 
 
 
 
DU145 
PC-3 
Human 
embryonic kidney 
cells 
 
 
Human metastatic 
prostate cancer 
cells 
Dulbecco’s Modified Eagle’s Medium (DMEM), 
10 % Foetal calf serum (FCS), 1% penicillin-
streptomycin (P/S), 1 % non-essential amino 
acids, 1 % L-glutamine 
 
Roswell Park Memorial Institute (RPMI) 1640 
medium, 10 % FCS, 1 % L-glutamine, 1 % P/S  
Table 2.3.1 - Mammalian cell lines and culture media used in this research. 
2.3.2. Cell maintenance  
Cells were grown up to 70-80 % confluency. Media was removed, and cells washed 
with DPBS (Dulbecco’s PBS) (Gibco, Thermo Fisher). 2-5 mL TrypLE Express (Gibco, 
Thermo Fisher) was added and the flask incubated for 3 min at 37 °C. The contents of 
the flask were transferred to a centrifuge tube containing 2-5 mL media and centrifuged 
at 1200 x g 22 °C for 5 min. The supernatant was discarded, and the cell pellet 
resuspended in 1 mL media. A proportion of the 1 mL cell suspension was added to 
5/10 mL fresh media in a T25/T75 flask at dilutions ranging from 1 in 10 to 1 in 3. Flasks 
were transferred to an incubator and the cells left to grow. 
2.3.3. 6-24 well plate preparation 
Cells were prepared as described in section 2.3.2, however the pellet was resuspended 
in 5 mL/well per 6 well plate and 1 mL/well per 24 well plate (Nunclon Delta 6- and 
24-well, Thermo Fisher). Plates were incubated to ~80 % confluency.  
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2.3.4. Scratch assays 
24 well plates were grown until a monolayer had formed in the wells. A P2 (Gilson) 
pipette tip was used to create a scratch. After media was removed, the wells were 
washed with DPBS. 5 % FBS RPMI 1640 (and supplements described in Table 2.3.1) 
containing 0.1 % DMSO or 10 μM compound in 0.1 % DMSO was added to the 
appropriate wells. Blank media was used as a control. Plates undergoing TGF-b 
stimulation were incubated for 1 hr in the lower serum media before compound addition. 
TGF-b stimulation was carried out at 20 ng/ml. Time point images were collected 
between 0 hr and 44 hr until scratches were completely healed. Images were analysed 
using MRI wound healing macro plugin for Image J (Baecker, 2011; Schneider et al., 
2012; Schindelin et al., 2012). Graphs and statistical analysis was carried out using 
GraphPad Prism 7. 
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2.4. NMR-based procedures 
2.4.1. NMR sample preparation 
NMR protein samples were dialysed into NMR buffer (20 mM Na2HPO4, 50 mM NaCl 
pH 6.8) and spin concentrated to 0.5 – 1 mL using a Vivaspin 20 spin concentrator 
(Sartorius) at 4300 x g 4 °C (Heraeus Megafuge 1.0R). The sample was then prepared 
as described in Table 2.4.1, filtered using a 0.22 μm spin filter (Corning) and transferred 
to an NMR tube (5mm Wilmad 535PP).  
Component Volume 
Protein sample 
1.5 % sodium azide 
DSS 
D2O 
500 μL 
11.7 μL 
11.7 μL 
58.1 μL 
Table 2.4.1 - NMR sample preparation components and volumes. 
DSS - 4,4-dimethyl-4-silapentane-1-sulfonic acid. 
2.4.2. NMR spectroscopy experiments 
All experimental data was collected using either a Bruker Avance III 800 MHz 
spectrometer or a Bruker Avance I 500 MHz spectrometer equipped with triple 
resonance probes at 298 K. For the GB1-WW1 backbone assignment, experiments 
included: [1H-15N]-HSQC, HNCACB and CBCA(CO)NH as described in Table 2.4.2. 
The backbone resonance assignments for Smad-7 peptide bound-GB1-WW2 were 
obtained from Danielle Bourcier. For GB1-WW4, all experiments collected are 
described in Table 2.4.2 with a sample concentration of 2 mM. Other experiments and 
backbone assignments used for structural analysis of GB1-WW4 were collected by 
Lloyd Wahl (2016). The aro-NOESY (1H-1H 2D plane NOESY-HSQC at 120 ppm for 
13C) had a mixing time of 50 ms, whereas the 13C-NOESY-HSQC and 
15N-NOESY-HSQC acquired by Lloyd Wahl (2016) had mixing times of 100 ms. 
Fluorine spectra were also run on two titration samples to help understand the results. 
These were carried out in a Bruker Avance III  500 MHz spectrometer with a broadband 
probe.  
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Experiment Scans Complex 
points 
Spectral widths 
15N 13C 1H 15N 13C 
[1H-15N]-HSQC 
HNCACB 
CBCA(CO)NH 
8 
32 
32 
128 
32 
32 
- 
64 
53 
12019 
12019 
12019 
2594.7 
2594.7 
2594.7 
- 
15105.7 
15105.7 
Table 2.4.2 - Acquisition parameters for GB1-WW1 NMR experiments.  
All experiments were carried out in the 800 MHz spectrometer. All experiments used 1024 
complex points for 1H. 
Experiment Scans Complex 
points 
Spectral widths 
15N 13C 1H 15N 13C 
[1H-15N]-HSQCb 
HCCH-TOCSYb 
CCH-TOCSYb 
Aro-NOESYa (1H-1H 2D 
plane NOESY-HSQC @ 
120 ppm for 13C) 
HbCbCgCdHda 
8 
8 
8 
16 
 
 
256 
128 
120(1H) 
120(13C) 
256(1H) 
 
 
- 
- 
32 
32 
0 
 
 
48 
7507.5 
7507.5 
7507.5 
12019 
 
 
12820.5 
1620.4 
6995.6(1H) 
9423.8(13C) 
10395(1H) 
 
 
- 
- 
9423.8 
9423.8 
15105.7 
 
 
6038.6 
Table 2.4.3 - Acquisition parameters for GB1-WW4 NMR experiments.  
a indicates experiments carried out in the 800 MHz spectrometer and b in the 500 MHz 
spectrometer. All experiments used 1024 complex points for 1H.  
2.4.3. NMR titrations 
All experimental data was collected from the same spectrometers as described in 
section 2.4.2. NMR titrations were run using 15N-labelled GB1-WW1 and GB1-WW1-2 
and synthetic peptides based on Smad proteins 2, 3 and 7. The synthetic peptides were 
purchased from Proteogenix and Peptide Synthetics. Synthetic peptide sequences are 
described in Table 2.4.4. GB1-tagged protein samples were prepared as described in 
Table 2.4.1.  Titrations were carried out using concentrated peptide in µL amounts as 
described in Tables 2.4.5 – 2.4.10.  
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Peptide Amino acid sequence 
(SUMO)-Smad 2 
(SUMO)-Smad 3 
Smad 2 
Smad 3 
Smad 7 
IEPQSNYIPETPPPGYISEDGE 
IEPQSNIPETPPPGYLSEDGE 
IPETPPPGYISEDGE 
IPETPPPGYLSEDGE 
ELESPPPPYSRYPMD 
Table 2.4.4 - Residue sequences for the recombinant peptides and synthetic peptides 
used in expressed-peptide generation and NMR titration analyses, respectively.  
Molar Ratio [Smad 2 peptide] 
(mM) 
Volume Smad 2 peptide 
added (μL stock – 100 mM) 
1:0 
1:0.12 
1:0.23 
1:0.46 
1:0.92 
0 
0.07 
0.14 
0.28 
0.55 
0 
0.4 
0.4 
0.8 
1.6 
Table 2.4.5 - Conditions used during GB1-WW1 titration with synthetic Smad 2 peptide. 
A concentration of 0.6 mM 15N-GB1-WW1 was used in this titration. 
Molar Ratio [Smad 3 peptide] 
(mM) 
Volume Smad 3 peptide 
added (μL stock – 100 mM) 
1:0 
1:0.13 
1:0.26 
1:0.5 
1:1 
1:2.1 
1:4.1 
1:6 
1:7.9 
1:9.7 
0 
0.08 
0.16 
0.32 
0.64 
1.24 
2.43 
3.59 
4.73 
5.84 
0 
0.4 
0.4 
0.8 
1.6 
3.2 
6.3 
6.3 
6.3 
6.3 
Table 2.4.6 - Peptide additions and concentrations throughout the GB1-WW1 titration 
using synthetic Smad 3 peptide. 
A concentration of 0.6 mM 15N-GB1-WW1 was used in this titration. 
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Molar Ratio [Smad 7 peptide] 
(mM) 
Volume Smad 7 peptide 
added (μL stock – 10/100 mM) 
1:0 
1:0.08 
1:0.17 
1:0.43 
1:0.87 
1:1.7 
1:3.4 
1:5.1 
1:6.8 
1:8.5 
0 
0.005 
0.010 
0.026 
0.052 
0.10 
0.20 
0.31 
0.41 
0.51 
0 
0.3 
0.3 
0.9 
1.5 
2.9 
0.59 
0.59 
0.59 
0.59 
Table 2.4.7 - Conditions used during the GB1-WW1 titration with synthetic Smad 7.  
Italics refer to additions made using 100 mM rather than 10 mM. Titration carried out with Dr 
Lloyd Wahl. A concentration of 0.06 mM 15N-GB1-WW1 was used in this titration. 
Molar Ratio [Smad 2 peptide] 
(mM) 
Volume Smad 2 peptide 
added (μL stock – 100 mM) 
1:0 
1:0.125 
1:0.25 
1:0.5 
1:1 
1:2 
1:4 
1:6 
1:8 
1:10 
0 
0.09 
0.18 
0.36 
0.71 
1.43 
2.86 
4.29 
5.72 
7.15 
0 
0.5 
0.5 
1.0 
2.0 
3.95 
7.85 
7.85 
7.85 
7.85 
Table 2.4.8 - GB1-WW1-2 titration conditions using synthetic Smad 2 peptide. 
A concentration of 0.7 mM 15N-GB1-WW1-2 was used in this titration. 
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Molar Ratio [Smad 3 peptide] (mM) Volume Smad 3 peptide 
added (μL stock – 100 mM) 
1:0 
1:0.2 
1:0.5 
1:0.9 
1:1.6 
1:2.4 
1:4.9 
1:7.4 
1:9.8 
0 
0.07 
0.14 
0.28 
0.48 
0.72 
1.47 
2.21 
2.95 
0 
0.4 
0.4 
0.8 
1.2 
1.4 
4.3 
4.3 
4.3 
Table 2.4.9 - Concentrations used, and peptide additions during GB1-WW1-2 titration with 
synthetic Smad 3 peptide. 
A concentration of 0.3 mM 15N-GB1-WW1-2 was used in this titration. 
Molar Ratio [Smad 7 peptide] (mM) Volume Smad 7 peptide 
added (μL stock – 100 mM) 
1:0 
1:0.13 
1:0.27 
1:0.5 
1:1 
1:2.26 
1:4.6 
1:6.9 
1:9.2 
1:11.6 
0 
0.02 
0.04 
0.08 
0.15 
0.34 
0.69 
1.04 
1.39 
1.74 
0 
0.1 
0.1 
0.2 
0.4 
0.9 
1.75 
1.75 
1.75 
1.75 
Table 2.4.10 - Smad 7 peptide additions and concentrations in GB1-WW1-2 titration.  
A concentration of 0.15 mM 15N-GB1-WW1-2 was used in this titration. 
2.4.4. Processing and analysis of spectra 
Spectra were processed using NMRPipe software (Delaglio et al., 1995) in which 
phasing, zero filling, linear prediction and baseline corrections where necessary were 
applied to spectra. Analysis of spectra was carried out in CCPN analysis (Vranken et 
al., 2005). 
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2.4.5. Structural calculations 
Dihedral restraints were calculated using DANGLE (Cheung et al., 2010) set to reject 
predictions with over 2 islands. Predictions with 2 regions were either accepted or 
rejected based on the  F and Y boundary limits, generating an initial 192 restraints. 
Distance restraints were calculated within CCPN analysis using the unassigned peaks 
in the 13C-NOESY-HSQC, 15N-NOESY-HSQC and a 2D 1H-1H plane of a 
13C-HSQC-NOESY, with 13C centred at 120 ppm (aro-NOESY). Shift match restraints 
used the average peak volume as representative of 3.2 Å, which was then used to 
generate a list of distance restraints. These restraints lists were split into ambiguous 
and unambiguous. The ccpn project was then submitted to the CCPN NMR grid (Fogh 
et al., 2005; Nilges et al., 2008; Rieping et al., 2007; Vranken et al., 2005) to run 
ARIA-based structural calculations. A total of 8 iterations were carried out with 20 initial 
models that were then refined in explicit water to 10 refined models. The updated 
project which was analysed in CCPN Analysis which contained a structural ensemble, 
a list of peak assignments and new restraints lists with violations. Violations with a 
mean violation of 0.2 or higher were analysed within the project and their source 
(misassignments, for example) corrected where possible, before another set of 
restraints were generated using the new assignments and the project submitted again 
for structural calculations. 27 runs were carried out in this manner. When no more 
corrections could be made using this method, further calculations were carried out 
using the WeNMR ARIA 1.2 HJ webportal (Linge et al., 2003; Linge et al., 2003; Linge 
et al., 2001; Linge and Nilges, 1999; Nilges and O’Donoghue, 1998; Nilges, 1997; 
enmr.chemie.uni-frankfurt.de/portal/aria). This enabled the calculation of more 
structures per iteration and manual correction of restraint limits when restraints were at 
acceptable distances. Sequence, unambiguous/ambiguous/dihedral restraints, peak 
lists and chemical shift data were exported from the CCPN Analysis project after the 
27th run, using CNS/NMRView formatting. The parameters and settings used in the 
WeNMR webportal are described in Table 2.4.11. The structural ensemble was 
visualised using Chimera (Pettersen et al., 2004). New assignments and violations 
were checked against the original spectral data and corrected where possible. A further 
49 runs were carried out this way, until no further violations with an average error above 
0.3 Å were present.  
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Parameter Setting 
Number of structures per iteration 
Number of structures in last cycle 
Number of refined structures 
Seed for the calculation  
13C-NOESY/15N-NOESY 
Proton 1 
Hetero 1 
Proton 2 
NOESY mixing time 
Rotation correlation time 
Spectrometer frequency 
Spin diffusion 
Peak assignments 
Aro-NOESY 
Proton 1 
Proton 2 
NOESY mixing time 
Rotation correlation time 
Spectrometer frequency 
Spin diffusion 
Peak assignments 
50 
100 
20 
6789 (default) 
 
Tolerance 0.02 
Tolerance 0.50 
Tolerance 0.02 
100 ms 
6 ns 
800 MHz (13C)/500 MHz (15N) 
Corrected 
Use all peaks and keep assigned peaks  
 
Tolerance 0.02 
Tolerance 0.02 
50 ms 
6 ns 
800 MHz 
Corrected 
Use only assigned peaks 
Table 2.4.11 - Parameter settings used for the WeNMR ARIA 1.2 HJ webportal structural 
calculations.  
2.4.6. Structural validation 
Structural validation was performed using PSVS 1.5 (Bhattacharya et al., 2007), 
Molprobity (Duke, US; Lovell et al., 2003) and wwPDB (www.wwpdb.org; 
validate-rcsb-3.wwpbd.org, part of the Protein Data Bank; Berman et al., 2003; Berman 
et al., 2007). 
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3. Structural Characterisation of WW4  
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3.1.  Introduction 
Drug discovery utilises many different approaches with the aim of improving the 
specificity and efficacy of potential therapeutics. One such method involves knowledge 
of the target structure to design therapies based on protein folding and side chain 
positioning. This chapter looks at the structural solution of the fourth WW domain of the 
protein WWP2 using solution state NMR and how this can be used for peptide design.  
 
NMR spectroscopy uses the relationship between particles and their ability to absorb 
and emit electromagnetic energy to manipulate an inherent property of atomic nuclei 
referred to as spin. Spin is a quantum property of subatomic particles that have an 
angular momentum, but this does not mean a rotational movement as the term may 
suggest (Keeler, 2010). A vector model is commonly used to describe this property, 
with both a direction and magnitude. Quantum spin is expressed in integer terms where 
both the neutron and proton each have a ½ spin. Neutrons and protons combine to 
give the overall quantum spin value. Protein NMR utilises the half-integer spin 
properties of nuclei as these spectra are the easiest to interpret, with the simplest nuclei 
being 1H with a total quantum spin of ½, although deuterium is also used which has an 
integer spin of 1. Other commonly used isotopes are 13C and 15N, also with total 
quantum spin of ½. However, as these only exist naturally to a very low abundance, in 
protein NMR incorporation into the protein is required and involves recombinant 
expression of the protein or selective labelling which can be expensive and time-
consuming.  
 
Within spin ½ nuclei, there are two spin states, described by their position either with 
(up) or against (down) the magnetic field. In the absence of a magnetic field, the spin 
states across a sample randomly orientate between up and down positions resulting in 
degenerate orientations that have the same energy level. However, in the presence of 
a bulk magnetic field (B0), the spin state energy levels change leading to a split into 
occupying either a lower energy state (a which aligns with the magnetic field) or a 
higher energy state (b which aligns against the magnetic field). The average of these 
states at equilibrium under B0 create a net magnetisation vector along the z-axis of the 
spin vector model (Keeler, 2010) due to a tendency for more spins to exist at ground 
state. Additionally, after a set period of time, B0 induces the magnetisation of the nuclei 
to precess about the z-axis at a fixed angle known as the angle of precession. Larmor 
frequency is the term used to describe the relationship between the strength of the 
external magnetic field and the gyromagnetic ratio of the nuclei of interest, and in turn 
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the frequency of procession of the nuclei magnetisation. This Larmor precession sets 
the basis for the rotational frame and vector model transitions that classically describe 
the nuclei during an NMR experiment.  
 
The NMR signal that is collected during an experiment in its basic form develops via 3 
stages (Keeler, 2010). Firstly, an initial period T1 in the presence of the bulk magnetic 
field allows the sample spins to reach equilibrium; this is shortly followed by the 
application of a radiofrequency (RF) pulse at the frequency of the Larmor precession 
along the x or y axis, inducing a change in the magnetisation vector position away from 
the z-axis (the simplest being a change of 90°); and lastly the bulk magnetisation is 
measured from its precession along the x-y plane to its return to equilibrium. The signal 
collected from the change in magnetisation via the spectrometer coil is called the 
free-induction decay (FID). However, as there is usually more than one spin type that 
is detectable within a protein sample, each with different rates of Lamour precession, 
separate channels are used to individually excite specific nuclei at the same time. By 
using the proton for indirect detection of other nuclei, this utilises the higher 
gyromagnetic ratio of 1H resulting in increased sensitivity and better spectra can be 
obtained. After the collection of many FID signals to increase the signal-to-noise ratio, 
the data is then converted into a form which relates to the frequencies of the nuclei. 
This is known as Fourier transformation, and presents the data as frequency peaks for 
easier analysis and interpretation. 
 
As previously mentioned, the Larmor frequency of nuclei is dependent on the strength 
of the external magnetic field resulting in resonances having different frequencies under 
different magnetic field strengths. In order to compare chemical shift frequencies 
between experiments carried out using different strengths of magnet, Fourier 
transformed data is commonly described in parts per million, instead of frequency. This 
normalises the data so that the same atom that presents a peak at 500 Hz in a spectrum 
collected using a 500 MHz spectrometer, but has a frequency peak of 800 Hz in a 
spectrum acquired using an 800 MHz spectrometer, will result in both peaks residing 
at 1 ppm. Each atom will exist in slightly different chemical environments despite being 
of the same element, so the ppm value differs slightly for each atom and is referred to 
as the chemical shift. The chemical shift therefore corresponds to particular types of 
atoms in the surrounding chemical space of the sample, thus the type of protein NMR 
experiment can determine which chemical shifts are observed.  
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Different pulse sequences are used to determine distinctive aspects of the protein 
sample to build up an atomic picture of the protein. For assignment and structural 
studies, 2D and 3D experiments are used. The sequence of a standard 2D pulse 
sequence (outlined in Figure 3.1.1A) involves an initial preparation step in which 
coherence is reached by the equilibrium magnetisation (Keeler, 2010). This step can 
be either simple like a 90° pulse or more complex such as combinations of pulses used 
to transfer magnetisation to another nucleus. The coherence then processes and 
evolves during the evolution period, t1. This period can last for any time frame as it is 
determined by the number of increments in the experimental design and is important 
for labelling the magnetisation with the chemical shift of the indirect nucleus. After this 
period, the coherence is converted to an observable signal during the mixing period, 
which is also the step that determines the type of information collected from the 
experiment. The data is then recorded during t2, the detection period. So, during a 2D 
experiment the pulse sequence is initiated for a set number of increments, each with 
an increasing sampling period for t1 (described in Figure 3.1.1B). This collected data is 
then Fourier transformed in both the t1 and t2 into the well-known 2D frequency spectra 
that can then be easily compared and analysed. The same principles apply to triple 
resonance experiments; however, these tend to be more complex on account of 
multiple types of through-bond connections transferring magnetisation to the nuclei of 
interest. The data collected from such experiments enables the sequential assignment 
of residues based on chemical shift values characteristic of the residue type and 
connecting residues. This is especially valuable if the spectra lack residue-specific peak 
positions. The combination of several triple resonance experiments linking the 
backbone with the side-chains, as well as identifying atoms in close proximity in space, 
builds a complex network of bonds and restraints into a 3D structure of the protein 
being observed. 
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Figure 3.1.1 - Schematic representations of a general 2D NMR experiment.  
A) Diagram representing the general composition of a 2D NMR experiment. B) Diagram showing 
the principle of recording FIDs with increasing increments of a 2D NMR experiment. Light grey 
box refers to the preparation period; dark grey box represents the mixing period. Adapted from 
Keeler (2010).  
 
The heteronuclear single-quantum correlation (HSQC) experiment is one of the 
principal 2D NMR experiments for the analysis of proteins. Heteronuclei, for example 
1H and 15N or 1H and 13C, which are directly bound generate cross peaks from the 
transfer of magnetisation from one nucleus to the other via J-coupling (Keeler, 2010). 
In simplified terms, the pulse sequence involves magnetisation initially being 
transferred from the first spin (1H) to the second (13C or 15N) using a series of pulses 
called INEPT (insensitive nuclei enhanced by polarisation transfer). The second spin 
then evolves for t1 before magnetisation is transferred back to the first spin which is 
subsequently observed. By directly detecting the proton, the highest sensitivity can be 
achieved as the nitrogen/carbon signal is much weaker. In combination with isotopic 
labelling of the other nucleus (13C or 15N), this provides clean peak separation across 
both dimensions, where each dimension corresponds to the different nuclei. This 
produces single peaks for each amide moiety of the protein sequence, the exception 
being proline as it lacks the amide. Additional peaks for tryptophan and arginine NeHe 
can also be observed although the latter tends to appear as aliased peaks due to being 
outside the spectral region. However, the NH2 side-chains of asparagine and glutamine 
A
B
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can be observed as two peaks at different 1H shift values but the same 15N chemical 
shift position. Taken together with triple resonance data sets, peaks can be assigned 
to individual residue atoms of the protein sequence. In addition to identifying the 
individual amide groups in the protein, other aspects of the sample can also be 
determined, such as whether the protein concentration is high enough to produce a 
good signal-to-noise ratio or identify regions of the protein that may be unfolded. 
Furthermore, the influence of other factors on the protein such as temperature, pH and 
the presence of ligand can be observed. It is due to these reasons that a HSQC 
experiment is most commonly one of the first spectra to be acquired for a protein 
sample and can determine whether further characterisation by protein NMR is 
worthwhile.  
 
In the case of WWP2, substrate selection is carried out by four WW domains. As 
mentioned earlier, WW domains are composed of 30-40 amino acids with two 
tryptophan residues and a highly conserved proline residue (Kasanov et al., 2001; 
Panwalker et al., 2017). These domains interact with a PPxY motif via an anti-parallel 
b-sheet fold consisting of three strands. The positioning of aromatic residues on the 
surface of the b-sheet has been shown to create grooves known as XP grooves, which 
facilitate the binding of the substrate. Furthermore, key residues in other parts of the 
structure have been found to affect the affinities of the WW domain towards particular 
substrates (Kasanov et al., 2001). Interestingly, the fourth WW domain within WWP2 
lacks the 2nd tryptophan residue which is replaced by phenylalanine but seems to retain 
other highly conserved residues, described in chapter 1, which are required for function. 
Understanding the structure of particular WW domains and the orientations of key 
residues can provide vital information on the functionality and the selection of 
substrates.  
 
Knowing the structure of the protein is useful in many regards. In drug design, it is 
particularly useful in showing the arrangement of side chains that are involved in 
interactions or form the binding pocket, or in the case of bound structures, highlights 
key areas of conformational change induced by binding that may not necessarily be 
within the residues directly involved in binding. Therefore, both unbound and bound 
structures are information rich and can be used for more intelligent and specific design 
of compounds or peptides. In order to enable inhibitor design using a structure-based 
approach, the aim of this chapter was to solve the WW4 domain conformation using 
solution state NMR. Previous work by Dr Lloyd Wahl (2016) using 13C-15N-GB1-WW4 
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presented a partially refined structure for WW4 of WWP2, however further assignment 
of atoms was required in order to produce a fully refined ensemble for WW4. Building 
upon the data from Dr Lloyd Wahl, the addition of further experiments in this thesis, to 
increase the unambiguous and more complete assignment of WW4 resonances, 
allowed for the automated assignment of NOESY-based restraints, and iterative 
structural calculations using the CCPN Grid (Boucher et al., 2005; Nilges et al., 2008; 
Rieping et al., 2007; Vranken et al., 2005) and WeNMR ARIA 1.2 HJ webportal 
(http://enmr.chemie.uni-frankfurt.de/portal/index.html).  
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3.2. Results 
The use of the solubility tag GB1 enabled the expression and purification of WW4 in 
isotopically labelled media for use in NMR experiments. The tag was not cleaved before 
experimentation as previous work showed removal resulted in protein precipitation 
(Lloyd Wahl, 2016; unpublished observations).  
3.2.1. HSQC analysis for sample comparison of double labelled WW4 
In order to acquire additional triple resonance experiments for use alongside those 
collected by Dr Lloyd Wahl (2016), a double-labelled sample of GB1-WW4 at 2 mM in 
sodium phosphate buffer was produced using bacterial expression and protein 
purification methods described in sections 2.2.2 and 2.2.4. Initial HSQC analysis of the 
sample looked as expected when compared to the previous GB1-WW4 HSQC 
spectrum (Wahl, 2016) (Figure 3.2.1). Hence further acquisition of triple resonance 
experiments was carried out using the 800 MHz spectrometer.  
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Figure 3.2.1 - Comparison of double-labelled 13C-15N-GB1-WW4 samples by HSQC. 
Overlaid HSQCs of Lloyd Wahl’s WW4 sample (teal) used for previous data collection, and the 
HSQC of the sample used in this research (dark blue) for additional experiment acquisition. ppm 
– parts per million. 
 
3.2.2. Assignment of GB1-WW4 side chains 
Previous work towards the structural solution of WW4 (Wahl, 2016) was built upon by 
obtaining further triple resonance experiments for side chain assignment. Spectral data 
was transformed and processed using NMRPipe and NMRDraw (Delaglio et al., 1995). 
The HCCH-TOCSY and CCH-TOCSY were obtained and assigned for aliphatic side 
chain resonances, and the HBCBCGCDHD and a 2D 1H-1H plane of a 
13C-NOESY-HSQC with the 13C centred at 120 ppm (aro-NOESY) were acquired and 
assigned for aromatic side chain resonances, using CCPN Analysis (Vranken et al., 
2005).  
 
3.2.3. ARIA: automated peak assignment, structural calculations and 
water refinement     
For structural calculations, assignment of nuclear Overhauser effect (NOESY) spectra 
peaks determines which residue atoms were within 5-6 Å of each other. It is possible 
HSQC_WW4_samples.pdf Fri Jun  1 09:49:47 2018
1H (ppm)
15
N 
(p
pm
)
67891011
67891011
105
110
115
120
125
130
105
110
115
120
125
130
 74 
to manually assign each peak from other resonance values that have already been 
assigned in other spectra. However, as this stage in data analysis is the most time-
consuming part due to numerous possible assignments, the presence of potential noise 
peaks/solvent peaks and proton overlaps, there are now automated methods of 
NOESY peak assignment which can overcome such obstacles.  
 
After manual peak picking in the 13C-NOESY-HSQC, 15N-NOESY-HSQC and 
aro-NOESY spectra to facilitate automated assignment at a later stage, the next step 
was to generate distance and dihedral restraints which provided information about the 
spatial arrangement of atoms.  These restraints were generated using DANGLE 
(Dihedral ANgles from Global Likelihood Estimates; Cheung et al., 2010) and 
‘Structure: Make Distance restraints’ within CCPN Analysis. DANGLE uses a 
combination of the molecule sequence, the chemical shift data present in the CCPN 
project, and comparison to known protein shifts and structures to predict the probability 
of given backbone orientations in space. A total of 192  F and Y backbone restraints 
were calculated using a maximum setting of 2 predicted islands, and all other settings 
at default. Any residues with over 2 islands predicted in Ramachandran space were 
automatically removed, and those outside of the  F and Y upper and lower limits were 
also discounted resulting in dihedral angles for 98 of 109 residues. As the outliers were 
mainly at the N-terminal regions and flexible linker between amino acids 62 and 73, 
this was deemed adequate for further progression to structural calculations. As for 
distance restraints, 123 unambiguous and 2420 ambiguous distance restraints were 
initially generated within CCPN Analysis. The software utilised average peak volume 
as an intensity reference for a distance of 3.2 Å (Skinner et al., 2015), and then derived 
individual NOE distances from this value based on the specific intensity values for each 
peak. After the restraints were created, the lists were merged and split according to 
whether they were unambiguous or ambiguous ready for use in structural calculations. 
 
The project was then submitted to the CCPN grid for the next stage of structure 
generation. The CCPN NMR grid (Fogh et al., 2005; Nilges et al., 2008; Rieping et al., 
2007; Vranken et al., 2005) was used for automated assignment and structural 
calculations up to a total of 27 runs. This portal used a combination of the CCPN data 
model, ARIA 2.1 and CONDOR and enabled an alternative way of using ARIA-based 
iterative calculations rather than via a local source due to previous problems with local 
versions of ARIA. Within each run, there were 8 iterations with 20 models, and a final 
ensemble of 10 models with the lowest energies were produced after water refinement. 
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For example, the first ensemble from run 1 for the GB1 and WW4 regions shown in 
Figure 3.2.2A and B, respectively. All assignment, restraint and structural data was 
retrieved as a CCPN project and analysed in Analysis. A total of 2652 peaks were 
present in the final iteration of the first CCPN grid run, compared with 3091 in the 
original input lists. This suggested the presence of erroneous peaks - peaks that could 
not be assigned by ARIA, potentially due to ambiguity, overlap or lack of any 
assignments for the given atoms in the project. The rejected restraints (i.e. violations), 
which were not compatible with the structures calculated, were checked and corrected 
from the most severe (red) to the least (yellow), where possible. After 27 runs using the 
CCPN grid, violations were still present, in which the majority appeared to be within the 
absolute distance limits with correct assignments based on the spectral connections 
analysed. At this stage, it was decided that changing software to one which would 
generate a greater number of models per iteration and allow manual correction of 
restraint distance limits, within acceptable bounds, may be more beneficial for 
analysing and correcting the remaining errors, enabling improvement towards a better-
quality structure.   
 
 
Figure 3.2.2 - Initial partially refined GB1 and WW4 ensemble alignment from CCPN grid 
run 1.  
A) GB1 ensemble (1 – 61) consisting of 10 models with the helix in red, b-strands in purple and 
random coils in grey. B) WW4 ensemble (73 – 106) of 10 refined models with the b-strands in 
purple and random coils in grey. Residues 62 – 72 are not shown as the region was disordered 
and prevented sufficient alignment of the independent domains for analysis. Images were 
created using Chimera (Pettersen et al., 2004). N and C refer to the amino and carboxyl termini. 
 
Sequence, chemical shifts, ARIA-based peak lists and restraints data were exported 
from CCPN Analysis from the last CCPN Grid result project to facilitate the use of the 
WeNMR ARIA 1.2 HJ webportal for further assignment, structural calculations and 
A B
C N
N
C
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refinement. 50 structures were generated per iteration with 100 structures in the last 
cycle. A final set of 20 models were generated after refinement in explicit water. A total 
of 49 runs were carried out using this portal. The final iteration of the final run used a 
total of 1803 restraints, with the distribution of 873 intra-residue, 400 sequential, 118 
medium range and 412 long range. Minimal restraints were present for the linker region 
between GB1 and WW4, while no restraints spanned GB1 to WW4, highlighting each 
domain as independently folding within the sample. The final refined ensemble can be 
seen in Figure 3.2.3A, where the GB1 domain has been aligned. The same overall 
secondary structures for the individual GB1 (Figure 3.2.3B) and WW4 (Figure 3.2.3D) 
domains are mirrored in this ensemble when compared to the initial structural models 
shown in Figure 3.2.2 A and B respectively, showing that this folding pattern is derived 
from the NOEs and restraints derived from the experimental data. The backbone atom 
root mean standard deviation (RMSD) for this final ensemble over residues 1-109 is 
8.9 Å, with a heavy atom RMSD at 9.1 Å. This value is very high for a final structure, 
however due to the highly flexible, ill-defined linker region between the two domains 
with very few restraints, it is not surprising as this linker results in many different spatial 
arrangements of WW4. When restricted to just the well-defined core regions of GB1 
and WW4 consisting of residues 3-59 and 75-101 respectively (as calculated by 
wwPDB validation service, discussed later) the RMSD values for the backbone atoms 
was much lower at 0.4 Å for both domain regions and the heavy atoms RMSD reduced 
to 0.8 Å and 0.9 Å for GB1 3-59 and WW4 75-101 respectively (calculated by PSVS). 
This suggests that the variation between the models of these core regions is low and 
supports this ensemble being a good quality model when considering each of the 
individual core regions. Furthermore, analysis of the GB1 tag compared to the 
published structure of PDB code 3GB1 (Juszewski et al., 1999; Berman et al., 2000), 
shown in Figure 3.2.4, showed only minimal differences between the tag structures. 
Overall, each domain presented with a medoid model which refers to the model that 
reflects the most similarity to the other structures in the ensemble. These are shown in 
Figure 3.2.3C for GB1 (model 16) and Figure 3.2.3E for WW4 (model 7). 
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Figure 3.2.3 - Final refined ensemble for GB1-WW4 from the WeNMR ARIA 1.2 HJ 
webportal calculations.  
A) 20 refined models for GB1-WW4 amino acids 1-109 with GB1 region aligned. B) GB1 
ensemble ranging from amino acid 1 to 61 consisting of 20 models. C) Most representative 
model (number 16) of GB1 as defined by wwPDB validation analysis, from amino acid 3 to 59. 
D) 20 refined models for WW4 from residue 73 to 109. E) Most representative model for WW4 
(model number 7) from amino acid 75 to 101. Images were generated using Chimera (Pettersen 
et al., 2004). N and C refer to the amino and carboxyl termini. 
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Figure 3.2.4 - Ensemble comparison of GB1 in GB1-WW4 with published 3GB1. 
A) 32 3GB1 models (light blue) aligned with 20 refined GB1 models (red – helix; 
purple - b-strands). B) Most representative model of GB1 in GB1-WW4 ensemble aligned with 
the first model of PDB 3GB1. Alignments and images generated using Chimera (Pettersen et 
al., 2004). N and C refer to the amino and carboxyl termini. 
 
3.2.4. Structure Validation 
In order to truly assess the quality of the final ensemble generated by structural 
calculations and refinement discussed in the previous section, structural validation 
software PSVS 1.5 (Bhattacharya et al., 2007), MolProbity (Duke, US; Lovell et al., 
2003) and wwPDB (Berman et al., 2003; Berman et al., 2007) were employed.  
 
PSVS utilises evaluation tools such as PROCHECK (Laskowski et al., 1993), 
MolProbity (Lovell et al., 2003), Verify3D (Luthy et al., 1992) and Prosa II (Sippl, 1993) 
to look at how well the structure fits with already published X-ray structures, and the 
experimental data. The global quality scores give an indication of how well the 
ensemble performs based on certain criteria: Verify3d assesses the probability that the 
3D structure reflects the predicted amino acid sequence-based spatial conformations; 
Prosa II looks at b-carbons close together spatially to derive the energy value of the 
interaction; Procheck analyses the dihedral angles j (phi) and y (psi) in the backbone 
(Ramachandran plot analysis) as well as overall stereochemistry analysis to determine 
the quality of the ensemble; and lastly, MolProbity identifies any bad contacts which 
result in steric clashes or overlap of atoms, analyses how favourable the b-carbons 
spatial arrangements with regards to the backbone conformation and side-chain 
orientations as well as Ramachandran plot analysis. A summary of the PSVS output is 
shown in Table 3.2.2. As previously mentioned, the RMSD values for the backbone 
and heavy atoms when analysing all residues of the construct is high, but when only 
A B
N
NC C
 79 
considering the core regions, reduces to an acceptable value for each domain 
ensemble suggesting they are reliable representations of the structural architecture. 
Ramachandran plot analysis was carried out using both Procheck and MolProbity 
within PSVS. By plotting the j and y angle values against each other, the regions of 
distinct secondary structures and the residues which adopt these particular ideal angles 
can be identified. Likewise, outliers, angles for residues which fall outside of the ideal 
values, can also be highlighted. For the core regions analysed by PSVS, as outlined in 
Table 3.2.2, no dihedral angles were disallowed, with the majority residing in favourable 
conformations, suggesting that the ensemble portrays structural angles in the ideal 
region. The webserver for MolProbity was also was used to analyse all residues from 
1-109 with respect to the dihedral angle acceptability. The resulting plots can be seen 
in Figure 3.2.5. 92.7 % were favourable, 6.7 % within the allowed boundaries, and 
0.6 % disallowed. All the outlying residues resided either within the flexible linker or at 
the N-terminal region of the construct. This is potentially due to these regions being 
unable to produce NOEs because they are disordered and/or solvent exposed. While 
the values in Table 3.2.2 and Figure 3.2.5 do indicate a good level of quality, it does 
not completely eliminate the possibility of errors with bond lengths, angles, chirality and 
planarity within the structures. Overall, however, the ensemble performs well showing 
the structural model is of good quality. 
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Criteria GB1-WW4 1-109 GB1 3-59 WW4 75-101 
RMSD 
Backbone atoms 
Heavy atoms 
Bond angles 
Bond lengths 
 
Global quality scores  
Verify3D 
Prosa II (-ve) 
Procheck (phi/psi) b 
Procheck (all) b 
MolProbity clashscore 
 
Ramachandran plot -Procheck 
Most favoured 
Allowed 
Generously allowed 
Disallowed 
Ramachandran plot -MolProbity 
Most favoured 
Allowed 
Disallowed 
 
8.9 Å 
9.1 Å 
0.8° 
0.008 Å 
 
(raw/z-scorea) 
0.36    -1.61 
0.61   -0.17 
-0.35   -1.06 
-0.42   -2.48 
13.02   -0.71 
 
(3-59,71-73,75-107) 
90.4 % 
9.6 % 
0.0 % 
0.0 % 
(3-59,71-73,75-107) 
98.5 % 
1.5 % 
0.0 % 
 
0.4 Å 
0.8 Å 
0.9° 
0.008 Å 
 
(raw/z-scorea) 
0.43 -0.48 
0.80 0.62 
-0.26 -0.71 
-0.38 -2.25 
16.43 -1.29 
 
 
93.4 % 
6.6 % 
0.0 % 
0.0% 
 
99.2 % 
0.8 % 
0.0 % 
 
0.4 Å 
0.9 Å 
0.8° 
0.009 Å 
 
(raw/z-scorea) 
0.27 -3.05 
0.30 -1.45 
-0.34 -1.02 
-0.35 -2.07 
9.63 -0.13 
 
 
86.3 % 
13.7 % 
0.0 % 
0.0 % 
 
97.2 % 
2.8 % 
0.0 % 
Table 3.2.2 - Summary of PSVS validation of GB1-WW4 and individual GB1 and WW4 core 
regions.  
PSVS validation analysis of the final GB1-WW4 ensemble of 20 models. Regions analysed by 
PSVS are outlined either in the column heading or in brackets. a relative to 252 X-ray structures 
with < 500 residues and resolution of £ 1.8 Å, R-factor £ 0.25 and R-free £ 0.28. Positive values 
indicate a better than average score. Adapted table from PSVS results report. RMSD – root 
mean standard deviation. 
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Figure 3.2.5 - MolProbity Ramachandran plots representing the analysis of 20 water 
refined models of GB1-WW4.  
Structure quality analysis by Ramachandran plot for amino acids 1-109 across the final 20 water 
refined models of GB1-WW4. Light blue corresponds to favourable regions, whereas dark blue 
highlights allowed regions. Outliers shown as pink (general amino acids) /red (isoleucine and 
valine) /green (glycine) dots with model number and residue annotated. 92.7 % of all residues 
within the favoured regions, and 99.4 % within the allowed regions. Analysis carried out using 
MolProbity webserver (Duke, US; Lovell et al., 2003).  
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The final piece of validation software used for the final ensemble of 20 GB1-WW4 
refined models was the One Dep wwPDB Validation service. The wwPDB is the place 
where final structural ensembles are deposited. However, these validation tests can 
also be run separately from deposition as a standalone validation service to determine 
the quality of the protein ensemble according to the deposition criteria at any time. The 
report presented an overall summary using a percentage slider scale for the ranking of 
clash score, Ramachandran outliers and side chain outliers (MolProbity; Chen et al., 
2010), in comparison with either all deposited structures (both crystal and NMR 
structures), or just NMR structures. GB1-WW4 scored well compared to all structures 
except for side-chain outliers that presented a slightly ‘worse’ score at 6.4% (Figure 
3.2.6A). However, when compared to only NMR structures, GB1-WW4 ranks for all 
criteria were on the ‘better’ side of the scale. This suggests that the ensemble is well 
refined.  
 
The wwPDB validation software only validates the well-defined regions of the protein 
PDB ensembles derived from NMR data that are submitted (Kirchner and Güntert, 
2011; Montelione et al., 2013). In this case, only residues 3-59 and 75-101 were 
included in the analysis parameters which mirrors the fact that the construct consists 
of 2 independent domains – the initial being the GB1 solubility tag and the latter being 
the domain of interest WW4. This is further supported by the random coil analysis 
carried out by the wwPDB (Figure 3.2.6B) showing 60-74 and the C-terminus as 
disordered. The validation of the GB1 domain supports the quality of the calculated 
ensemble from the NMR data, as another solution structure of GB1 has already been 
deposited to the PDB providing a good quality structure for comparison, as shown 
previously in Figure 3.2.4. Furthermore, as the GB1 structures align very well between 
the published and the GB1-WW4 ensemble, this highlights the absence of effect from 
the presence of GB1 on the overall structure of WW4 and vice versa other than 
improving the solubility of the construct. Analysis of the chain geometric quality based 
on outlier presence (red/orange/yellow) for individual amino acids, shown in Figure 
3.2.6C and D, also indicates a good quality structural model. Investigation of the 
ensembles well-defined regions by the wwPDB is summarised in Table 3.2.3, and 
further reflects that the ensemble is well-refined and in good agreement with the other 
validation results. There were a few outliers regarding bond lengths, all within aromatic 
residue side-chains, probably from a missing assignment or loose/tight restraint. 
Chemical shift validation was also carried out by the wwPDB validation service on the 
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final ensemble, with Table 3.2.4 outlining the completeness of assignment for 
GB1-WW4. A total 1249 chemical shifts were analysed, with only 9 outliers identified. 
Analysis of the outliers suggest that the unusual shifts are most likely the result of 
nearby aromatic rings being close enough that the magnetic field generated by the 
delocalised electrons of the ring have influenced the frequency of the observed nuclei. 
Furthermore, comparison of the ppm values for the GB1-based outliers are consistent 
with those submitted to the BMRB for GB1 (PDB: 3GB1), supporting the conclusion 
that these are correct chemical shift values. As for the completeness of assignments, 
this assessed the number of assigned peaks in the entire structure and the well-defined 
core regions compared to the total number of assignable nuclei (Montelione et al., 
2013). Briefly, this includes backbone atoms C’, N, HN and Ha, side chain aliphatic 
nuclei from Cb including carbon, hydrogen and nitrogen atoms, and all nuclei of the 
aromatic rings. Considering that the OH of tyrosine rings and CO groups were not 
assigned, and that the first few residues could not be seen, the overall percentage of 
assigned nuclei is good. Collectively, the wwPDB validation results showed that despite 
the ensemble having a few less-than-ideal aspects, the ensemble is well refined and is 
in good agreement with the other validation results. 
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Figure 3.2.6 - wwPDB validation result summaries for refined GB1-WW4 ensemble.  
A) Comparison of the final GB1-WW4 ensemble of 20 refined models with all/NMR only 
deposited PDB entries. Slider scale representing overall quality of the ensemble from worse to 
better than those in the database. B) Random coil index results for GB1-WW4 construct 1-109. 
The probability results for individual residues to occupy a random coil conformation based on 
the chemical shift data and amino acid sequence. Values higher than 0.2 indicate a significant 
likelihood of disorder. Black – well-defined residues; blue – poorly defined residues. C) Overall 
quality analysis of geometry across all 20 refined models for GB1-WW4. D) Individual residue 
geometric quality analysis for GB1-WW4 ensemble. Green - no outliers; yellow – one outlier; 
blue – poorly defined. Short green connecting segments represent 2 or more residues which 
have no outliers. Image derived from the preliminary report produced after wwPDB validation 
(validate-rcsb-3.wwpdb.org; Berman et al., 2003; Berman et al., 2007). 
A
B
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Criteria GB1-WW4: 3-59 and 75-101 
(ensemble average) 
RMSD - backbone 
GB1: 3-59 
WW4: 75 - 101 
Bond lengths  
RMSZ 
#Z > 5 
Bond angles 
RMSZ 
#Z > 5 
Chirality outliers 
Planarity outliers 
Clashes 
Ramachandran analysis 
Analysed  
Favoured 
Allowed 
Outliers 
% compared out PDB entries (NMR) 
Side chain analysis 
Analysed 
Rotameric 
Outliers 
% compared to PDB entries (NMR) 
 
0.26 Å 
0.3 Å 
 
0.53 ± 0.11 
1 ± 2 / 693 (0.2 ± 0.2 %) 
 
0.50 ± 0.02 
0 ± 0 / 944 (0.0 ± 0.0 %) 
0.0 ± 0.0 
0.3 ± 0.05 
6 ± 2 
 
84/109 (77 %) 
82 ± 1 (98 ± 1 %) 
2 ± 1 (2 ± 1 %) 
0 ± 0 (0 %) 
100 % 
 
72/87 (83 %) 
67 ± 2 (94 ± 2 %) 
5 ± 2 (6 ± 2 %) 
71 % 
Table 3.2.3 - Summary of the criteria and validation results carried out by wwPDB on 
GB1-WW4 ensemble.  
Model quality results from the preliminary wwPDB validation report on GB1-WW4 residues 3-
59 and 75-101 (total = 84/109 residues). Results given are average values for across the 
structural ensemble. % in brackets where available. RMSD – root mean standard deviation; 
RMSZ – root mean square of all Z-scores. Adapted from the wwPDB validation report. 
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 Total 1H 13C 15N 
Backbone 
Side chain 
Aromatic 
Overall 
410/416 (99 %) 
396/477 (83 %) 
93/115 (81 %) 
899/1008 (89 %) 
164/166 (99 %) 
247/275 (90 %) 
51/59 (86 %) 
462/500 (92 %) 
166/168 (99 %) 
143/183 (78 %) 
40/50 (80 %) 
349/401 (87 %) 
80/82 (98 %) 
6/19 (32 %) 
2/6 (33 %) 
88/107 (82 %) 
Table 3.2.4 - Summary of assignment completeness for GB1-WW4 core regions as 
determined by wwPDB.  
Data from the preliminary report provided by wwPDB validation service for core regions 3-59 
and 75-101. 899 atoms out of 1008 for these core regions were assigned.  
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3.3. Discussion 
Structure-based inhibitor design consists of several stages and rounds of modifications 
until a drug lead can move forward into clinical trials. Initially, the target of choice has 
to be cloned, expressed and purified. Next, structure determination is carried out to 
understand the spatial conformation of the protein. This develops into compound or 
peptide screening based on modelling of potential hits into favourable sites on the 
structure. Biochemical analysis then shortly follows to determine the affinity and 
efficacy of the compound/peptide. Without knowledge of the target structure, selective 
drug design towards a specific target is extremely difficult. In the case of WWP2, the 
presence of highly selective WW domains makes them ideal targets for novel 
anti-cancer therapies. Yet, none of the WW domains have been structurally solved to 
date, due to problems with protein stability and expression levels. The aim of this 
chapter was to reveal the structure of the fourth WW domain of WWP2 to facilitate the 
design of novel inhibitors against this E3 ligase.  
 
The whole ensemble of structures performed well in the structure validation criteria. 
The results for GB1 alone, which as it is already published can act as a control, support 
the conformation shown in this chapter as the native form of WW4. Closer comparison 
of the published GB1 and the medoid model 16 (Figure 3.2.4B) showed that while a lot 
of the side-chains were very similar, there was still variations in these across the 
structure. This is probably due to the differences in construct/solution/environment 
between the two methods of structural solution and does not mean that those in this 
structural ensemble are necessarily incorrect. As for the backbone, there is little 
difference between the overall structures. The quality of the overall ensemble is 
supported by the absence of NOE violations above 0.3 Å, lack of dihedral outliers and 
low RMSD values. The presence of some errors in rotamer positions and aromatic bond 
lengths suggests some less than ideal aspects of the structure. Although, it is important 
to remember that comparison to only NMR-based structures, rather than to all PDB 
entries, the ensemble ranked better than average in quality. This may be due to more 
stringent validation parameters in place for X-ray crystal structures based on their fixed 
nature, though the vast majority are still applicable to NMR structures.  
 
WW domain structures for other Nedd4 E3 ligases have previously been published, 
such as Nedd4 WW3 (PDB: 4N7F and 5AHT; Qi et al., 2014; Panwalker et al., 2016) 
and WWP1 WW4 domain (PDB: 2OP7), as well as Smad 7 bound structures of Smurf 2 
WW2-3 (PDB: 2KXQ; Chong et al., 2010) and Nedd4L (PDB: 2LTY; Aragon et al., 
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2012) to name a few. Across these domains, a b-sheet consisting of three anti-parallel 
b-strands with a twist was observed, suggesting this conformation is a conserved 
folding pattern important to the function of these domains. Solution state NMR has 
revealed that the same is true for WW4 within WWP2. Collectively, they all show a twist 
in the first loop region towards the 2nd loop. This suggests that the curve may orientate 
the side chains of residues into favourable positions to facilitate substrate binding. Work 
carried out by Kasanov et al. (2001), with WW domains of proteins such as Nedd4, 
WWP1 and WWP2 found that the conserved histidine at position 94 and threonine at 
99, according to WWP2 WW4 domain sequence shown in Figure 4.3.1A, were 
important in substrate recognition. When looking at these residues in WW4, as well as 
the XP groove consisting of tyrosine (Y90) and substituted phenylalanine (F101) 
(shown in Figure 4.3.1), the residues appear to reside on either side of the diagonal 
groove generated by this twist supporting the involvement of these residues in the 
function of this domain. Although the side-chain orientations of the residues H94 and 
F101 are not as well-defined as those located in the b-strands, potentially due to natural 
variation from solvent exposure in turn producing fewer restraints as a limited number 
of contacts are possible, they still present this overall pattern of defining a groove in the 
structure implicated in substrate recognition. Another important residue is valine 88 
(V88), as this amino acid has been found to determine the class of the WW domain 
and in turn the substrate selection motif. Espanal and Sudol (1999) found that by 
mutating the amino acid at this position from a leucine to a tryptophan, the domain 
would change from a class I (PPxY) to a class II (PPLP). Mutation of the histidine 
residue at +2 had a lower degree of effect on motif recognition. This suggests that this 
being a valine in WW4, and likewise in the other three WW domains of WWP2, supports 
the recognition of these domains towards only PPxY-motif containing substrates.  
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Figure 4.3.1 - WW4 structure showing XP groove and other conserved residues.  
A) Amino acid sequence of WW4 with conserved residues and XP groove residues in bold. 
Number in brackets refers to numbering in WWP2-FL sequence. B) Side-chains of residues 
tyrosine 90 (Y90) and phenylalanine 101 (F101) that form the XP groove and conserved 
histidine 94 (H94) and threonine 99 (T99) for the 20 final structures of WW4. Arrow indicates 
potential region of peptide interactions.  
 
Panwalker and colleagues (2017) found that the 3rd b-strand of Nedd4 WW3 was the 
first region to dissociate from the substrate as well as the one that significantly 
stabilised and increased rigidity upon substrate binding. As this region shows a very 
conserved structure and contains residues important for direct binding to the prolines 
of the PPxY motif, this may also be the case for WW4 in WWP2. This is further 
suggested from work carried out by Lloyd Wahl (2016) which identified the residues of 
the last b-strand as the ones which underwent the most perturbation in NMR titration 
analysis with substrate peptides. However, as other residues were also found to be 
involved in substrate binding in the other b-strands rather than just the conserved 
residues mentioned previously, this could imply an allosteric effect across the domain 
A
WW4: (444)73-PALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRPGFE-109(477)
B
H94
Y90
F101
T99
N
C
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rather than direct binding. Further analysis of the conformational changes upon 
substrate interaction is required to conclusively say whether this is the case for WW4. 
Nevertheless, designing peptides to mimic this partial flexibility of the 3rd b-strand 
alongside the other key residues may in fact be difficult, thus mimicking the substrate 
to competitively block the binding site may be a more appropriate avenue of 
investigation using structure-based methods. 
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4. WW domain interaction analysis 
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4.1. Introduction 
The ubiquitination of substrates is important for the regulation of many cellular 
signalling pathways. Nedd4 family E3 ligases such as Nedd4, Smurfs 1 and 2, and 
WWP1 and 2 interact with secondary messengers such as PTEN and the Smad 
proteins involved in PI3K/AKT and TGF-b signalling respectively, as discussed in 
chapter 1. The overexpression of these ligases has been linked to oncogenesis via the 
increased degradation of these tumour suppressor proteins. WWP2 has been 
implicated in prostate cancer development, with significant influence from the WWP2-N 
isoform upregulated in earlier stages (Soond et al., 2013), due to its ubiquitination of 
both PTEN and Smad proteins leading to PI3K/AKT and TGF-b overactivation and 
cellular survival. Thus, understanding these binding partners and how they interact with 
the different isoforms can direct the design of novel therapeutics, in which very few 
inhibitors are currently known. It is also of interest from a biological perspective to 
understand how the substrates are selected and targeted for degradation at a 
molecular level. 
 
WWP2-FL was isolated in mass spectrometry analysis of PTEN interaction partners 
back in 2011 by Maddika and colleagues, introducing a new substrate to the few 
discovered for WWP2. PTEN is a negative regulator of the PI3K/AKT signalling 
pathway, described in detail in chapter 1. Overexpression and silencing of WWP2 
showed a WWP2-dependence for the turnover of PTEN, contradicting previous data 
that Nedd4-1 was the primary E3 ligase that controlled PTEN turnover. This was 
supported by the lack of Nedd4-1 in the mass spectrometry and immunoprecipitation 
results (Maddika et al., 2011), and later concluded that while Nedd4-1 does target 
PTEN, the dominant E3 ligase for PTEN ubiquitination is WWP2. Work by Chen et al. 
(2016) further supported this conclusion but also highlighted the importance of the 
PTEN phosphorylation status in controlling PTEN degradation by WWP2. The WWP2 
interaction site on PTEN was isolated to between 100 and 187 residues, however there 
is no PPxY motif in this region, or anywhere in PTEN. This implies that either the WW 
domains of WWP2 are not exclusively group I WW domains and can bind to motifs 
other than PPxY, or that binding to PTEN is not mediated via the WW domains. There 
is also currently no published evidence of N and C isoform interactions with PTEN 
which may uncover how these two proteins interact and regulate activity levels in 
relation to PI3K/AKT signalling. 
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The independent folding domains of WWP2 have a layout common to the Nedd4 family 
of proteins consisting of an N-terminal phospholipid-binding C2 domain, a C-terminal 
domain containing the catalytic cysteine called the HECT domain, and four central WW 
domains. Soond and Chantry (2011) published data confirming the presence of WWP2 
isoforms with WW domains from opposing regions of the full-length protein, as 
discussed in chapter 1. Immunoprecipitation assays revealed that WWP2-FL was 
capable of binding Smad proteins 2, 3 and 7 but had preferential binding to Smad 7. In 
comparison, WWP2-N only interacted with R-Smads 2 and 3, whereas WWP2-C bound 
to Smad 7 only. WWP2-FL interactions with Smad 7 were also further increased by 
TGF-b stimulation. Interestingly, WWP2-N was also shown to interact with WWP2-FL. 
They proposed that in the absence of TGF-b stimulation, WWP2-FL remains in an 
autoinhibitory conformation, evidence of which was later published by Chen et al. 
(2017) establishing the 2-3 linker as the mediator of this autoinhibition. However, when 
WWP2-N is expressed under TGF-b negative conditions, this isoform interacts with and 
activates WWP2-FL leading to rapid degradation of regulatory Smads 2 and 3. 
Dimerization of WW domains has previous been found for Smurf 1/2 (Aragón et al., 
2012) which may be how these two isoforms interact to relieve the autoinhibitory 
conformation. This results in activated WWP2-FL which is primed for substrate 
interactions. In turn, when the pathway is stimulated, the preferred target for WWP2-FL 
changes towards inhibitory Smad 7 which is also targeted by the C isoform, although 
the regulation of isoform expression is still unclear.  Due to WWP2-N lacking any 
intrinsic ubiquitination activity, its interaction with Smads 2 and 3 is thought to stabilise 
the expression levels of these proteins by competing with WWP2-FL, or by recruiting 
these proteins to WWP2-FL for ubiquitination (Soond and Chantry, 2011) 
Understanding the nature of these interactions may reveal more about this bias in 
substrate targeting by the isoforms and lead to ways of selectively targeting these 
interaction patterns.  
 
The structural basis of the substrate interactions with Nedd4 family proteins are not 
fully known due to difficulties obtaining stable and abundant independent WW domains 
for structural studies. The WW domains of WWP2 are 33-34 amino acids in length 
containing 1-2 tryptophan residues, fold into the characteristic three antiparallel 
b-strands, similar to the structure shown in the previous chapter for WW4, and 
commonly bind to PPxY motifs. Sequence alignment between each of the WW domains 
(Figure 4.1.1) highlighted WW1, 2 and 3 as 70-75 % similar, however comparison of 1, 
2 and 3 each with WW4 was between 55-60 %. This suggests the difference in binding 
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preferences between WW1 and WW4 as seen via the N and C isoforms is not 
particularly surprising. However, little is currently known about the binding activities of 
WW2 and WW3 within WWP2-FL, which may help elucidate whether this sequence 
similarity is reflected in binding preferences and affinities, or whether it is the structure 
and side chain rotamer orientations that decide this. 
 
WW4      PALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRP  
WW3      GPLPPGWEKRQD-NGRVYYVNHNTRTTQWEDPRT  
WW1      DALPAGWEQRELPNGRVYYVDHNTKTTTWERPLP  
WW2      RPLPPGWEKRTDPRGRFYYVDHNTRTTTWQRPTA  
     ** *** :   .*  *:*:***:** :: * 
Figure 4.1.1 - Sequence comparison of WWP2 WW domains.  
Alignment analysis of the amino acid sequences for the four WW domains present in WWP2. 
* refers to fully conserved residues; : represents conservation of residue properties of strong 
similarity; . represents conservation of residue properties of weak similarity. 
There is building evidence of WW domains acting in tandem rather than exclusively 
independent, with 5 proposed modes of action (Dodson et al., 2015). By acting in pairs, 
this enables a tighter regulation of substrate selection and ubiquitination in a cell-based 
context. Evidence of increased binding affinity by the interaction of both WW domains 
to different motifs where the binding of one is regulated by the binding of the other has 
been found for Nedd4L (Aragón et al., 2011), and suggested for Smurf 1/2 (Chong et 
al., 2010). Nedd4L WW2 and WW3 domains interacted with phosphorylated Smad 3 at 
adjacent binding motifs. WW2 recognised the PPxY motif and a phospho-Threonine 
(pT) site whereas WW3 bound to phospho-Serine (pS) adjacent to the other motifs, 
with the binding of WW3 leading to an increase in overall affinity. Similarly, Smurf 2 
showed cooperative WW domain binding to Smad 7 via WW2 and WW3 where WW2 
created additional contacts with negatively charged residues and prolines N-terminal 
to the PPxY motif to increase the binding of WW3 to Smad 7. However, this is 
controversial as data published by the same group a year later suggested that rather 
than interacting with an upstream motif to increase binding, it might be that the ability 
of WW2 to dimerise results in increased stability of the tandem domain leading to a rise 
in affinity (Aragón et al., 2012). While both of these examples involving Nedd4 E3 
ligases highlight the occurrence of 2 of 5 models in tandem domain cooperativity 
(Dodson et al., 2015), it does not rule out the possibility of independent binding to 
different motifs leading to an additive affinity, a change in ligand preference of the first 
domain due to the presence of the second altering the structure of the first, or the 
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presence of the second domain reducing the likelihood of interaction by obtaining an 
unfavourable conformation. Another aspect discovered to influence tandem domain 
activity was the length of the linker region between the two domains. A reduced affinity 
for Smad 7 was observed for the longer Smurf 1 isoform, which has an extra 26 
residues, unlike the shorter isoform which used WW domain coupling in its interaction 
(Chong et al., 2010). The lack of linker between WW1-2 in WWP2 and only 6 amino 
acids between WW3-4 suggests that WW domain coupling may be a regulatory 
mechanism adopted by WWP2-FL for controlling substrate interactions.  
 
Changes to the protein-protein interactions discussed above by overexpression of one 
or more component/isoform contributes to the development of cancer. Targeting these 
protein-protein interactions has become increasingly popular for drug design.  
Peptide-based therapies as novel drugs are favourable over small molecules due to 
their specificity and increased efficacy towards the intended target. Evidence from the 
analysis of protein-protein interfaces showed an increased propensity for certain amino 
acids such as aromatic residues (Sillerud and Larson, 2005). It is thought that these 
residues along with arginine and a few aliphatic residues (proline and isoleucine) which 
are predominant at interaction sites contribute to the overall binding energy of the 
interaction. Additionally, the presence of 2 tryptophan residues (phenylalanine in the 
place of the second in a few cases) and other favourable residues in these WW 
domains make them ideal templates. This is why understanding which residues are 
involved in WWP2: substrate binding will aid the design of peptidomimetics against the 
interactions associated with oncogenesis.  
 
The use of NMR titration analysis can identify the key residues involved in 
protein-protein interactions. NMR titrations reveal changes in the protein upon 
substrate binding at an atomic level. [1H-15N]-HSQCs are used in this project to trace 
the chemical shift changes of amide groups induced by either direct binding of the 
peptides or by conformational alterations induced by the binding. A change in the 
chemical environment of an atom, referred to as exchange, is reflected in an alteration 
in the spin system resonant frequency (Keeler, 2010), which can be visibly observed in 
the spectrum after data is collated. Three possible types of exchange may occur during 
a protein-ligand interaction experiment determined by the rate constant for exchange. 
Each nucleus can exist at two chemical shift values, one characteristic of the unbound 
conformation (A) and the other the bound conformation (B). If the interaction results in 
many exchanges between the unbound and bound conformations during the 
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experimental time-frame then an average of the two chemical shifts is observed. This 
is referred to as fast exchange. The observed chemical shift value is dictated by the 
proportion of nuclei in each conformation. For example, at the start of a titration more 
nuclei precess at the frequency of the unbound conformation, producing a peak at 
chemical shift A. As ligand is gradually added, the population may shift towards the 
bound conformation resulting in steady movement towards chemical shift B. In the 
absence of exchange within the detection period (slow exchange), if only one 
conformation exists then only one peak is observed, or if there are populations of both 
conformations, peaks are observed at positions A and B. The last possible exchange 
type is intermediate exchange. This is where the exchange rate between the 
conformations increases enough that the time of precession at each frequency 
ultimately cancels each other out and results in line broadening. Understanding each 
of these situations can provide information about key residues on the interaction 
interface. As such, peaks which are involved in peptide binding or undergo allosteric 
changes will migrate towards the bound chemical shift position according to the rate of 
binding. The association between the rate of exchange and ligand binding can be used 
to calculate dissociation constants for the specific residues involved in the interaction. 
In some cases, however, peaks can disappear and reappear at a different chemical 
shift making it difficult to determine a dissociation constant. The focus of this work 
however, was using NMR titrations to further understand the key residues involved in 
the interactions rather than affinities.  
 
In the previous chapter, a structure-based approach to targeting the overexpression of 
WWP2 was discussed in relation to the fourth WW domain. Building upon this concept, 
this chapter discusses WWP2 interactions with substrates: PTEN, Smad 2, 3, and 7, 
directed towards the use of NMR titrations in peptidomimetic design. Given that PTEN 
lacks a known WW domain interaction motif, the initial aim was to determine whether 
the three WWP2 isoforms FL, N and C could interact with PTEN. The next aim was to 
use titration analysis to understand the binding of substrates on an atomic level to 
WWP2. Initially, the interaction with PTEN was the focus, however, due to problems 
isolating a single region of WWP2 that interacted with PTEN, the aim changed to look 
at Smad protein binding to WW1 due to its presence in the N isoform and the WW1-2 
tandem domain which lacks an obvious linker region, using peptides based around the 
PPxY motifs. The objective was to identify the key residues involved in substrate 
binding in order to design peptidomimetics, which with the presence of two tryptophan 
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residues and several aromatic groups provided a favourable basis for inhibitory peptide 
design. 
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4.2. Results 
 
4.2.1. WWP2-PTEN interaction analysis 
Previous research indicated that PTEN interaction with WWP2 is mediated via amino 
acids 100-187 of PTEN (Maddika et al., 2011). However, the region within WWP2 that 
binds to PTEN remains unknown. Due to the lack of PPxY motif in PTEN, this also 
suggests that the WW domains of WWP2 may interact with alternative substrate-based 
motifs. Therefore, pull-down analysis of WWP2 isoforms with PTEN may provide more 
information about how WWP2 targets this substrate. In order to look at the binding of 
WWP2 isoforms to PTEN, full-length PTEN (GST-PTEN-FL), and GST-PTEN deletion 
constructs 1-274 and D274-342 (Figure 4.2.1A) were bacterially expressed and purified 
on glutathione beads. WWP2-FL, WWP2-C and WWP2-N were expressed as 
Flag-tagged proteins in mammalian HEK 293A cells, and the lysate added directly to 
the bead samples. Analysis was carried out on the proteins bound to the beads using 
SDS-PAGE and western blotting with anti-flag antibody. Results showed that 
WWP2-FL bound to full-length PTEN but not constructs 1-274 and D274-342 (Figure 
4.2.1B), potentially due to lower affinity for mutated forms of PTEN perhaps due to loss 
of an additive binding region although this requires further investigation. In contrast to 
this, WWP2-C showed binding to only PTEN-FL and D274-342, whereas WWP2-N 
interacted with all constructs. This suggested that the WWP2 isoforms may interact 
differently with PTEN, potentially resulting in different consequences. It is important to 
note that the majority of expressed GST-PTEN constructs were present in the insoluble 
material during purification, suggesting the presence of inclusion bodies. This may 
explain the difference in WWP2-FL results as the abundance of constructs 1-274 and 
D274-342 was lower than GST-PTEN-FL as seen in the SDS-PAGE image for the 
samples used (Figure 4.2.1B lower panel), however the results of N and C isoform 
pull-downs would indicate otherwise.  
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Figure 4.2.1 - WWP2 isoform interaction analysis shows binding differences.  
A) Schematic representation of the constructs used in B. Flag-tagged isoforms: WWP2-FL 
(full-length), -N (N-terminal) and C (C-terminal); GST-tagged tumour derived PTEN constructs 
spanning amino acids 1-403 (FL - full-length), 1-274 and deletion construct missing residues 
274-342. GST – glutathione S transferase (tag); PBD – phospholipid binding domain; PDZ-BD 
– PDZ binding domain. B) GST-coated or GST-PTEN-coated glutathione beads were incubated 
with cellular lysate containing expressed Flag-WWP2-FL, -WWP2-C or -WWP2-N. Beads were 
B
A
 100 
then washed, and the proteins eluted. Samples were analysed by SDS-PAGE and western blot 
using anti-flag antibody (n=1). Negative controls included ‘GST only’ - GST-coated beads 
incubated in buffer, and ‘GST’ - GST-coated beads incubated with lysate expressing flag-tagged 
protein. GroEL refers to the chaperone protein present in bacteria such as E.coli. 
 
To further investigate the difference in isoform binding, PTEN deletion constructs were 
synthesised by mutagenesis spanning from the first amino acid up to the end of the 
phosphatase domain (1-185) or to the end of the C2 domain (1-350) (Figure 4.2.2A). 
Constructs were expressed and purified on glutathione beads as described in section 
2.2.4.5. Pull-down analysis using lysates expressing the N and C isoforms was carried 
out and the purified proteins analysed by SDS-PAGE and western blot. The N-isoform 
is known to run at ~50 kDa and the C-isoform at ~45 kDa (Wahl, 2016), which was 
further backed up in this work by plasmid sequencing to verify the plasmids and 
associated expression bands on SDS-PAGE. A band consistent with the N isoform is 
present in all PTEN sample lanes suggesting binding occurs between each N-terminal 
domain of the proteins (Figure 4.2.2B). In contrast, the C isoform showed binding to 
full-length PTEN and no interaction with 1-350 truncated protein. It is unclear whether 
the C isoform interacts with construct 1-185 as both proteins migrate to ~45 kDa. The 
presence of PTEN bands on the anti-Flag western blot, in particular the WWP2-N + 
PTEN 1-185 lane, suggested that this band may be due to non-specific antibody 
interaction with GST-PTEN 1-185 and not the C isoform. However, this cannot be 
concluded and would require further analysis. Overall the data supports the conclusion 
that the isoforms interact with alternate ends of the PTEN protein, perhaps indicating 
separate mechanisms of regulation and turnover dependent on the isoform and cellular 
signalling status of PTEN activity. 
 
 101 
 
Figure 4.2.2 - Pull-down analysis of PTEN deletion construct interactions with WWP2 
isoforms N and C.  
A) Schematic diagram showing the constructs of GST-PTEN and Flag-WWP2 used in part B. 
PBD - phospholipid binding domain; PDZ-BD - PDZ binding domain; FL – full length. B) 
Glutathione beads bound by GST or GST-PTEN constructs were incubated with flag-tagged N 
and C WWP2 isoform containing lysates. Bound proteins were eluted and analysed by 
SDS-PAGE and western blot against flag-tag (n=1). Negative controls were GST-coated beads 
either incubated in buffer (‘GST only’ lane) or with isoform lysate (‘GST’ lane). White asterisks 
(*) refer to PTEN bands based on molecular weight migration pattern.   
 
  
A
B
* * 
* 
* * 
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Another aspect of interest are the WW domains, as these convey substrate specificity. 
Due to the lack of PPxY motif in PTEN, the next step was to determine whether PTEN 
is capable of interacting with WW domains, as the presence of WW1 in the N isoform 
and WW4 in the C isoform may be involved in PTEN binding. Due to difficulties 
expressing individual WW domains for pull-down analysis, HA-tagged tandem domain 
constructs WW1-2 and WW3-4 were used (produced by Tiffany Yim). Constructs were 
expressed in HEK 293A cells and the lysates added to GST-PTEN-FL, 
GST-PTEN 1-185 or GST-PTEN 1-100 coated beads. Constructs are outlined in Figure 
4.2.3A. After incubation, the beads were washed, and purified proteins analysed by 
SDS-PAGE and western blot. Results showed that WW1-2 only interacted with 
full-length PTEN, whereas WW3-4 showed interaction with all constructs (Figure 
4.2.3B). These results suggest that these tandem domains also interact with opposing 
sides of PTEN. Compared to the isoform results, these tandem domains showed a 
different pattern of binding, suggesting that perhaps when expressed as isolated 
regions, these domains seem to be able to bind to alternative sites in PTEN, perhaps 
one that is adjacent to the N-isoform C2 interaction site or HECT binding site for the C 
isoform in PTEN. However, it was interesting that the WW domains were still able to 
interact with these constructs despite the lack of the well-known motif targeted by these 
WW domains and further investigation may reveal the amino acids involved in the 
interaction within both proteins. Collectively, the data suggests that the binding region 
of WWP2 to PTEN seems to depend on the isoform and that the binding site may in 
fact consist of several regions across the WWP2 protein and PTEN. For this reason, 
along with the low bacterial expression levels of PTEN constructs due to the formation 
of inclusion bodies, further investigation of this interaction using NMR was not pursued. 
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Figure 4.2.3 - GST-pull-down analysis of tandem WW domains with PTEN constructs. 
A) Representative diagrams of the constructs used in part B. WW – double tryptophan domain; 
HECT – homologous to E6AP C-terminal domain; HA – tag derived from human influenza 
hemagglutinin; GST – glutathione S transferase (tag); PBD – phospholipid binding domain; 
PDZ-BD – PDZ-binding domain B) GST-coated beads or GST-PTEN-coated beads were 
incubated with lysates expressing HA-WW1-2 or HA-WW3-4 then washed several times. Bound 
proteins were analysed by western blotting against HA (upper panel). SDS-PAGE was used to 
determine the levels of PTEN in the experiment (lower panel). Images in B representative of 2 
experiments (n=2).  
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4.2.2. Smad peptide generation 
Due to pull-down assays indicating the binding region between PTEN and WWP2 may 
actually include several regions across WWP2, this meant analysis of the PTEN-WWP2 
interaction was not investigated by NMR titrations at this stage. Furthermore, the 
presence of inclusion bodies reducing the proportion of soluble PTEN constructs 
suggested that obtaining a high enough concentration would also have proven 
challenging. Therefore, focus shifted towards the Smad proteins 2, 3, and 7 which are 
known interactors of WWP2 WW domains (Soond and Chantry, 2011).  
 
In order to carry out titration analysis, peptides were designed based on the PPxY motif 
in the linker regions of Smad 2 and 3 and incorporating residues on either side of this 
motif, outlined in Figure 4.2.4A. Bacterial expression and purification was investigated 
for the production of recombinant peptides. Previous work in the lab showed that this 
was possible for Smad 7 peptide but had yet to be tested for Smad 2 and 3. pET21d 
plasmids containing the sequences for Smad 2 and Smad 3 peptides were generated 
using in-fusion cloning to create His-SUMO-fusion constructs. Bacterial expression and 
Ni-affinity purification showed high quantities of recombinant protein could be 
expressed and isolated (Figure 4.2.4B). However, upon digestion using commercial 
SUMO-protease at room temperature after dialysis into SUMO-protease buffer, as 
recommended, no digestion was present in the first 21 hours (data not shown). After 
further incubation, precipitate formed before complete digestion could be achieved. 
Analysis of the precipitate showed increasing MW bands from 6.5 kDa all the way up 
to 200 kDa, as well as undigested and digested SUMO construct bands (Figure 4.2.5A). 
This suggested partial digestion and potential aggregation of the free peptides. A 
sample of in-lab expressed and purified ULP-1 was also tested at a ratio of 0.5:60 to 
determine whether the previous sample had low activity levels or whether the added 
quantity could increase the digestion rate. No precipitate formed with the new UPL-1 
present, however by 72 hours at room temperature degradation was observed with 
incomplete digestion at up to 50 % which did not occur for Smad 7 peptide generation, 
shown in Figure 4.2.5B. Taking forward the partial digestion to see whether any 
peptides were present, results showed faint peptide bands at 2.5 and 3 kDa equating 
to the size of the Smad 2 and Smad 3 peptides, respectively. This suggests that the 
generation of these peptides may be possible, however when this was repeated, using 
ULP-1 at a 0.25:30 ratio, degradation was observed before adequate digestion (data 
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not shown). It is possible that the protein molecules were folded in a manner which 
sterically hindered access to the di-Gly digestion site in the majority of the sample, or 
that the original constructs are just too unstable for the timeframe required for complete 
digestion. The latter is suggested due to the lower MW bands present in some fractions 
at the initial purification stage (Figure 4.2.4B), although this may be residual 
non-specific proteins from the Ni-affinity column. One aspect which could have had an 
effect was the concentration of the protein sample, as the expression level was very 
high and the volume at digestion was only 25-30 mL. Overall, Smad 2 and 3 peptide 
generation using bacterial expression and purification was unsuccessful at this stage, 
but it may be possible with further optimisation analysis. Therefore, synthetic peptides 
with the sequences described in Figure 4.2.6 were purchased for use in titration 
analysis. 
 
 
Figure 4.2.4 - His-SUMO-Smad 2 and -Smad 3 peptide construct purification by Ni-NTA 
affinity purification. 
A) Amino acid sequences for the Smad 2 and Smad 3 peptide constructs. B) 15 % SDS-PAGE 
analysis of the whole, insoluble, soluble, and Ni-affinity purifications of Smad 2 and Smad 3 
constructs. Purification was performed using ÄKTA-FPLC with fractions collected under UV 
monitoring at 280nm, with every other the peak fraction analysed by SDS-PAGE. 
Representative gels for 4 experiments (n=4). 
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Figure 4.2.5 - Digestion analysis of Smad 2 and Smad 3 peptide constructs.  
A) SDS-PAGE analysis using Coomassie staining of digestion samples with commercial SUMO 
protease. B) Comparison of His-SUMO-Smad 7 peptide digestion to His-SUMO-Smad 2 and -3 
using in-lab expressed ULP-1 at a ratio of 0.25:30 (ULP-1: His-SUMO-Smad2/3). C) Silver 
stained tricine gradient gel of Smad 2 and Smad 3 peptide samples. ? indicates potential 
contaminant bands. Gel images representative from 4 experiments (n=4). 
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Figure 4.2.6 - Synthetic peptide sequences for Smad 2, 3 and 7 used in titration analysis. 
Amino acid sequences for peptides based on the PPxY motif and surrounding residues of 
Smad 2, Smad 3 and Smad 7, with the start and end residue numbers according to the 
full-length proteins.  
4.2.3. GB1-WW1 backbone assignment 
Peaks in NMR spectra can be allocated to the specific nuclei in the protein residues 
based on the chemical shift positions, often referred to as peak assignment. The 
assignment of amide groups in [1H-15N]-HSQC spectra for each residue is necessary 
for understanding NMR titration data and is the starting point for NMR-based structural 
analysis of proteins. To investigate the WW1 domain of WWP2, the domain was 
generated as a fusion protein with GB1 to overcome previous insolubility problems 
seen with WW domains when expressed on their own (Kristine Kay, 2012, personal 
communication). His-GB1-WW1 was bacterially expressed in double-labelled 13C-15N 
minimal media, digested using thrombin and purified using affinity-tag purification. 
HSQC, HNCaCb and CbCaCONH NMR spectra were collected at 800 MHz. GB1 
assignments were obtained from Lloyd Wahl. No significant difference in peak positions 
were observed between GB1 when fused to either WW1, WW3 or WW4 (data not 
shown) suggesting GB1 has no significant interaction with the WW domain, and only 
influences the solubility of the construct by preventing aggregation. Sequential 
assignment of 13C-15N-GB1-WW1 was carried out using CcpNmr Analysis. Overall, 
86.5 % of GB1-WW1 was assigned (70 % of WW1 only) with the exception of proline 
residues and 1 Gly, 2 Ser, 63 Ala, 83 Tyr, 84 Val, 85 Asp, 86 His, and 95 Arg.  A 
[1H-15N]-HSQC spectrum displaying the assigned peaks and 10 unassigned peaks is 
shown in Figure 4.2.7A. The presence of peak broadening, shown by residues 50 Asp, 
70 Gly and 79 Gly for example (Figure 4.2.7B), suggests that these residues are 
undergoing slow chemical exchange in the experimental timeframe, potentially due to 
more than one conformation. The unassigned peaks may therefore be from an 
alternative conformation of the protein, rather than the missing peaks for the residues 
mentioned above, as suggested by the Ca and Cb chemical shift values (data not 
shown). Also, the clustering of many WW1 peaks towards the centre of the spectrum, 
SMAD 2: (217) IPETPPPGYISEDGE (231)
SMAD 3: (176) IPETPPPGYLSEDGE (190)
SMAD 7: (203) ELESPPPPYSRYPMD (217)
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with relatively low 1H dispersion compared to GB1 peaks surrounding this region, also 
suggests incomplete folding. This result meant that further structural work with unbound 
WW1 was not possible, however interaction analysis using titrations may still provide 
information about how WW1 interacts with substrates. 
 
 Figure 4.2.7 - Assigned peaks of 15N-GB1-WW1.  
A) [1H-15N]-HSQC spectrum of 15N-GB1-WW1 recombinant protein, annotated with peak 
assignments. B) Examples of peaks undergoing chemical exchange in the experimental 
timescale – 50 Asp (left), 70 Gly (middle), 79 Gly (right). Ppm – parts per million.  
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4.2.4.  Titration analysis of WW1 interactions with Smad protein-based 
peptides  
Evidence published by Soond and colleagues (2013) highlighted the preferential 
binding of the WW domains in WWP2 towards particular Smad proteins. Synthetic 
peptides based on the Smad protein PPxY region were used to investigate the binding 
between WW domains and Smad proteins. The following work looks at WW1 
interactions using NMR titration analysis. 
 
4.2.4.1. GB1-WW1 titration with Smad 2 peptide 
To investigate the interaction of Smad 2 with WW1, purified 15N-GB1-WW1 in NMR 
buffer was prepared as described in section 2.4.1. A 1D-1H-NMR spectrum and 
[1H-15N]-HSQC (800 MHz) were obtained before starting the titration to check the 
sample for degradation or contaminants and provide a pre-titration spectrum for 
comparison to titration points with the presence of peptide. A few differences in the 
central cluster of peaks in the HSQC were observed (black boxes in Figure 4.2.8) 
compared to the previous HSQC, suggesting slightly different chemical environments 
and motions than the previous preparation of 15N-GB1-WW1, however as the shifts and 
number of new peaks are minimal, this was not deemed a problem for further work. 
The titration was carried out as described in section 2.4.3 with sequential additions of 
synthetic Smad 2 peptide up to a ratio of 1:0.92. Due to loss of the sample, no further 
titration points could be carried out. Very few changes were observed as shown in 
Figure 4.2.9, which includes the increasing peak intensity of 87 Asn, decreasing 
intensity and peak migration for 92 Thr (Figure 4.2.9B), and the appearance of an 
unassigned peak. These changes could be explained by peptide interaction with these 
residues inducing a change in folding, but as 92 Thr presents with exchange 
broadening with no peak reappearance, this implies incomplete binding, which is 
explainable by the lack of peptide saturation. As the titration was only to a 1:0.92 ratio 
with incomplete binding, due to time restrictions preventing repeat expression and 
purification of 15N-GB1-WW1, further titration points are required to conclusively 
determine the interacting residues of WW1 with Smad 2 peptide.  
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Figure 4.2.8 - [1H-15N]-HSQC comparison of a 13C-15N-GB1-WW1 sample and 
15N-GB1-WW1 sample.  
Overlaid HSQCs of double-labelled (DL) GB1-WW1 used for backbone amide assignment 
(blue) and single-labelled (SL) GB1-WW1 used for the Smad 2 titration (red). ppm – parts per 
million. 
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Figure 4.2.9 - Titration of GB1-WW1 with Smad 2 peptide.  
Synthetic Smad 2 peptide was added sequentially to a sample of 15N-GB1-WW1, ranging from 
a ratio of 1:0 (light pink) to 1:0.92 (red). A) Overlaid [1H-15N]-HSQCs for ratio points 1:0 to 1:0.92. 
B) Spectral region showing decreasing intensity and peak shift for residue 92 Thr (92T), 
alongside an unmoving GB1 peak for comparison. X indicates no peak shifting, whereas the 
arrow indicates movement. The concentration of 15N-GB1-WW1 was 0.6 mM across all titration 
points, with a final Smad 2 peptide concentration of 0.55 mM. ppm – parts per million.  
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4.2.4.2. GB1-WW1 titration with Smad 3 peptide 
WWP2-N isoform has been shown to interact with both Smad 2 and Smad 3 so the 
next step was to investigate the interaction of WW1 with Smad 3 peptide. A titration 
using synthetic Smad 3 peptide was carried out as described in section 2.4.3 at 
500 MHz. Several peaks were shifted by the end of the titration as shown in Figure 
4.2.10A. Many peaks that migrated were GB1 peaks, with some examples highlighted 
by red boxes, suggesting Smad 3 interaction with GB1. However, previous GB1 fusion 
protein titrations with the same peptide sequence showed minimal interaction of 
Smad 3 with GB1 (Wahl, 2016). Furthermore, the majority of peak migration is towards 
the centre of the spectrum. Clustering of peaks in this manner, towards the centre of 
the spectrum, is characteristic of unfolded proteins due to increased hydrogen 
exchange with water hence lower 1H dispersion. Therefore, these results are more 
indicative of protein denaturation rather than peptide interaction. Further analysis was 
carried out to determine the cause of this denaturation. Due to the use of synthetic 
peptides, 19F-NMR was used to find out whether the presence of trifluoroacetic acid 
(TFA) from the synthetic peptide synthesis process could be the problem. Previous 
work with synthetic peptides purchased as TFA salts showed no denaturation (Wahl, 
2016), however the 19F-NMR for the titration sample suggests that there is a high 
concentration present in this experiment (Figure 4.2.10B). This explained the 
denaturation of GB1-WW1 at the later titration points. Samples of peptide used 
previously may have had a much lower concentration of TFA hence the lack of 
denaturation. Analysis of the titration points before GB1 peak migration shows residue 
87 Asn increasing in intensity suggesting a transition from more than one unbound 
conformation to a bound conformation with increasing proportions in the bound state 
resulting in an observed change to the fast exchange regime. 88 Thr also presents a 
small shift in peak position, and 92 Thr appears to transition from an unbound 
conformation to a mixed population of bound and unbound presenting as intermediate 
exchange during the timescale of the experiment (Figure 4.2.11A). These changes are 
shown in closer detail in Figure 4.2.11B. The changes in 87 Asn and 92 Thr suggests 
similar interaction residues in WW1 for Smad 2 and Smad 3 peptides, however the lack 
of movement by 88 Thr suggests either there is a slight difference in binding interface 
between Smad 2 and 3 peptides with WW1 or that the movement of 88 Thr was not 
observed for Smad 2 because the titration had not reached the equivalent ratio. The 
latter is more likely due to only 2 differences in the amino acid sequences for Smad 2 
and Smad 3 peptides. 
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Figure 4.2.10 - 15N-GB1-WW1 titration with increasing Smad 3 peptide additions.  
A) Overlaid HSQCs of titration points 1:0 (light blue) to 1:9.7 (black). Red boxes indicate 
examples of GB1 peak movement. B) 19F-NMR spectrum of 15N-GB1-WW1:Smad3 after the 
final titration point. The concentration of 15N-GB1-WW1 used in the titration was 0.6 mM, with a 
final concentration of 5.85 mM Smad 3 peptide. ppm – parts per million. 
-75.39
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Figure 4.2.11 - Titration points 1:0 to 1:2 for 15N-GB1-WW1: Smad 3.  
A) 15N-GB1-WW1 titration with synthetic Smad 3 peptide, ranging from 1:0 (light blue) to 1:2 
(dark blue). B) Spectral regions of amino acids 87 Asn (87N), 88 Thr (88T) and 92 Thr (92T), 
highlighting the changes observed over the first half of the titration. Arrows indicate direction of 
migration and X marking no change in position. ppm – parts per million. 
 
4.2.4.3. GB1-WW1 titration with Smad 7 peptide 
Lastly, Smad 7 peptide was used to confirm the lack of binding observed for WWP2-N 
by investigating the interaction between WW1 and Smad 7 peptide. Due to previous 
titration analysis of WW4 with Smad peptides showing interaction capabilities with 
Smad 2 and 3 as well as 7, but at a lower affinity for the R-Smads (Wahl, 2016), the 
analysis here was used to determine whether an inverse interaction pattern to WW4, 
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where lower affinity is present for the I-Smad instead, could exist between WW1 and 
Smad 7. A titration was set up as described in section 2.4.3 and HSQC spectra acquired 
at 800 MHz. Comparison of all titration points showed the appearance of a few sharp 
peaks around 15N~130 ppm, 1H~8 ppm (Figure 4.2.12), suggesting the presence of 
degradation. Due to previous data showing no interaction of Smad 7 with WWP2-N and 
the location of these peaks towards the bottom of the spectra, it is more likely that these 
peaks are due to degradation rather than folding of WW1 upon Smad 7 binding. 
However, the appearance of peaks in the central cluster and beside 70 Gly and 79 Gly 
at 15N~110 ppm with 79 Gly disappearing from the later spectra, and the appearance 
of 88 Thr in later HSQCs suggests that there is a change in folding. It is difficult however 
to conclude that there could be weak interaction of Smad 7 with WW1, because of the 
lack of significant changes, and presence of degradation. 
 
Figure 4.2.12 - Titration HSQCs of 15N-GB1-WW1 with increasing concentrations of Smad 
7 peptide.  
Overlaid HSQC spectra for Smad 7 peptide titration points ranging from 1:0 (light purple) to 
1:8.5 (dark purple). 0.06 mM 15N-GB1-WW1 was used throughout the titration with a final 
concentration of 0.51 mM Smad 7 peptide at 1:8.5 ratio. ppm – parts per million. 
 
GB1-WW1 Smad7 titration
1H (ppm)
15
N 
(p
pm
)
6.06.57.07.58.08.59.09.510.010.5
6.06.57.07.58.08.59.09.510.010.5
105
110
115
120
125
130
105
110
115
120
125
130
1:0 1:8.5
 116 
4.2.5. Partial assignment of 15N-GB1-WW1-2 
Studies have suggested coupled activity of WW domains in other Nedd4 E3 ligases, 
which had not yet been analysed in WWP2. The end of WW1 and start of WW2 overlap 
in sequence slightly and therefore lack an obvious linker region between the two 
domains, suggesting that perhaps when both are present within WWP2-FL they may 
function in a cooperative manner unlike when WW1 is isolated in the WWP2-N isoform.  
In order to begin investigations into whether WW domains 1 and 2 influence each other 
when present in WWP2-FL, GB1-WW1-2 fusion protein was bacterially expressed and 
purified as described in section 2. [1H-15N]-HSQC analysis to look at the amide group 
positions was carried out to determine if there were any significant differences 
compared to GB1-WW1 and GB1-WW2. GB1-WW1-2 has a total of 124 assignable 
residues excluding prolines, however only 98 peaks excluding side chains were present 
in the HSQC (Figure 4.2.13). This suggests the other 34 peaks are in intermediate 
exchange and unobservable under the conditions and timescale of the experiment. As 
there were too many peaks in intermediate exchange to acquire triple resonance data 
on GB1-WW1-2, the partial assignments for WW1 (Figure 4.2.7) and WW2, provided 
by Danielle Bourcier, were used to try and assign some of the peaks in WW1-2. Only 
75.8 % of peaks were assignable, with the majority being GB1 peaks.  When the HSQC 
spectrum for 15N-GB1-WW1-2 was compared with 15N-GB1-WW1 and 15N-GB1-WW2, 
there were several differences observed (Figure 4.2.14). The majority of GB1 peaks 
were identical between the constructs, except for some deviation seen for residues 
6 Tyr and 23 Ala in GB1-WW2. Several peaks showed no overlap with those from 
GB1-WW1 or GB1-WW2 suggesting WW1-2 has a different fold to either independent 
domain. One similarity across all three constructs though was missing peaks and 
intermediate exchange. This may suggest that these domains have an intrinsically 
unfolded structure when unbound.  
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Figure 4.2.13 - [1H-15N]-HSQC with partial backbone assignment for 15N-GB1-WW1-2. 
Annotated HSQC of GB1-tagged WWP2 WW1-2 tandem domain with the backbone amide 
group assignment where possible. ppm – parts per million. 
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Figure 4.2.14 - GB1-WW1, -WW2 and -WW1-2 HSQC spectra overlaid.  
Single-labelled GB1-tagged WW1 (green), WW2 (orange) and WW1-2 (blue) HSQC spectra. 
ppm – parts per million. 
 
4.2.6. Titration analysis of 15N-GB1-WW1-2 tandem domain with Smad-
based peptides 
The amino acid sequence for WW1-2 has often been depicted by having a linker region 
between the domains. Closer analysis of the end point of the N isoform and the start of 
the WW2 domain however suggests that there could potentially be an overlap of the 
330-RPLP-333 sequence at the end of WW1 and start of WW2. This suggests that 
these domains may influence each other in FL isoform, unlike when WW1 is isolated in 
the N isoform, possibly resulting in different outcomes. The next section looks into the 
binding of Smad peptides to the tandem domain WW1-2, with comparison to WW1 and 
WW2 individually. 
4.2.6.1. GB1-WW1-2 titration with Smad 2 peptide 
To look at the binding of Smad 2 peptide with WW1-2, 15N-GB1-WW1-2 was bacterially 
expressed and purified as described in sections 2.2.2 and 2.2.4. Sequential additions 
of peptide were made to the sample and [1H-15N]-HSQCs acquired after each addition, 
up to a ratio of 1:10 protein to peptide. Comparison of the HSQCs showed the same 
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pattern of GB1 migration (examples highlighted in red boxes in Figure 4.2.15A) as 
observed for GB1-WW1 with Smad 3 peptide previously discussed in section 4.2.4.2. 
19F-NMR confirmed the presence of TFA in this sample of peptide (Figure 4.2.15B), 
resulting in denaturation of 15N-GB1-WW1-2 after a 1:4 ratio of protein to peptide. 
Analysis of the titration before denaturation though, showed some very interesting 
changes, highlighted in Figure 4.2.16A. One significant aspect is the migration of the 
tryptophan side chains located to the bottom left region of the spectra (Figure 4.2.16A 
and B), suggesting the side chains are changing chemical environment, perhaps due 
to peptide binding inducing protein folding or the result of direct binding as the expected 
binding site, the XP pocket, contains a tryptophan residue. It is clear that 2 side chains 
undergo a greater perturbation in chemical shift than the other 2. As there are currently 
no side-chain assignments for WW1-2, using the overlaid spectra of WW1 and WW2, 
it is clear that one peak which showed a reduced degree of migration was located in 
WW2, however it is unclear which of the other 3 belong to each domain. The movement 
of the tryptophan side-chains was not present in the previous WW1 titrations 
suggesting that the presence of WW2 has either altered the residues involved in 
binding or an increase in the affinity of the domains for Smad 2 peptide has occurred. 
However, elucidating which is the case requires further assignments and 
experimentation. Another observation was the appearance of new peaks, as shown by 
the purple boxes in Figure 4.2.16A. It was clear that residues 100 Gly, 108 Arg and 
119 Arg were shifting as the peptide concentration increased (Figure 4.2.16C showing 
100 Gly and 119 Arg in closer detail). This suggests WW2 within the WW1-2 construct 
is capable of binding to Smad 2 peptide, which was previously unknown. Intriguingly, 
no significant changes were observed for 87 Asn and 92 Thr which were missing 
throughout the titration or present at an alternative position, further supporting a 
difference between the interaction and folding of WW1 only and WW1-2 in the presence 
of Smad 2 peptide. These domains may be worth further investigation by collecting 
backbone assignments, which was not carried out here due to time restrictions, for the 
bound tandem domain as there is an increased number of peaks to 114 by ratio point 
1:4 and in turn could possibly increase further if the protein becomes saturated with 
peptide, potentially inducing complete folding. 
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Figure 4.2.15 - Titration analysis of 15N-GB1-WW1-2 with Smad 2 peptide shows protein 
denaturation.  
A) [1H-15N]-HSQC spectra overlaid for titration points 1:0 (light green) to 1:10 (dark green). Red 
boxes show examples of GB1 peak perturbations. B) 19F-NMR of the sample used in A. 
15N-GB1-WW1-2 was 0.72 mM across titration points, with a final Smad 2 peptide concentration 
of 7.2 mM. ppm – parts per million. 
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Figure 4.2.16 - [1H-15N]-HSQCs from 1:0 to 1:4 for 15N-GB1-WW1-2 titration with Smad 2 
peptide before denaturation.  
A) Titration points 1:0 (light green) to 1:4 (dark green) for 15N-GB1-WW1-2 with increasing 
concentrations of Smad 2 peptide. Purple boxes highlighting new peaks, and tryptophan side 
chain migrations. B) Spectral region of the tryptophan side-chains showing non-moving GB1 
tryptophan side chain and 55 Tyr peaks compared to WW1 and WW2 tryptophan side-chains 
perturbation. C) 100 Gly and 119 Arg regions showing peak shifts and new peak appearance. 
Arrows indicate direction of movement, and X marks non-moving peaks. ppm – parts per million. 
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4.2.6.2. 15N-GB1-WW1-2 titration analysis with Smad 3 peptide 
Similar to previous experiments, 15N-labelled GB1-WW1-2 was expressed and purified 
as outlined in sections 2.2.2 and 2.2.4. Smad 3 peptide was added to the NMR sample 
tube in amounts equivalent to a ratio of 1:0 up to 1:9.8 of protein to peptide (Table 
2.4.9). [1H-15N]-HSCQs were acquired at every titration point. Unlike the 15N-GB1-WW1 
titration with Smad 3 peptide, which used a different synthetic peptide sample, and the 
Smad 2 titration with 15N-GB1-W1-2, there was very little movement of GB1 which was 
only observed for the last titration point (Figure 4.2.17), and therefore this point was not 
included in further analysis. Several changes in peak positions for residues within 
WW1-2 were observed as the peptide ratio increased, as seen in Figure 4.2.18A. In a 
similar manner to the Smad 2 titration (Figure 4.2.16), residues 100 Gly, 108 Arg and 
119 Arg showed a transition from unbound conformations in intermediate exchange 
towards a bound conformation, suggesting that these residues in WW2 are involved in 
R-Smad peptide binding. The identification of the same residues was not surprising 
due to the amino acid sequences for Smad 2 and 3 peptides being very similar. The 
migration of tryptophan side-chains in an identical pattern to the Smad 2 titration further 
supports these residues as general R-Smad interaction points. In contrast, several 
peaks appeared around 31 Lys (1H~7ppm, 15N~117ppm). This region is shown in closer 
detail in Figure 4.2.18B overlaid with the same region for the WW1-2: Smad2 peptide 
titration at approximately equivalent ratios. The lack of overlap for the majority of these 
peaks between the two titrations initially suggested that these residue peaks may be 
an important difference between the Smad 2 and 3 interactions, however further 
analysis showed the peaks which failed to overlap in the original spectrum were aliased 
peaks which overlap at ~85 ppm (Figure 4.2.18B, right panel), characteristic of arginine 
NeHe side chain peaks. As arginine side chain amide peaks are only observed under 
certain conditions, this suggests that either the pH of the samples became more acidic 
over the course of the titration, which is unlikely as no water peak movement was 
present for the Smad 3 titration. Another possibility is that these arginine side-chains 
may be involved in hydrogen-bonding in the presence of peptide or they are being 
buried by the folding of the domain. The new peaks which overlap in the original 
spectrum are most likely main-chain NH peaks as they are not pairs, which then 
suggests that these residues are potentially involved in another folding arrangement 
induced by the specific Smad that is bound. These possibilities require further 
investigation as understanding the differences may reveal how the selectivity of 
WWP2-FL towards particular Smad proteins is controlled. 
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Figure 4.2.17 - 15N-GB1-WW1-2 titration with increasing Smad 3 peptide concentration 
leads to changes in peak chemical shifts.  
Overlaid [1H-15N]-HSQCs starting with ratio 1:0 of 15N-GB1-WW1-2 to Smad 3 peptide up to a 
ratio of 1:9.8. Minimal GB1 peak movement highlighted by red boxes. 0.3 mM 15N-GB1-WW1-2 
was used and a final Smad 3 peptide concentration of 2.95 mM. ppm – parts per million.  
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Figure 4.2.18 - Increasing Smad 3 peptide concentration leads to chemical shift 
perturbation of 15N-GB1-WW1-2.  
A) [1H-15N]-HSQC spectra overlaid from 1:0 to 1:7.5 of WW1-2: Smad 3 peptide, excluding the 
final point due to GB1 movement. Purple boxes highlighting peak appearance as seen in Smad 
2 titration as well. B) Spectral regions showing aliased peaks present at ratio 1:4 in the Smad 2 
(blue) titration and ratio 1:7.5 for the Smad 3 (brown) titration. X marks the folded peaks.ppm – 
parts per million. 
 
4.2.6.3. GB1-WW1-2 titration analysis using Smad 7 peptide 
The final titration with Smad 7 peptide was carried out to investigate whether the 
presence of WW2 may alter the role of WW1, and vice versa, in relation to Smad 7 
binding. Previous work has shown that Smad 7 binding to WW1 was not clearly 
observed in the titration in section 4.2.4.3 but Smad 7 has been shown to interact with 
WW2 and induce folding (Danielle Bourcier, personal communications). 15N-labelled 
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GB1-WW1-2 was prepared as described in sections 2.2.2 and 2.2.4. No movement of 
GB1 was detected throughout this titration meaning all changes observed were due to 
the binding of Smad 7 peptide (Figure 4.2.19A). Several new peaks were present at 
the end of the titration suggesting folding of the tandem domains into a bound 
conformation upon Smad 7 binding. Interestingly, the tryptophan side chain peaks and 
a few other peaks (Figure 4.2.19B) in this titration disappear and re-appear, indicative 
of a transition from a single unbound conformation to a bound conformation, rather than 
having a traceable migration path as observed in the Smad 2 titration. There were 124 
peaks present for 15N-GB1-WW1-2: Smad 7 at the last titration point. When taking 
proline residues into account, this indicates that the amide groups were all visible by 
the end of the titration in the experimental timeframe, suggesting that the tandem 
domain underwent complete folding in the presence of Smad 7. The appearance of 
peaks in similar positions to those present in the Smad 7 bound state of GB1-WW2 
(examples highlighted by blue boxes in Figure 4.2.19A) (GB1-WW2: Smad 7 work 
carried out by Danielle Bourcier), suggests that even in the presence of WW1, the 
chemical environments of most residue amide groups in WW2 are not dissimilar to that 
of WW2 only in presence of Smad 7. Furthermore, the migration of all four tryptophan 
side chains supports the folding of WW1-2 in the presence of Smad 7 peptide as well 
as direct peptide binding, due to the 1st tryptophan residue of each domain being 
associated with domain folding and stability, and peptide binding involving the 2nd 
tryptophan residue of each domain residing in the XP pocket.  
 
Comparison of all three GB1-WW1-2 titrations highlighted peaks unlikely to converge 
upon saturation, such as the peaks on the left side of the spectra (1H - ~9.5, 
15N - ~120-125) (Figure 4.2.20A, purple box) and two of the four tryptophan side chain 
amide groups (Figure 4.2.20A, blue box). This shows that slightly different chemical 
environments were observed between the R-Smads and I-Smad, supporting the 
possibility that when both domains are present in WWP2-FL it may be the concerted 
actions of WW1 and WW2 that determine which type of Smad protein is targeted and 
when, especially since WW1 appears to respond differently as a tandem domain with 
Smad 7 compared to on its own. As for the aliased peaks, only 6 out of 8 possible 
arginine residue peaks are present for WW1-2. These peaks are observed in all 3 
titrations with GB1-WW1-2 (Figure 4.2.20 A and B). When compared to the GB1-WW1 
titrations, only a single peak in this region appeared in the Smad 2 and Smad 3 titrations 
with WW1, but not in the Smad 7 titration which used the same peptide sample. As the 
side chain amide peaks broaden in the pH range of pH 6 – 7.2 (Yavari and Roberts, 
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1978), and the pH of the GB1-WW1-2: Smad 7 titration changed slightly by -0.25 from 
an initial pH of 6.5, this suggests that even with the decrease in pH it is unlikely that 
these peaks should be present. Hence it is possible these are the consequence of 
hydrogen bonding. Furthermore, these peaks are not present in the Smad 7 titration 
with GB1-WW2 (Danielle Bourcier, personal communication), suggesting that this may 
be a tandem domain result with regards to the presence of WW1. It is, however, 
important to remember that as saturation was not reached with Smad 2 and Smad 3 
peptides as previously mentioned, the comparison between the 3 substrate peptides 
with GB1-WW1-2 should be taken lightly, and further analysis and data is necessary to 
draw more accurate conclusions. 
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Figure 4.2.19 - [1H-15N]-HSQC spectra of increasing Smad 7 peptide concentration against 
15N-GB1-WW1-2. 
A) Ratio 1:0 (light gray) to 1:11 (black) and intermediate ratio [1H-15N]-HSQCs for 
15N-GB1-WW1-2 with the addition of Smad 7 peptide at each point. The final concentration of 
Smad 7 peptide used was 1.7 mM, with 0.15 mM 15N-GB1-WW1-2 used in the titration. Blue 
boxes highlight example WW2 peaks that are identical in chemical shifts between the WW2 and 
WW1-2 titrations with Smad 7 peptide. B) Examples of peaks which disappeared and 
reappeared across the titration points – left panel shows the tryptophan side chain region; right 
panel shows examples of other peaks. ppm – parts per million. 
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Figure 4.2.20 - Comparison of [1H-15N]-HSQC spectra of WW1-2: Smad7 at 1:11 with 
WW1-2: Smad 2 1:4 and WW1-2: Smad 3 1:7.5.  
A) Overlaid spectra for GB1-WW-1-2 titrations with Smad 2 (red), 3 (green) and 7 (black) at the 
points just before GB1 movement or final titration point. Purple boxes show an example of 
different peak positions between the spectra. B) Comparison of the spectral region around ~85 
ppm for the same spectra as part A, where X denotes the aliased peaks. ppm – parts per million. 
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4.3. Discussion 
Understanding the relationship between structure, binding and function is vital to the 
development of effective therapies. Many pharmaceutical companies utilise information 
regarding selective protein-protein interactions to direct the design of peptide-based 
drugs that mimic biologically relevant interactions associated with disease. WWP2 
resides in a group of HECT E3 ligases associated with oncogenesis when 
overexpressed. The domain architecture of WWP2 makes it ideal for novel therapeutics 
with its four WW domains that selectively target tumour suppressor proteins, as 
described previously and in more detail in chapter 1. The aim of this chapter was to 
utilise pull-down and NMR titration analysis to understand WW domain interactions with 
specific substrates in the hopes of enabling the design of potential inhibitory peptides.  
 
The high prevalence of PTEN loss in prostate cancer by both genetic abnormalities and 
protein-associated depletion indicates the importance of PTEN tumour suppressive 
activities (Wang et al., 1998). Previous studies by Trotman et al. (2007) and Wang et 
al. (2007) suggested that Nedd4-1 was the main E3 ligase for PTEN. Evidence 
suggested that Nedd4-1 controlled both the nuclear shuttling of PTEN via 
mono-ubiquitination and the labelling of PTEN for degradation in the cytoplasm via 
poly-ubiquitination. The regulation of cellular localisation and turnover by Nedd4-1 
instils E3 ligase activity as a switch for the regulation of PTEN tumour suppressor 
activity shown in studies involving prostate cancer cell lines as well as mouse model 
xenografts (Wang et al., 2007). The increase in PTEN accumulation associated with 
Nedd4-1 mediated ubiquitination of PTEN resulted in suppression of AKT 
phosphorylation and in turn downstream signalling (Trotman et al., 2007).  This 
suggested that the recovery of PTEN levels in cancer cells by preventing 
ubiquitination-mediated degradation may be a possible method of therapy. Later work 
published by Maddika et al. (2011) established a second HECT E3 ligase, WWP2, as 
a regulator of PTEN activity via polyubiquitination. The knockdown of WWP2 was also 
shown to increase the endogenous levels of PTEN and in turn decrease phospho-AKT 
and prostate cancer cell line survival. In contrast, overexpression led to decreased 
PTEN and increased proliferation. At the time of this research by Maddika and 
colleagues was the first confirmation of WWP2 isoform activity in cancer development. 
Evidence of a role of other WWP2 isoforms in the regulation remains unanswered 
despite the data supporting WWP2 as the predominant regulator of PTEN activity. Initial 
investigations in this project attempted to uncover the sites of PTEN interaction on 
WWP2 in order to isolate a specific region of WWP2 for use in further studies. Pull-down 
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analysis of PTEN and WWP2 constructs revealed the potential for a wider interaction 
site across both proteins. WWP2-C showed binding to the C2 domain of PTEN, 
whereas WWP2-N bound to the phosphatase domain. This suggested that the binding 
of isoforms C and N to PTEN may indicate a role for these isoforms in the control of 
PTEN, adding to the already complex regulatory network. The binding of the N isoform 
to the phosphatase domain is in parallel with WWP2-FL as shown by Maddika et al. 
(2011). This suggests that the N isoform may function to prevent the interaction of 
WWP2-FL with PTEN. Alternatively, WWP2-N may actually recruit PTEN moieties to 
the full-length protein increasing the likelihood of PTEN ubiquitination. Georgescu et al. 
(1999) analysed the degradation rates of PTEN and PTEN mutants and found that 
while there was a constant decrease in the degradation of mutants, the levels of 
PTEN-WT stabilised. They proposed that sequestration of new PTEN moieties could 
be preventing their degradation. It would be interesting to determine whether WWP2-N 
is involved in this observation or whether some other factor is involved in PTEN 
steady-state expression levels. Further work is therefore required to determine the 
biological function behind these interactions.  
 
In contrast, binding of WWP2-C to C-terminal tail of PTEN was observed. Interestingly, 
this region of PTEN conveys stability and acts as an inhibitor of PTEN activity 
(Odriozola et al., 2007; Vazquez et al., 2000). Furthermore, the tail of PTEN contains 
a cluster of serine and threonine residues that undergo phosphorylation important for 
function. In conjunction with the loss of the tail promoting PTEN activity yet reducing 
half-life, mutation of these phosphorylation sites also resulted in a decrease in stability 
and half-life, and an increase in activity (Vazquez et al., 2000). This suggests that this 
region of PTEN is important in the regulation of degradation. Interaction of WWP2-C 
with the C-terminal tail of PTEN may be the interaction promoting the rapid degradation 
of PTEN when the tail is unphosphorylated or mutated. Whether this interaction occurs 
with the phosphorylated form of PTEN has yet to be established. However, Chen et al. 
(2016) observed a marked decrease in WWP2-FL-mediated ubiquitination when the 
C-terminal tail of PTEN was phosphorylated. This opens up more questions as to the 
role of WWP2 isoforms in PTEN regulation and the difference in binding sites observed 
may confer different consequences based on the cellular environment and PTEN 
status.  
 
Further investigation into WWP2 interactions with PTEN used pull-down analysis with 
tandem WW domains 1-2 and 3-4 to determine whether these domains were involved 
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in WWP2-FL interaction. Jiang et al. (2015) stated that the WW domains of WWP2 
were exclusively PPxY motif binding domains, however binding was observed for both 
tandem domains to PTEN constructs. WW1-2 bound to the C2 domain or C-terminal 
tail, whereas WW3-4 seemed to interact between amino acids 1-100. One possibility 
for the opposing sites of interaction observed for WW1-2 and WW3-4 compared to the 
isoforms could be that the WW domains 1 and 4 in the N and C isoforms, respectively, 
may bridge across to interact with the other domain of PTEN, in turn stabilising the 
interaction. The overall size of PTEN at 430 amino acids, and the fairly compact 
structure solved by X-ray crystallography (PBD: 1D5R, Lee et al., 1999; lacks the first 
13 residues and the C-terminal tail) suggests the possibility of interaction with both 
domains. Although evidence from interaction analysis of the yeast Nedd4-like ubiquitin 
ligase Rsp5 has implied the HECT domain could be involved in substrate interactions 
(Lee at al., 2009) this has yet to be shown for human Nedd4 E3 ligases, but the results 
of this pull-down analysis and lack of WW domain binding motif in PTEN may turn out 
to be a cooperative binding event of multiple domains within WWP2. The other 
possibility that cannot be excluded is an independent function of these WW domains 
as tandem domains. Emerging evidence of the concerted action of WW domains for 
other Nedd4 E3 ligases (Aragón et al., 2012; Chong et al., 2010) and preliminary data 
for WW3-4 of WWP2 (Wahl, 2016) suggests these domains may influence the binding 
events of each domain when present together. However, as this work only looked at 
whether there was binding or not and not function or interaction kinetics with PTEN, 
this requires further exploration. Lastly, one aspect that cannot be dismissed is that the 
tandem WW domains and isoform constructs were used as whole cell lysates in the 
pull-downs, therefore the role of adaptor proteins facilitating the interactions with PTEN 
should be taken into consideration. For example, NDFIPs are known adaptor proteins 
for Nedd4 E3 ligases which can either act to relieve auto-inhibition or facilitate the 
recruitment and interaction between substrates and Nedd4 E3 ligases (Riling et al., 
2015; Trimpert et al., 2017). Uncovering the binding sites of WWP2 isoforms to PTEN 
could reveal a whole new area of interactions and functional roles for WWP2 that can 
explain why WWP2 ubiquitinates PTEN and in what cellular context. 
 
As discussed above, there appears to more complexity to the PTEN interaction within 
WWP2 than originally thought. In conjunction with reduced expression levels of 
truncated PTEN proteins, inclusion bodies of PTEN constructs and lack of an isolated 
interaction site, it seemed that NMR analysis of this was not achievable at this stage of 
investigations. Therefore, the focus shifted towards Smad protein substrates due to the 
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presence of an isolated region of these proteins ideal for NMR analysis. Within the 
Smad proteins linker region exists a well-known PPxY motif targeted by Nedd4 E3 
ligases (Aragón et al. 2012; Chong et al. 2006; Lin et al, 2000; Soond and Chantry, 
2001a). While many studies which looked at small regions of interacting partners with 
WW domains utilised synthetic peptides to understand the structural basis behind the 
contacts (Aragon et al., 2012; Panwalker et al., 2016), there is evidence that 
recombinant means can also be used (Chong et al., 2006; Chong et al., 2010). There 
are advantages to using recombinant peptides which include no limit to the length of 
peptide, due to the difficulties associated with purification of longer peptides from 
chemical synthesis, and the ability to isotopically label them for use in structure-based 
experiments. In this project an attempt to generate similar peptides using recombinant 
means was analysed, however was unsuccessful. Previous work showed that Smad 7 
peptide could be generated with the use of a His-SUMO-tagged construct (Wahl, 2016). 
This enabled nickel affinity purification, and also utilised the SUMO-tag associated 
advantage of retaining the true N-terminal region of the peptide, conveyed by the ability 
of SUMO-protease to cleave the di-Gly with all amino acids except proline at the +1 
position (Malakov et al., 2004). Four extra amino acids were included at the beginning 
for the Smad 7 peptide to increase the molecular weight thus reducing the potential for 
peptide loss upon dialysis. Thus, N-terminal extensions were used for the Smad 2 and 
Smad 3 recombinant peptides to account for this aspect of the purification procedure. 
Malakov et al. (2004) established that Ulp-1 tended to work optimally at between 22 
and 37 °C and pHs 8-10. As these experiments were run at room temperature and pH 
8, it is unlikely that these factors were responsible for the lack of digestion or apparent 
activity of the enzyme. This therefore suggests that the construct is either too unstable 
in those conditions or another factor is involved. It is possible, as briefly mentioned 
previously, that the N-terminal region of the Smad 2 and 3 peptides may be sterically 
hindering the SUMO protease from gaining access to the di-Gly motif. Future work into 
this may want to test the presence of a weak denaturant to determine whether this 
could relieve any tight conformation that could be blocking the digestion site. As these 
peptides are derived from the linker regions of Smad 2 and 3, this implies no significant 
secondary structure formation and a flexible nature which would be unlikely to be 
affected by denaturing conditions, which would argue that steric hindrance may not be 
the problem, but this is still a set of conditions worth trying at this stage. Rather than 
focus on developing this and given the increasing literature showing successful use of 
synthetic peptides, Smad 2 and 3 peptides were purchased instead for NMR-based 
investigations of WW domain interactions. 
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No evidence of direct binding between the first WW domain of WWP2 to Smad proteins 
has been published, although this has been implied from WWP2-N interaction analysis 
(Soond and Chantry, 2011a). Smads 2 and 3 were identified to interact with WWP2-N, 
but not Smad 7. This contrasted greatly from the C isoform in immunoprecipitation 
experiments which only bound to Smad 7 and not Smads 2 and 3. Intriguingly, 
NMR-based investigation of the isolated WW4 domain with peptides based on the 
PPxY region of Smad proteins 2, 3, and 7 revealed that WW4 does in fact bind to Smad 
2 and 3 but with lower affinities than Smad 7 or phospho-Smad 7 (Wahl, 2016). The 
biological relevance of these interactions however remained unknown. Based on these 
investigations, it was thought that perhaps a similar effect may be seen for WW1. 
Investigations of WW1 also had the advantage of potentially identifying the amino acids 
involved in interactions for manipulation in peptide design since WWP2-N has 
previously been identified as a significant contributor to prostate cancer development 
(Soond et al., 2013).  
 
Initial observations characterised WW1 as one of the less stable WW domains due to 
the short half-life and incomplete folding shown by missing peaks and the appearance 
of degradation after 3 days, unlike WW2 and WW4 samples (used by Lloyd Wahl and 
Danielle Bourcier). Jiang et al. (2015) failed to express WW1 as a GST-tagged protein, 
suggesting that the use of a GB1-tag has increased the expression of this protein 
domain potentially enabling further analysis of this domain by NMR. However, as the 
backbone assignment and HSQC results suggest, unbound WW1 still remains 
troublesome for structural solution. One explanation though for having an incomplete 
folding pattern when in the absence of a substrate, may be that WW1 only folds 
completely upon binding of its substrates. Analysis of the closely related WW3 domain 
of Nedd4-1 found that in the absence of ligand, WW3 existed in both an unfolded state 
and a conformation primed for substrate binding (Panwalker et al., 2016). Upon the 
addition of ligand however the only state detected was the completely folded 
ligand-bound WW3. Hence, addition of substrate may be able induce complete folding 
of WW1 enabling further research into the role and targeting of this domain.  
 
Smad proteins 2, 3 and 7 are known to interact with several members of the Nedd4 
family. While all WW domains of Nedd4L, Smurf 1 and Smurf 2 showed some kind of 
binding to Smad 7 peptide in ITC experiments (Aragón et al., 2012), NMR analysis of 
WWP2 WW1 showed no significant binding of Smad 7 peptide in contrast to all other 
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WWP2 WW domains which have been shown to interact with Smad 7 peptide. This 
suggests that WW1 is unique within WWP2 in its ability to solely bind to R-Smads 
instead of I-Smad 7 as well. As for WW1 interactions with Smad 2 and 3 peptides, 
changes in 2-3 residues were observed suggesting either the start of direct binding of 
Smad 2 and 3 peptides to the domain or that WW1 was beginning to fold. Due to a lack 
of saturation however the exact nature of the interaction could not be completely 
deduced. The changes in residues 322 Asn (87 Asn in GB1-WW1 and GB1-WW1-2) 
and 327 Thr (92 Thr) in the Smad 2 titration and 322 Asn, 323 Thr (88 Thr) and 327 
Thr in the Smad 3 titration suggest a very similar initial change in WW1 in the presence 
of these peptides. This is most likely due to single amino acid difference, hence further 
exploration of this at higher saturation points is required to determine whether these 
peptides do interact with slightly different residues or in different orientations. The minor 
observations in these titrations that appear to indicate the start of binding contradict 
previous work which suggested that Smad 2 and 3 had to be phosphorylated at least 
at T179 by CDK for interaction with Nedd4 E3 ligases (Aragón et al., 2011; Gao et al., 
2009; Wang et al., 2009). As phosphorylation of these proteins plays a major role in 
regulating their secondary messenger activities, this is something that requires further 
exploration to determine whether WWP2 could be a phosphorylation-independent E3 
ligase for these proteins. Additionally, determining whether the presence of a 
phosphate group influences the side chains that interact may unveil another level of 
specificity that could be targeted via WW domain interaction surface mimics. 
Interestingly, using Jpred 4 (Drozdetskiy et al., 2015; Cole et al., 2008) for structural 
prediction of WW1, to get an idea of the location of the residues 322, 327 and 323, 
suggested that they reside in the loop region after the second b-strand and the third 
b-strand. While other Nedd4 E3 ligases have shown the involvement of residues in loop 
regions, this may suggest that the changing chemical shift positions may be more likely 
due to allosteric conformational change induced by the presence of peptide rather than 
direct binding to these residues, but as mentioned earlier more work is needed.  
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 WW1:  ALPAGWEQRELPNGRVYYVDHNTKTTTWERPLP 
   ------EEEE-----EEEEE----EEE------ 
 
 
 
 
 WW1-2:  ALPAGWEQRELPNGRVYYVDHNTKTTTWERPLP 
   ------EEEE-----EEEEE------------- 
 
   PGWEKRTDPRGRFYYVDHNTRTTTWQRPTAEYVR 
   ---EEEE-----EEEEE----EEEEE-------- 
 
Figure 4.3.1 - Jpred 4 simplified representation of WW1 and WW1-2 predicted structures.  
– refers to flexible regions; E represents a b-strand region. 
 
In comparison to WW1, the structural predictions for WW1-2 construct presented 5 not 
6 b-strands (Figure 4.3.1). This seems to suggest that the third b-strand of WW1 might 
fail to form and instead may remain flexible producing a “linker” region between the two 
domains. In doing so, this may be a mechanism of regulation by WWP2-FL in 
controlling interactions with substrates. As briefly mentioned previously, tandem 
domain cooperativity is gaining increasing evidence, suggesting this as a possible 
regulator of WW domain activity of Nedd4 E3 ligases (Aragón et al., 2012; Chong et 
al., 2010; Dodson et al., 2015; Fedoroff et al., 2004). To further understand this region 
of WWP2-FL, the tandem domain GB1-WW1-2 was also used in titration analysis. 
Results showed significant differences to the WW1 only results, suggesting that the 
presence of WW2 influences the folding and binding of WW1 to substrates. Due to only 
partial assignments at this stage, it is difficult to determine which residues across both 
domains are able to interact with the Smad peptides. However, changes in 335 Gly 
(100 Gly in GB1-WW1-2), 343 Arg (108Arg) and 354 Arg (119 Arg) suggest WW2 can 
bind Smad 2 and 3 peptides, which has yet to be analysed. As to whether a single 
moiety of Smad 2/3 binds to both domains or whether one domain binds and folds the 
other has yet to be elucidated. As many peaks are seen to undergo perturbation during 
the titration, this supports these domains being able to interact without the presence of 
phosphorylation, although this modification may change the interactions. The tandem 
domain seemed to also undergo folding upon interaction with the peptides, reflecting a 
previously mentioned argument that this region of WWP2 may only fold upon substrate 
binding in an induced fit mechanism of action. Analysis of the Smad 7 interaction with 
WW1-2 also highlighted folding upon Smad 7 interaction, although this is hypothesised 
to be from binding of the second WW domain to Smad 7 peptide inducing folding of 
WW2 which in turn induced WW1 folding. It would be interesting to determine whether 
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this is the case or if the binding of Smad 7 to WW2 forces an interaction between WW1 
and the peptide. Due to the inability to transfer all assignments from a fully assigned 
Smad7 bound GB1-WW2, this suggests WW2 within WW1-2 is in a slightly different 
conformation when WW1 is present therefore WW1 does have some influence on WW2 
when its adjacent. Given the 5 different models for cooperative activity of tandem 
domains summarised by Dodson et al. (2015), in conjunction with the lack of a clear 
linker region between WW1 and WW2 in the full-length protein, tandem domain WW1-2 
requires further investigation as to what role each domain plays when present together, 
and to structurally determine the bound states of these to potentially uncover the 
structural basis of the mechanism of action as well as the key residues on the 
interaction interface.  
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5. High-throughput screening of compounds for WWP2 
inhibitor discovery 
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5.1.    Introduction 
WWP2 resides in the Nedd4 family of HECT E3 ligases (Pirozzi et al., 1997). This ligase 
is known to interact with tumour suppressors such as Smads 2, 3 and 7 in the TGF-b 
signalling pathway (Soond and Chantry, 2011a; Soond and Chantry, 2011b) and 
PTEN, a negative regulator of AKT signalling (Maddika et al., 2011). Ubiquitination and 
in turn proteasomal degradation of these substrates by WWP2 is believed to be vital to 
the regulation of these signalling pathways. Dysfunction in the expression of WWP2, 
and its close relative WWP1, has been linked to the development and progression of 
cancer (Soond et al., 2013; Chen et al., 2006). Previous work by Soond and Chantry 
(2013) suggests WWP2 overexpression leads to decreased availability of inhibitory 
Smad 7 and stabilisation in the level of Smad 3, leading to cancer cell survival and 
EMT. Using the knowledge of how these ligases target and modify tumour suppressors, 
novel therapies can be developed for use in cancer treatment. In the previous chapter, 
the use of NMR titrations for interaction analysis was discussed with the future potential 
for inhibitory peptide design. While peptide-based inhibitors have shown high selectivity 
and efficacy, there are many difficulties yet to be overcome such as drug delivery, 
peptide half-life, and the ability to migrate across the cell membrane (Lau and Dunn, 
2018). One way to overcome some of these disadvantages is to use small molecules. 
This chapter focuses on small molecule screening using a biochemical assay as an 
alternative approach to the discovery of WWP2 inhibitors.  
 
Small molecule inhibitors of Nedd4 E3 ligases are becoming of interest as a focus for 
research into novel therapies. However, due to the complex nature of the ubiquitination 
cascade very few have been published to date. These enzymes rely on protein-protein 
interactions and thioester-based reactions to function, making them very difficult to 
selectively target.  The first E3 ligase inhibitors to be discovered were the nutlins, which 
inhibit the RING E3 ligase Mdm2 preventing interaction with p53, a well-known tumour 
suppressor protein (Vassilev et al., 2004).  This was the first evidence that inhibition of 
these ligases was possible using small molecules. This then led to further research into 
whether this could be implemented for HECT E3 ligases as well. In 2014, a small 
molecule inhibitor known as heclin was discovered (Mund et al., 2014). Heclin showed 
inhibition of a variety of Nedd4 E3 ligases with IC50 values in the micromolar range, 
suggesting good effectiveness at inhibiting members of the Nedd4 family. Similarly, the 
FDA approved drug clomipramine was shown to inhibit Itch (Rossi et al., 2014). 
However, both studies highlighted a lack of selectivity in targeting a specific Nedd4 E3 
ligase over others. This evidence suggests that while it is possible to use small 
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molecules to inhibit Nedd4 E3 ligases, they currently lack the specificity towards 
individual HECT E3 ligases. Further investigation into inhibitor discovery against Nedd4 
E3 ligases has identified additional compounds capable of reducing ubiquitination 
activity. An active anti-proliferative compound found in cruciferous vegetables called 
indole-3-carbinol (IC3) stabilised PTEN levels in melanoma cells by preventing the 
ubiquitination and degradation of PTEN mediated by Nedd4 (Aronchik et al., 2014). 
Development upon this work with analogues of I3C showed these compounds to be 
very effective against Nedd4 and directly binds to Nedd4, supporting these compounds 
as a new group of Nedd4 inhibitors (Quirit et al., 2017). In silico modelling predicted the 
binding site to reside within the HECT domain, similar to the other inhibitors currently 
discovered, and be selective towards Nedd4 based on HECT domain sequence 
similarities and absence of a similar predicted binding site within the other ligases. As 
other ligases were not experimentally tested, it would be interesting to see conclusively 
whether these are specific to Nedd4 or can inhibit other family members. Other 
research has also identified a covalent inhibitor of Nedd4 HECT activity (Kathman et 
al., 2015). Compound 1 in this work was found to interact with a non-catalytic cysteine 
residue in the HECT domain. The resultant effect was a switch in activity from 
processive polyubiquitin chain formation, where only one E3~substrate binding event 
is required for polyubiquitination, to a distributive in which multiple encounters are 
required for polyubiquitin chain formation on the substrate. This highlighted that not 
only is the catalytic cysteine residue a target for inhibition but other areas of the HECT 
domain may also be manipulated in drug design to alter the activities of Nedd4 E3 
ligases. Furthermore, the selectivity of compound 1 appeared to be towards ligases 
which contained this specific cysteine residue as no interaction was observed with 
E6-AP and WWP1, suggesting that inhibitor design towards specific Nedd4 E3 ligases 
is possible with further understanding of the mechanisms and differences in both 
structure and function of these ligases.  
 
The discovery of the small molecule inhibitors commonly uses compound libraries, as 
described by Rossi et al. (2014). These libraries can consist of compounds with a wide 
range of structures and functional groups, fragment-based sets or even approved FDA 
therapies. Choosing the right set of compounds is important for the protein of interest 
and assay type being used. This method provides a quick and efficient screen for initial 
inhibitory hit compounds. Any hits identified then undergo further testing and 
modification to increase the specificity and inhibitory effect. There are many types of 
assays used for compound screening, such as virtual screening, biochemical assay 
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screening and compound binding assays.  Unlike virtual screening and binding assays, 
the use of a biochemical assay for compound screening can give more biologically 
relevant results as to whether a compound is capable of inhibiting the target protein 
activity. 
 
The main aim of this chapter is to use small molecule screening as an alternative 
approach to NMR-based peptide design. The compound screening in this chapter 
utilised small molecules in an enzymatic plate assay using auto-ubiquitination as a 
readout to find initial hits. Compound libraries used in this work were chosen on the 
basis of utilising the continual refinement of the NIH NCI compound sets that aims to 
reduce potential interference/non-specific compound activity, while retaining a wide 
variety of molecule structures. In addition to the diversity set and natural products, the 
oncology set was also screened to determine whether any current FDA approved 
cancer therapies are active inhibitors of the ubiquitination mechanism. Positive hits for 
inhibition were then further tested in triplicate and in dose-dependent assays to 
determine the effectiveness of these compounds. The second aim is to determine 
whether the compounds selectively inhibit WWP2. This was carried out using 
ubiquitination assays against UbcH7, Uba1, Nedd4 and WWP1. The final aim is to 
determine whether these compounds had a significant effect on the migration of 
prostate cancer cells. Malignant prostate cancer cell lines PC-3 and DU-145 were 
chosen for these experiments due to both being androgen insensitive and TGF-b 
sensitive. This was exploited to reduce the likelihood of any effects being due to 
androgen-TGF-b signalling pathway cross-talk. Additionally, while DU145 are PTEN 
positive, PC-3 are PTEN negative thus providing alternative pathway statuses for 
comparison when testing the effect of compounds. 
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5.2.    Results 
 
5.2.1. Auto-ubiquitination biochemical assay optimisation 
A truncated isoform of WWP2 (WWP2-C) which exists within cells was initially used for 
compound screen assay set-up. To determine whether WWP2-C can be used in an 
auto-ubiquitination assay, GST-tagged WWP2-C and WWP2-CC399A, a mutant version 
where the catalytic cysteine in the HECT domain was replaced with alanine, were 
purified on glutathione coated beads. Reactions were set up as described in section 
2.2.9.1, with the appropriate controls as shown in Figure 5.2.1. Samples were analysed 
by western blot using an anti-HRP-streptavidin conjugated antibody to detect 
biotinylated-ubiquitin. Figure 5.2.1A shows the presence of poly-ubiquitin chains and 
ubiquitin-bound higher molecular weight proteins with GST-WWP2-C but not 
GST-WWP2-CC399A. This indicates that WWP2-C is capable of auto-ubiquitination, and 
that this activity is vastly reduced by mutation of the catalytic cysteine residue, which 
could be used as a low activity control. The presence of ubiquitin charged E1 with the 
mutant supports the difference in ubiquitination levels being due to WWP2-C and not 
earlier in the ubiquitination mechanism.  
 
The next step was to determine whether GST-WWP2-C auto-ubiquitination could be 
inhibited using a known inhibitor of Nedd4. Reactions were set up as described in 
section 2.2.9.1 with heclin added in a dose-dependent manner. Samples were 
analysed by SDS-PAGE and western blotting against biotinylated ubiquitin. A 
noticeable decrease in auto-ubiquitination was observed at 50 µM and 100 µM 
(Figure 5.2.1B) compared to the control, suggesting that heclin inhibits WWP2-C. This 
supports the use of WWP2-C for inhibitor discovery, however prevents the use of heclin 
as a positive control for inhibition due to the high concentration required for inhibition 
to be detected.  
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Figure 5.2.1 - GST-WWP2-C auto-ubiquitination and inhibition test.  
GST-WWP2-C/-CC399A coated glutathione beads were incubated with components described in 
the figure and samples analysed by SDS-PAGE and western blot using anti-HRP-streptavidin 
against biotinylated ubiquitin (Bio-Ub). UbcH7 – E2 conjugating enzyme; Uba1 – E1 activating 
enzyme. A) Auto-ubiquitination assay using GST-WWP2-C and GST-WWP2-CC399A beads 
incubated with components described and analysed by SDS-PAGE and western blot against 
HRP-streptavidin (n = 1). B) Dose-dependent GST-WWP2-C auto-ubiquitination assay using 
Heclin (n = 1).  
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Similar reactions were set up in 96 well format on glutathione-coated plates (adapted 
from Rossi et al., 2014) to see whether WWP2-C auto-ubiquitination could also occur 
in plate format as a high through-put screening method. The plate was initially 
incubated with cell lysate to immobilise GST-WWP2-C. Reactions were set-up as 
described in section 2.2.9.2, and auto-ubiquitination detected using anti-HRP-
streptavidin and TMB. The TMB reaction was stopped using HCl. Absorbance was 
measured at 450 nm using a Hidex Sense microplate reader. There was no significant 
difference between WWP2-C and WWP2-CC339A across all samples (Figure 5.2.2A). 
This indicates auto-ubiquitination did not occur, as all OD values fell below 0.25 with 
no significant difference compared to buffer alone. The assay was also tested using 
varying concentrations of components, fresh expression pellets, an additional BSA 
blocking step and FLAG-tagged ubiquitin and anti-FLAG-HRP conjugate to determine 
if the problem was the assay quantities and set-up, however similar results were 
observed (data not shown). Western analysis showed binding of GST-WWP2-C to the 
microplates, however no laddering was detected, indicating the problem was the 
reaction (Figure 5.2.2B). This suggests that the level of WWP2-C auto-ubiquitination is 
too low, if present at all when immobilised, for use in this assay. This is potentially due 
to the limited number of ubiquitination sites within WWP2-C which only consists of 
WW4 and the HECT domain.  
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Figure 5.2.2 - GST-WWP2-C plate assay optimisation.  
GST-WWP2-C and -CC399A were incubated with E1 (His-Uba1), E2 (His-UbcH7) and biotinylated 
ubiquitin (Bio-Ub). A) After plate washing, anti-HRP(horse-radish peroxidase)-streptavidin and 
TMB (3,3’,5,5’-tetramethylbenzidine) were used to detect and quantify auto-ubiquitination 
levels. Data shown is from 3 independent experiments (n=3). Error bars show SD; statistical 
analysis using two-way ANOVA and Tukey’s multiple comparison across all means, P > 0.1. B) 
Western blot analysis of microplate samples after plate washing, using anti-HRP-streptavidin 
and anti-GST antibodies (n = 1). Data representative of 3 repeats. 
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Due to WWP2-C producing no significant readout, full-length WWP2 protein was 
chosen for the microplate assay. GST-tagged WWP2-FL and GST-WWP2-FLC838A 
were synthesised using phusion and in-fusion cloning outlined in section 2.1.2 and 
2.1.4, followed by bacterial expression as described in section 2.2.1. An optimisation 
test was carried out using the same quantities and protocol as outlined in section 
2.2.9.2, using the appropriate controls as seen in Figure 5.2.3. Results showed a 
significant increase in activity when E1, E2 and Ub were present for WWP2-FL, 
however no significant effect was observed for WWP2-FLC838A. Furthermore, all 
controls showed no significant increase in OD compared to buffer. This suggests that 
the plate assay set up was successful with WWP2-FL and can be used in further 
experiments. By mutating the catalytically active cysteine residue 838, there is no 
significant auto-ubiquitination detectable, showing that this residue is vital for 
detectable auto-ubiquitination levels.  
 
 
Figure 5.2.3 - GST-WWP2-FL plate assay optimisation.  
GST-WWP2-FL and -FLC838A were incubated with E1 (Uba1), E2 (UbcH7), Flag-ubiquitin (Ub) 
and ATP. Levels of auto-ubiquitination were detected and quantified using anti-Flag-HRP 
(horse-radish peroxidase) and TMB (3,3’,5,5’-tetramethylbenzidine). The data shown is from 3 
independent experiments (n=3). Error bars showing standard deviation; statistical analysis 
using two-way ANOVA with Tukey’s multiple comparisons of all means to each other, 
****P < 0.0001. 
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5.2.2. Initial screening of compound libraries 
On the basis that GST-WWP2-FL provides a reliable output in 96 well format, 
compound screens were set up as described in section 2.2.9.2. A total of 2141 
compounds were screened from NCI Oncology set II, Diversity set V and Natural 
Products set IV (NCI, US). Internal plate controls for 100% activity (DMSO – 
GST-WWP2-FL plus all reaction components and 0.1 % DMSO) and 0 % activity (E3 
only – GST-WWP2-FL in ubiquitination buffer) were used to calculate the percentage 
residual activity of the compound wells. The initial screens were run as single shot 
assays, with Z’ values over 0.5 suggesting that these plate assays were robust. The 
controls for each library screen (right panels in Figure 5.2.4) show no significant 
difference between the buffer and E3 only low controls. A significant increase was 
observed between the low and high controls, mirroring the results in Figure 5.2.3. No 
significant effect was observed in the presence of DMSO, suggesting any change in 
activity is not due to DMSO.  Results were normalised using the high and low controls 
mentioned above to calculate the percentage residual activity compared to DMSO 
control. A threshold of 70 % (> 2 SD from the DMSO control mean) was used to 
determine which compounds would be selected for further testing. The data shows 24 
hits from the diversity set (Figure 5.2.4A), no hits from the oncology set (Figure 5.2.4B) 
and 21 hits from the natural products (Figure 5.2.4C). 
 147 
 
Figure 5.2.4 - Compound screens using GST-WWP2-FL auto-ubiquitination assay. 
Assays were carried out using 10 μM compound at 0.1 % DMSO in single shot with internal 
controls for 100 % activity with DMSO (DMSO) and without DMSO (Rxn), and 0 % activity (E3 
only and Buffer) on each individual 96 well plate. Auto-ubiquitination levels were detected by 
anti-Flag-HRP (horse-radish peroxidase) conjugated antibody and TMB 
(3,3’,5,5’-tetramethylbenzidine). OD was measured at 450 nm. A) Diversity set V screen and 
plate controls (right panel) (n=1). B) Oncology set II screen and plate controls (right panel) 
performed as described in A (n=1). C) Natural Products set and plate controls (right panel) 
performed as described in A (n=1). E3 only – GST-WWP2-FL in ubiquitination buffer; Rxn – 
GST-WWP2-FL plus all reaction components. DMSO – GST-WWP2-FL reaction with 0.1 % 
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DMSO. All assays were normalised using 100 % and 0 % controls and had a threshold of 70 % 
(—). 0.5 < Z’ < 0.9 for all single shot assays. Error bars showing SD; statistical analysis of 
controls using one-way ANOVA with Tukey’s multiple comparisons of all means to each other, 
**** P < 0.0001.  
 
5.2.3. Secondary screening of potential hits 
Having identified several potential hits in the single shot assays, compounds below 
70 % required further testing in triplicate to validate the inhibitory effect seen in the 
initial screening. This was carried out in the same manner as the single shot assay at 
10 μM and 0.1 % DMSO, however each compound was tested in triplicate. Figure 
5.2.5A shows 18 compounds from the diversity set with a significant decrease in 
activity. Similarly, 10 compounds from the natural products set showed a significant 
decrease in activity. A threshold of 20 % and 50 % was set for the diversity set 
compounds (Figure 5.2.5A) and natural products (Figure 5.2.5B) respectively, to 
identify the best set of inhibitors to carry forward. 10 out of 18 diversity set compounds 
showed activity levels below the 20 % threshold, and 5 out of 10 hits from the natural 
products exhibited less than 50 %. This high stringency level allows only compounds 
showing greater inhibitory effect to be carried forward. 
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Figure 5.2.5 - Triplicate assays showing best potential hits from initial screen.  
A) Auto-ubiquitination assay on 24 Diversity set V hits from section 5.2.2 at 10 μM and 0.1 % 
DMSO with a threshold set at 20 % (—) (n=1). B) Natural product hits from section 5.2.2 at 
10 μM 0.1 % DMSO assayed in triplicate, with a threshold of 50 % (—) (n=1). E3 only – GST-
WWP2-FL in ubiquitination buffer; Rxn – GST-WWP2-FL plus all reaction components. DMSO 
– GST-WWP2-FL reaction with 0.1 % DMSO. All data normalised using 100 % and 0 % activity 
controls. Plate controls are shown to the right. Error bars showing standard deviation; statistical 
analysis using one-way ANOVA with Dunnett’s multiple comparison to DMSO control, * P < 0.5 
and **** P < 0.0001, and Tukey’s multiple comparison between all means (right panel), 
**** P < 0.0001.  
 
5.2.4. Dose-dependent analysis of hit compounds 
For these compounds to progress further as suitable hit compounds, a dose-dependent 
assay was used to assess the effectiveness of these compounds at inhibiting WWP2 
auto-ubiquitination. This was also to derive ~IC50 values for more stringent refinement 
of the compounds. Concentrations from 1 – 100 μM were tested at 1 % DMSO. Curves 
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were generated and IC50 values calculated using non-linear regression of inhibitor 
concentration vs response. Results are shown in Figure 5.2.6, and IC50 values with 
compound structures shown in Table 5.2.1. All compounds presented a 
dose-dependent inhibitory effect on WWP2 auto-ubiquitination, with IC50 values 
ranging from 0.4 – 10 μM. Compound 1 showed the highest effectiveness unlike 
compound 16 presenting the lowest effect across both sets of compounds. As all IC50 
values are ~10 μM or below, this suggests these are all good starting compounds for 
further investigation and modification towards potential novel therapies. 
 
Figure 5.2.6 - Dose-dependent assays on 15 hits.  
Auto-ubiquitination reactions used concentrations of compounds from 1 – 100 μM at 1 % 
DMSO. A) Dose curves for Diversity set compounds. B) Dose curves obtained for natural 
products. Data shown is from three independent experiments (n=3). Error bars show standard 
deviation; statistical analysis using non-linear regression of concentration vs response, R2 > 0.8.  
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Number NSC number Structure IC50 (µM) 
1 2805 
 
0.38 
2 650438 
 
0.77 
7 228155 
 
0.83 
12 44750 
 
0.85 
16 369066 
 
10.28 
17 3064 
 
6.51 
18 194308 
 
5.95 
19 228150 
 
1.29 
20 288387 
 
2.29 
21 8675 
 
 
 
5.39 
Table 5.2.1 - Diversity set compound NSC codes, structures and IC50 values derived from 
dose-dependent analysis.  
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Number NSC number Structure IC50 (µM) 
6 401005 
 
 
 
2.664 
14 785168 
 
 
 
5.736 
15 248605 
 
 
7.228 
17 169517 
 
 
 
1.337 
21 184398 
 
 
 
5.954 
Table 5.2.2 - Natural products NSC codes, structures and IC50 values derived from 
dose-dependent analysis. 
5.2.5. E2 and E1 counter screens 
Previous results have highlighted 15 hits which can potentially proceed towards 
becoming lead compounds, however auto-ubiquitination is a complex reaction involving 
2 other enzymes. Therefore, the next point of investigation was to test the specificity of 
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these hit compounds towards E3 ligases or whether they inhibit earlier in the 
auto-ubiquitination cascade. In order to determine the point of inhibition within the 
reaction pathway, ubiquitination assays were carried out using His-UbcH7 (His-E2) and 
GST-Uba1 (GST-E1) as described in sections 2.2.9.3 and 2.2.9.4, respectively. Initially, 
optimisation assays were carried to ensure that the assay could be used for compound 
analysis. These initial assays showed successful detection of ubiquitination of His-E2 
and GST-E1 as shown in Figure 5.2.7. A significant increase in activity was seen when 
all reaction components were present compared to the controls. Furthermore, there 
was no significant difference between the absence and presence of DMSO at 0.1 % 
suggesting that the DMSO will not have an effect when testing the compounds. The 
overall OD output of the GST-E1 optimisation assay was much lower than for the 
His-E2 assay. This suggests that the productivity of GST-E1 may be reduced when 
immobilised or expressed as a fusion protein, or that the assay may require further 
optimisation, however as there was a significant increase in activity compared to the 
controls, the assay was used for compound testing.  
 
 
Figure 5.2.7 - His-UbcH7 and GST-Uba1 counter assay optimisations.  
A) His-UbcH7 (E2) optimisation. E2 was coated onto nickel-coated plates and reactions 
containing E1, flag-ubiquitin (Ub) and ATP combinations were added. B) GST-Uba1 
ubiquitination assay optimisation, using flag-ubiquitin (Ub). Auto-ubiquitination was detected 
using anti-Flag-HRP (horse-radish peroxidase) and TMB (3,3’,5,5’-tetremethylbenzidine). The 
data shown is from three independent experiments (n=3). Error bars show standard deviation; 
statistical analysis using one-way ANOVA with Tukey’s multiple comparisons of all mean values 
to each other, **** P < 0.0001.  
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Once the assay was optimised to obtain significant 100 % and 0 % activity controls, 
compounds were tested at the same initial concentrations as used in the 
GST-WWP2-FL screening, as described in sections 2.2.9.3 and 2.2.9.4. Only 4 of the 
5 natural product hits could be tested due to availability of compounds. No significant 
decrease in activity was observed for all compounds in the His-E2 ubiquitination assay 
(Figure 5.2.8A), however all compounds in the GST-E1 assay showed significant 
decreases in activity levels compared to the DMSO control. All mean residual activity 
values were below the 70% threshold, suggesting all compounds have an inhibitory 
effect on GST-E1 in this assay.  
 
 
Figure 5.2.8 - Compound analysis against His-UbcH7 and GST-Uba1.  
A) His-UbcH7 was immobilised on a nickel-coated plate and the assay run using GST-E1 and 
flag-ubiquitin. E2 only – His-UbcH7 and buffer; Rxn – His-UbcH7, GST-E1 and flag-ubiquitin; 
DMSO – His-UbcH7, GST-E1, flag-ubiquitin and 1 % DMSO. B) GST-Uba1 was coated onto a 
glutathione-coated plate, and flag-ubiquitin and ATP were added. E1 only – GST-E1 and buffer; 
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Rxn – GST-E1 and flag-ubiquitin; DMSO – GST-E1, flag-ubiquitin and 1 % DMSO. 
Ubiquitination was analysed by anti-flag-HRP (horse-radish peroxidase) and TMB 
(3,3’,5,5’tertamethylbenzidine) substrate. Blue bars showing diversity set compounds and red 
bars are natural products. Plate controls are shown to the right. The data shown is from three 
independent experiments (n=3). Thresholds were set at 70 % residual activity (—). Error bars 
showing standard deviation; statistical analysis using one-way ANOVA with Dunnett’s multiple 
comparison with DMSO control, **** P < 0.0001, and Tukey’s multiple comparison of all means 
to each other (right panel), **** P < 0.0001.  
 
Due to the findings in the GST-E1 assay where all compounds showed a significant 
inhibitory effect on E1 activity, SDS-PAGE analysis of the GST-E1 reactions was used 
to validate these results. This was set up as described in section 2.2.9.5 and samples 
analysed by SDS-PAGE and coomassie staining. A single band was observed for 
His-E1 in the first lane of the DMSO control (Figure 5.2.9A and B). In the presence of 
ubiquitin, a second band appears at a higher molecular weight, as seen in lane 2, 
showing conjugation of ubiquitin to the E1 enzyme. This conjugation is prevented by 
the presence of b-mercaptoethanol as highlighted by the single band for His-E1 seen 
in lane 3. Comparatively, diversity set compounds 12, 16, 17, 20 and 21 all mirror this 
banding pattern showing no visible effect on E1 charging with ubiquitin (Figure 5.2.9A). 
It is unclear whether compound 1 had an effect on E1 activity because the bands were 
very faint, however the smearing in the second lane may suggest partial charging. 
Compounds 18 and 19 showed no clear separation of bands at the higher and lower 
molecular weight, making it unclear whether there has been E1-ubiquitin conjugation, 
however there may be some due the slightly higher position of banding in lane 2. The 
effect of compounds 2 and 7 were not determined due to time limitations, therefore 
require investigation to confirm activity on the E1 enzyme. As for the natural products 
shown in Figure 5.2.9B, all compounds show no significant effect on E1-ubiquitin 
complex formation as shown by the smearing in lane 2 which is not present in lanes 1 
or 3. This suggests that while the compounds may be having a partial inhibitory effect 
on E1 activity as shown in the plate assay (Figure 5.2.8), there is no complete inhibition 
of the E1 enzyme as seen below in Figure 5.2.9 supporting the evidence in Figures 
5.2.4 to 5.2.6 that the predominant inhibitory effect of these compounds is on E3 
activity. 
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Figure 5.2.9 - His-Uba1-ubiquitin charging assay.  
Purified His-Uba1 was incubated with either 0.1 % DMSO or 10 µM compound at 0.1 % DMSO 
in the presence or absence of ubiquitin (Bio-Ub) and 1 % b-mercaptoethanol, and samples 
analysed by SDS-PAGE and coomassie blue staining. A) E1 assay using Diversity set 
compounds (n = 1). B) E1 assay using Natural products (n = 1).  
 
5.2.6. Nedd4 and WWP1 counter screens 
Compounds were tested against Nedd4 and WWP1 to find out whether they were 
capable of inhibiting other HECT E3 ligases in the same family as WWP2. GST-tagged 
Nedd4 and His-tagged WWP1 were immobilised onto glutathione coated and nickel 
coated plates, respectively. Component reactions were prepared as described in 
section 2.2.9.6 and 2.2.9.7 and added to the appropriate wells. After incubation, 
auto-ubiquitination levels were determined using HRP-conjugated anti-Flag antibody 
and TMB substrate. Both Nedd4 and WWP1 produced a significant increase in OD 
when in the presence of E1, E2, and ubiquitin, unlike all other reactions (Figure 5.2.10). 
There was no significant difference between reactions which lacked one or more 
components, showing that Nedd4 and WWP1 are capable of auto-ubiquitination under 
these assay conditions, and provides both a 100 % and 0 % activity level which can be 
used to determine levels of inhibition by the 14 compounds.  
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Figure 5.2.10 - HECT E3 ligase auto-ubiquitination counter screen optimisation.  
A) GST-Nedd4 auto-ubiquitination optimisation. B) His-WWP1 auto-ubiquitination optimisation. 
HRP (horse-radish peroxidase) conjugated anti-Flag and TMB (3,3’,5,5’-tetremethylbenzidine) 
were used to detect the presence of flag-ubiquitin after incubation of the coated plates with 
reaction components described above and in sections 2.2.9.6 and 2.2.9.7. E1 – Uba1; E2 – 
UbcH7; Ub – flag-ubiquitin. The data shown is from three independent experiments (n=3). Error 
bars show standard deviation; statistical analysis using one-way ANOVA with Tukey’s multiple 
comparisons between all means, **** P < 0.0001.  
 
To test the effect of the compounds on Nedd4 and WWP1 auto-ubiquitination, assays 
were set up as described in sections 2.2.9.6 and 2.2.9.7. When compared to the DMSO 
control, only natural product 17 showed no significant decrease in GST-Nedd4 activity 
(Figure 5.2.11A). All other compounds showed a significant reduction in 
auto-ubiquitination levels, with natural product 6 exhibiting the greatest level of 
inhibition. As for His-WWP1, all compounds produced a significant reduction in 
auto-ubiquitination levels (Figure 5.2.11B), in a similar pattern to the GST-Nedd4 
assay. When comparing the 3 E3 ligase assays, some very clear differences between 
auto-ubiquitination levels were observed. Compounds 1, 2 and 12 from the diversity 
set and natural product 21 showed no significant difference between the HECT E3 
ligases, implying that these compounds are not selective towards one of the ligases 
(Figure 5.2.11C). Nevertheless, all 4 do show a significant reduction in activity for all 3 
proteins. Compounds 7, 19 and natural product 15 showed a significant difference 
between WWP2 and WWP1, and WWP1 and Nedd4 but 7 and 19 presented no 
difference between WWP2 and Nedd4. Natural product 15 showed a slightly higher % 
residual activity for Nedd4 than WWP2. This suggests a greater impact on WWP2 and 
Nedd4 activity over WWP1. Interestingly, compounds 16, 17, 18, 20 and 21 from the 
diversity set showed increased inhibition towards WWP2 over WWP1 and Nedd4, as 
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seen in Figure 5.2.11C. In contrast natural product 6 presented a greater effect on 
Nedd4 than WWP2 and WWP1. This implies these compounds show a relative degree 
of selectivity towards one of the 3 ligases analysed. 
 
At this stage, the number of compounds for further work was reduced from 14 to 7 on 
the basis of how effective they were at inhibiting WWP2, therefore a threshold of 3 μM 
IC50 value was used. Compound 2, cis-Erbstatin, was eliminated due to several reports 
of inhibitory activity by erbstatin against several other enzymes including tyrosine 
kinases (Imoto et al., 1990; Markovits et al., 1994), therefore the evidence acquired 
here may be due non-specific interactions rather than specific inhibition of the HECT 
E3 ligases. Also, compound 10, ethyl violet was removed from further work due to its 
established tumour cell toxicity properties via mitochondrial inhibition (Indig, 2002; 
Lewis and Goland, 1953) and use as a dye in histological techniques (Cong et al., 
2010). 
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Figure 5.2.11 - GST-Nedd4 and His-WWP1 compound assays. 
 GST-Nedd4 and His-WWP1 were immobilised on glutathione- and nickel-coated plates 
respectively. Compounds were added followed by reaction components as described in section 
2.2.9.6 and 2.2.9.7. Ubiquitin levels were quantified using anti-Flag-HRP (horse-radish 
peroxidase) and TMB (3,3’,5,5’-tetramethylbenzidine), then read at 450 nm. A) GST-Nedd4 and 
B) His-WWP1 auto-ubiquitination assays using compounds at 10 µM and 0.1 % DMSO. Blue 
bars showing diversity set compounds and red bars are natural products. Plate controls are 
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shown to the right. E3 only – Nedd4/WWP1 and buffer; Rxn – Nedd4/WWP1, UbcH7, Uba1 and 
flag-ubiquitin; DMSO - Nedd4/WWP1, UbcH7, Uba1, flag-ubiquitin and 1 % DMSO. The data 
shown is from three independent experiments (n=3). Thresholds were set at 70 % residual 
activity (—). C) Comparison of WWP2, WWP1 and Nedd4 compound inhibition (n=3). Error bars 
showing standard deviation; statistical analysis using one-way ANOVA with Dunnett’s multiple 
comparison with DMSO control and Tukey’s multiple comparison of all means to each other 
(right panel), **** P < 0.0001, *** P < 0.001, ** P < 0.01, * P < 0.05. 
 
5.2.7. Compound inhibition of substrate ubiquitination 
The previous data indicates that all 14 hit compounds, listed in Tables 5.2.1 and 5.2.2 
are able to inhibit auto-ubiquitination of WWP2-FL, Nedd4 and WWP1 to varying 
degrees, with no effect on E2-conjugating and partial effect on E1-activating enzyme. 
However, this data doesn’t indicate whether these compounds have the same effect on 
substrate ubiquitination. The next aim was to determine whether these 14 compounds 
could inhibit ubiquitination using GST-PTEN as a substrate. Reactions were composed 
of E1, E2, WWP2, PTEN, ubiquitin and ATP as described in section 2.2.9.8 and were 
analysed by western blotting using anti-GST, anti-Flag and anti-His antibodies. A 
reaction lacking WWP2 was used as a negative control (Figure 5.2.12A), and a reaction 
lacking E1 (Figure 5.2.12B). The presence of high molecular weight (MW) band in 
Figure 5.2.11A lane 3 suggests substrate ubiquitination, due to the absence of such 
banding when either PTEN or WWP2-FL are absent. This supports the band being a 
product of substrate ubiquitination and not WWP2-FL auto-ubiquitination. Figure 
5.2.12B suggests all compounds except natural product compound 6 have an inhibitory 
effect on PTEN poly-ubiquitination, due to the absence of the high MW band present 
in the positive control. Compound 6 showed a faint high MW band suggesting reduced 
ubiquitination but not complete lack of. Collectively, this evidence supports the 
progression of these compounds as initial hit inhibitors for modification and further 
investigation into their binding and effectiveness against WWP2 activity. 
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Figure 5.2.12 - GST-PTEN ubiquitination inhibition by compounds.  
In vitro GST-PTEN ubiquitination reactions in the absence and presence of compounds, 
analysed using western blotting with anti-GST, anti-Flag and anti-His antibodies (n=1). The 
reactions are outlined in section 2.2.9.8, and incubated for 2 hrs.  Reactions were stopped by 
boiling with laemmli buffer for 3 min. The negative control lacked WWP2 (A) or E1 (B). UbcH7 
– E2 enzyme; Uba1 – E1 enzyme; Ub – ubiquitin.  
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5.2.8.  Effect of compounds on advanced stage prostate cancer cell 
growth and migration 
This section investigates whether any of the compounds highlighted so far inhibit the 
wound healing capabilities of advanced prostate cancer (PCa) cell lines. Due to one of 
the major steps in cancer cell survival and growth involving TGF-b signalling imbalance 
by WWP2 overexpression, discussed in chapter 1, scratch assays in the absence and 
presence of TGF-b  were used to determine whether any of the small molecules could 
reduce cell growth/migration. PC-3 and DU145 cell lines were used as they are both 
metastatic PCa cell lines and present insensitivity to hormone treatment, a common 
characteristic of advanced prostate cancer (Cunningham and You, 2015; Kaighn et al., 
1979; Stone et al., 1978). Cell lines were grown to 100% confluency and a scratch 
made in the monolayer. The assay was set up as described in section 2.3.4. Images 
were taken using phase microscopy at the time points shown below in Figures 
5.2.13 - 5.2.20. Results were quantified to enable statistical analysis. Compound 7 
showed a significant reduction in wound healing at 44 hr, compared to the DMSO 
control (Figure 5.2.13). This is supported by no significant difference between the 
control and DMSO (Figure 5.2.13B right panel), showing no effect by the presence of 
DMSO. All other compounds showed no significant change in cell growth/migration at 
all time points. 
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Figure 5.2.13 - PC-3 scratch assays with diversity set compounds in the absence of TGF-b 
stimulation.  
PC-3 cells were grown to 100% confluency then incubated for 1 hour in 5 % FBS medium. Wells 
were washed after scratches were made and fresh medium containing the appropriate 
conditions, described in section 2.3.4, was added to wells. A) Images taken at 0, 8, 18 and 44 hr 
time points. Data representative of 6 technical repeats (n=6). B) Quantification of the change in 
area of scratches; statistical analysis using two-way ANOVA, with Dunnett’s (left panel) and 
Sidak’s (right panel) multiple comparisons; **** P < 0.0001.  
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With TGF-b stimulation, compounds 1 and 19 showed a decrease in migration at 44 hr 
(Figure 5.2.14), suggesting that these compounds inhibit scratch healing during 
activation of the TGF-b pathway. As for compound 7, a change in morphology and 
adherence was seen. Initially, cells were well adhered to the surface and presented 
mostly flat and some elongated forms. After the addition of compound 7 the cells began 
to change shape and became suspended in the media rather than fixed to the surface. 
This resulted in the inability to quantify wound healing. The cellular changes suggest 
that the compound may have either killed the cells during stimulation or altered 
EMT/adherence pathways, however this requires further investigation. All other 
compounds had no significant influence on growth/migration (Figure 5.2.14).  
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Figure 5.2.14 - PC-3 scratch assays under TGF-b positive conditions.  
Once at 100 % confluency, PC-3 cells were incubated for 1 hour in 5 % FBS medium. Scratches 
were made, wells washed and fresh medium containing the appropriate conditions, described 
in section 2.3.4, was added to wells. A) Images taken at 0, 8, 18 and 44 hr time points. Data 
representative of 6 technical repeats (n=6). B) Quantification of scratch assay; statistical 
analysis using two-way ANOVA, with Dunnett’s (left panel) and Sidak’s (right panel) multiple 
comparisons; *** P < 0.001.  
 
DMSO 1 12 19 20
0
100000
200000
300000
400000
500000
Treatment
C
ha
ng
e 
in
 a
re
a 
(µ
m
2 )
0
8
18
44
***
***
Control DMSO
0
100000
200000
300000
400000
500000
Treatment
C
ha
ng
e 
in
 a
re
a 
(µ
m
2 )
0
8
18
44
0hr 8hr 18hr 44hr
Control
DMSO
1
7
12
19
20
A
B
 166 
Results with the natural products 6 and 17 in the absence of TGF-b stimulation showed 
a significant decrease in wound healing at 44 hr with compound 6, but not 17 (Figure 
5.2.15A and B left panel). No difference was observed between the control and DMSO 
(Figure 5.2.15B right panel), supporting inhibition of growth/migration by compound 6. 
In contrast, when stimulated with TGF-b a significant increase in wound healing was 
seen for DMSO (Figure 5.2.16B right panel), which was significantly reduced by the 
presence of compound 6 (Figure 5.2.16B left panel). Upon statistical analysis of the 
control compared to compound 6, no significant difference in wound healing was 
observed, suggesting compound 6 was able to inhibit the increased growth/migration 
seen with DMSO down to that observed for the control. This implies compound 6 may 
be showing some inhibition but would require further testing to confirm this due to the 
effect shown by DMSO in this assay. 
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Figure 5.2.15 - Inhibition of PC-3 wound healing with natural products without TGF-b 
stimulation.  
At 100% confluency, PC-3 cells were incubated for 1 hour in 5 % FBS medium. Scratches were 
made, wells washed and fresh medium containing the appropriate conditions, described in 
section 2.3.4, added to wells. A) Images taken at 0, 8, 18 and 44 hr time points. Data 
representative of 6 technical repeats (n=6).  B) Quantification of the change in area of scratches; 
statistical analysis using two-way ANOVA, with Dunnett’s (left panel) and Sidak’s (right panel) 
multiple comparisons; * P < 0.05. 
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Figure 5.2.16 - Inhibition of PC-3 wound healing with natural products under TGF-b 
positive conditions.  
At 100% confluency, PC-3 cells were incubated for 1 hour in 5 % FBS medium. Scratches were 
made, wells washed and 5 % FBS medium containing the appropriate conditions, described in 
section 2.3.4, added to wells. A) Images taken at 0, 8 and 18 hr time points. Data representative 
of 6 technical repeats (n=6). B) Quantification of the change in area of scratches; statistical 
analysis using two-way ANOVA, with Dunnett’s (left panel) and Sidak’s (right panel) multiple 
comparisons; * P < 0.05, *** P = 0.001. 
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Similar to the results from the scratch assay with PC-3 in TGF-b negative conditions, 
only compound 7 presented a significant decrease in growth/migration compared to the 
DMSO control (Figure 5.2.17). No significant difference was detected with or without 
DMSO, supporting compound 7 as an inhibitor of wound healing when there is no 
stimulation of the TGF-b pathway. Interestingly, when the TGF-b signalling pathway is 
activated no significant difference is seen for any of the compounds (Figure 5.2.18) 
compared to the DMSO control. This contrasts with the results of the PC-3 +TGF-b 
where compound 1, 7 and 19 showed a response to the presence of compound (Figure 
5.2.14).  
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Figure 5.2.17 - DU145 scratch assays under TGF-b negative conditions.  
Scratches were made in the DU145 monolayer after 1 hr incubation in 5 % FBS medium. Wells 
were washed and fresh media containing no supplements, 0.1 % DMSO or 10 µM compound 
at 0.1 % DMSO was added to the appropriate wells. A) Images taken at time points: 0, 8 and 
18 hr. Data representative of 6 technical repeats (n=6). B) Quantification of change in scratch 
area at time point in A; statistical analysis using two-way ANOVA, with Dunnett’s (left panel) or 
Sidak’s (right panel) multiple comparisons, * P < 0.05.  
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Figure 5.2.18 - Diversity set compound DU145 scratch assays in the presence of TGF-b. 
After 1 hr incubation in 5 % FBS medium, scratches were made in the DU145 monolayer. Wells 
were washed and fresh media containing no supplements, 0.1 % DMSO or 10 µM compound 
at 0.1 % DMSO was added to the appropriate wells. A) Images taken at time points: 0, 8 and 
18 hr. Data representative of 6 technical repeats (n=6). B) Quantification of change in scratch 
area at time point in A; statistical analysis using two-way ANOVA, with Dunnett’s (left panel) or 
Sidak’s (right panel) multiple comparisons, P > 0.05.  
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The results from the natural products assays show that there is no significant difference 
between the DMSO treatment and compounds (Figure 5.2.19), however there is a 
significant reduction in wound healing between the control and DMSO (Figure 5.2.19B 
right panel). Due to the effect shown by DMSO, comparison of the compounds with the 
control was carried out and showed a significant reduction in growth/migration for 
compound 6 but not 17 (P < 0.01) suggesting that the decrease in wound healing in 
this case is most likely due to DMSO. This differs from the results shown for PC-3 in 
which compound 6 produced a response. No significant difference was observed 
between the control and DMSO in TGF-b positive conditions (Figure 5.2.20). A 
significant decrease in growth/migration was observed for compound 17 but not 
compound 6 when stimulated with TGF-b. While this is different to the -TGF-b results, 
this also differs with the PC-3 +TGF-b data where it was compound 6 which showed a 
reduction in wound healing. This suggests a difference in the cell line responses to 
these compounds in the absence and presence of TGF-b, and requires further 
investigation. 
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Figure 5.2.19 - DU145 scratch assay analysis of natural products 6 and 17 under TGF-b 
negative conditions.  
In the DU145 monolayer scratches were created, and cells washed. Fresh media containing no 
supplements, 0.1 % DMSO or 10 µM compound at 0.1 % DMSO was added to the appropriate 
wells. A) 0, 8 and 18 hr time point images. Data representative of 6 technical repeats (n=6). B) 
Quantification of change in scratch area at time point in A; statistical analysis using two-way 
ANOVA, with Dunnett’s (left panel) or SIdak’s (right panel) multiple comparisons, * P < 0.05.  
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Figure 5.2.20 - Natural product DU145 scratch assay analysis in the presence of TGF-b. 
After 1 hr incubation in 5 % FBS medium, scratches were made in the DU145 monolayer. Wells 
were washed and fresh media containing no supplements, 0.1 % DMSO or 10 µM compound 
at 0.1 % DMSO was added to the appropriate wells. A) Images taken at time points: 0, 8 and 
18 hr. Data representative of 6 technical repeats (n=6). B) Quantification of change in scratch 
area at 0, 8 and 18 hrs; statistical analysis using two-way ANOVA, with Dunnett’s (left panel) or 
SIdak’s (right panel) multiple comparisons, ** P < 0.001.   
DMSO 6 17
0
100000
200000
300000
400000
500000
Treatment
C
ha
ng
e 
in
 a
re
a 
(µ
m
2 )
0
8
18**
Control DMSO
0
100000
200000
300000
400000
500000
Treatment
C
ha
ng
e 
in
 a
re
a 
(µ
m
2 )
0
8
18
0hr 8hr 18hr
Control
DMSO
6
17
A
B
 175 
5.3.  Discussion 
Targeting the ubiquitination-proteasome system is of interest in cancer therapy. By 
using a method of selectively inhibiting an individual protein or group of proteins in this 
pathway and in turn alter their substrate targeting, this can potentially relieve the loss 
of protective tumour suppressor proteins. There has been progress in the development 
of small molecule inhibitors against the proteasome, such as Bortezomib and 
Carfilzomib. Bortezomib acts to block the activity of the proteasome in degrading 
proteins leading to a cellular build-up and cytotoxic consequences in cancerous cells 
(Orlowski et al., 2002; Richardson et al., 2003; Richardson et al., 2005). While similar 
in activity, Carfilzomib acts in a more selective and potent manner than Bortezomib on 
the proteasome (Demo et al., 2007). The success of these therapies however has been 
limited to the treatment of myeloma and lymphoma, as well as by the side effects and 
development of resistance. Efforts are being made to develop derivatives with higher 
potency, fewer off-target effects and reduce the chance of resistance (Edelmann et al., 
2011; Zhang and Sidhu, 2014). Consequently, attention was diverted towards the 
upstream proteins in the ubiquitination pathway. The discovery of RING E3 ligase 
inhibitors showed the potential in targeting the selective interactions as anti-cancer 
therapies. The overall aim of this chapter was to discover compounds with inhibitory 
activity against HECT E3 ligases, in particular WWP2, as potentially novel therapeutics. 
Initial work involved compound screening which successfully identified 28 inhibitors of 
WWP2-FL. Of these 28 compounds, 15 were chosen for further investigation after 
validation, then dose-dependent assays were performed to determine their 
effectiveness. Due to the ubiquitination process requiring 3 enzymes, the available 
compounds were also tested in counter assays against E1 and E2 enzymes. This 
revealed whether the inhibition detected so far was occurring in earlier stages of the 
pathway or directly upon E3 ligase activity. Next, the selectivity of the inhibitors was 
examined using two other members of the Nedd4 family, WWP1 and Nedd4. At this 
stage the final set of compounds to take forward was decided based on those with IC50 
values below 3 µM, indicating high effectiveness towards WWP2-FL. Substrate 
ubiquitination using PTEN was also used to determine if these compounds affected the 
ability of WWP2-FL in targeting and labelling substrates or whether the inhibition was 
isolated to auto-ubiquitination. Lastly, in vitro analysis using PC-3 and DU145 advanced 
prostate cancer cell lines revealed potential inhibition of cancer cell growth/migration.   
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Previous work by Rossi et al. (2014) established a proof of concept screening method 
using an Itch E3 ligase construct lacking the N-terminal C2 domain, a region later found 
to induce auto-inhibition of the ligase (Riling et al., 2015). This provided an experimental 
basis for the screening of compounds against WWP2, which could potentially work 
using truncated proteins rather than full-length. The C isoform, discussed in section 
1.4.1, was of interest for this assay due to the presence of the HECT domain with the 
catalytic cysteine residue and the lack of C2 and WW1-3 domains, thereby reducing 
the possible number of ligand binding sites within WWP2. Despite showing 
auto-ubiquitination capabilities in initial studies (section 5.2.1), WWP2-C 
auto-ubiquitination activity could not be detected in 96-well plate-format experiments. 
In comparison, WWP2-FL produced significant auto-ubiquitination levels and the assay 
was optimised for use with the full-length protein. The large standard deviation shown 
in the optimisation results could be due to varying expression levels of GST-WWP2-FL 
as fresh cell lysate was used to bind the ligase directly to the plates. This method was 
used because of prior problems trying to re-bind purified GST-tagged proteins (data 
not shown). The drastically different results between the 2 isoforms of WWP2 may be 
solely due to a lower number of residues available for ubiquitin binding in the C-isoform. 
Alternatively, this may suggest that WWP2-C is unable to ubiquitinate itself but requires 
interaction with another WWP2-C moiety or perhaps WWP2-FL for the activation of 
ubiquitination, which would be limited upon immobilisation and purification on the plate. 
The initiation of ubiquitination activity by isoform interaction has already been 
discovered for WWP2, in which WWP2-N is capable of interacting and activating 
WWP2-FL under TGF- b negative conditions (Soond et al., 2013). E6-AP has also 
shown increased activity upon dimerization/trimerisation of the HECT, although has yet 
to be shown for Nedd4 E3 ligases (Ronchi et al., 2014). Another mechanism may be 
that activation only occurs in an adaptor protein or substrate dependent manner. The 
identification of Nedd4 family interacting proteins 1 and 2 (NDFIP1 and NDFIP2) 
showed the presence of these proteins relieved the auto-inhibitory conformations of 
several Nedd4 family E3 ligases, in turn activating ubiquitination as well as facilitating 
substrate recruitment to the ligases (Jolliffe et al., 2000; Mund and Pelham, 2009; Oliver 
et al., 2006; Trimpert et al., 2017). Further work by Mund and colleagues (2018) 
identified substrate clustering as an additional method of regulating ligase activity. It is 
proposed that by aggregating PY-motif-containing substrates, the activity of Nedd4 E3 
ligases towards these substrates is favoured over reversion to their auto-inhibitory 
conformation (Mund et al., 2018). The self-regulation of the individual WWP2 isoforms 
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is currently not clear; however, this could be another area of research in understanding 
the turnover of these enzymes under both normal and aberrant conditions. 
 
After screening 2141 compounds in single-shot auto-ubiquitination assays, 15 
compounds were identified as potential hits. The overall hit rate at the thresholds set in 
section 5.2.3 were 0.94 % and 1.2 % for the diversity set and natural products, 
respectively. This suggests that despite using relatively small libraries of compounds, 
there was still a low hit rate, implying that small molecule inhibition of WWP2 is 
uncommon, which is similar to the findings by Rossi et al. (2014) for Itch ligase. Upon 
further analysis, however, not all hits from the single shot assay were later identified as 
true. This suggests the presence of assay artefacts. These compounds most likely 
absorb/emit light at the wavelength used in the assay. One way of overcoming this is 
to initially screen the compounds to account for additional signal from compound 
interference. An alternative but more extensive possibility would be to alter the assay 
design to either to shift the wavelength of data collection to a region where fewer 
compounds absorb/emit energy or collect at two or more wavelengths according to the 
method of detection so the interference cancels out. For comparative analysis to the 
enzymatic screening results, other methods were also used in the lab for inhibitor 
screening including virtual screening (carried out by Sam Walpole) and thermal shift 
assays (carried out by Greg Hughes) using the HECT domain of WWP2 due to the 
availability of the HECT structure (PDB: 4Y07) and difficulties purifying WWP2-FL. 
Virtual screening showed only compound 1 at position 13/53, and the 5 natural products 
at positions 406/968 or lower. Furthermore, only natural product 6 was identified in 
thermal shift assays screened at 10 µM compound. This highlighted the power of 
enzymatic assays in finding WWP2 inhibitors, and that experimental choice in 
screening can play a major role in small molecule inhibitor detection. Further 
investigations into the binding site of some of these compounds utilised ligand-based 
NMR techniques, as previous thermal shift analysis had failed to detect binding for all 
except one potential hit. The data revealed 6 of the diversity set compounds and 2 
natural products interacted with the WWP2 HECT domain (carried out by Sam Walpole 
and Serena Monaco; modelling of the putative HECT binding site carried out by Sam 
Walpole shown in Figure 5.3.1). As the HECT domain is composed of 2 lobes, the C-
lobe with the catalytic cysteine, and the N-lobe with E2~Ub binding site, it would be 
interesting to determine the precise location within this domain where these compounds 
interact.  
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Figure 5.3.1 - Structural modelling of the putative binding site in HECT domain of WWP2. 
Representative diagram of the binding site surface calculated using Sitemap and modelled by 
Sam Walpole (personal communication). Hydrophobic sites are yellow, hydrogen bond 
acceptors red and donors purple. Image generated by Sam Walpole (Watt et al., 2018). 
 
Work published by Mund et al. (2014) showed Heclin binding was predominantly 
located in the C-lobe towards the catalytic cysteine, with weaker binding in the hinge 
loop and N-lobe. This pattern of binding is thought to hinder the transfer of ubiquitin 
from the E2 enzyme to the intermediate cysteine residue by blocking the rotational 
motions of the lobes. It is possible that this is similarly the case with the compounds 
discovered so far that bind to the HECT domain, however investigations into whether 
ubiquitin is able to conjugate with the catalytic cysteine, or whether the inhibition may 
be due to the inability to re-orientate the 2 lobes remains to be answered. Preliminary 
data does suggest that these compounds may act upon the hinge loop on the opposing 
side of the HECT domain from the cysteine residue, thereby preventing the flexibility 
about the hinge rather than direct inhibition of the cysteine residue or E2~Ub binding 
site. The HECT domains of Nedd4, Nedd4-2 and Smurf 2 were shown to contain a 
non-covalent ubiquitin binding site, proposed to be involved in poly-ubiquitination 
(Maspero et al., 2011), providing another potential binding site for inhibitory activity by 
small molecules. Kathman et al. (2015) showed inhibition of the non-catalytic cysteine 
present in Nedd4 that is involved in poly-ubiquitin chain formation by small molecules, 
supporting this as a mechanism of inhibition for member of the Nedd4 family. However, 
as WWP2 appeared to lack such ubiquitin-binding capabilities of HECT in the study, 
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and a cysteine residue in the equivalent position, this suggests that this site may not 
be present in WWP2 and another mechanism may be employed. However, WWP2, 
WWP1 and Itch do share a cysteine residue further upstream which may be involved 
and could be an equivalent site for facilitating poly-ubiquitination and in turn inhibition, 
though this has yet to be investigated. 3 compounds showed no interaction with the 
HECT domain but showed inhibition of WWP2-FL activity, suggesting that these 
compounds bind outside of the HECT or bind with affinities too strong to be detected 
by ligand-based NMR. This then raises questions about how these compounds are 
inhibiting auto-ubiquitination if they bind outside the HECT domain – are they inducing 
an inhibitory conformation of the ligase? This may be possible via interaction with 
WW2-3 linker region that interacts with the HECT domain and auto-inhibits WWP2 
activity (Chen et al., 2017), or is there some other allosteric regulatory mechanism 
induced by the small molecule binding that is currently unknown? Alternatively, if these 
compounds are binding extremely tightly to HECT, this potentially suggests that these 
may be irreversible inhibitors of WWP2 with slow dissociation from the enzyme. These 
questions however remain to be investigated. Difficulties regarding stability of the 
remaining 3 compounds under the ligand-based NMR conditions meant that binding 
was not determined. Collectively, the combination of the enzymatic assay and 
ligand-based NMR supports the identification of compounds capable of inhibiting 
WWP2 by interaction with the HECT domain and opens up new avenues of potential 
mechanisms of inhibition.  
 
In order to confirm the inhibition of WWP2 and conclude that the point of inhibition is in 
the last step of ubiquitination, further analysis was carried out to elucidate any potential 
inhibitory action on E1-activiating and E2-conjugating enzymes upstream in the 
ubiquitination sequential cascade. Uba1 is a human E1 activating enzyme which can 
interact with many E2-conjugating enzymes. In a similar manner, E2-conjugating 
enzymes can interact with many E3 ligases, therefore it is key to not alter the function 
of these proteins significantly. Xu et al. (2010) showed that E1 inhibition by siRNA and 
small molecules could induce malignant cell death, therefore investigating whether 
these compounds have an effect of E1 or even E2 may also open up new avenues of 
research. The results of the E2 counter screen showed no evidence for inhibition of the 
E1 or E2 activity. However, E1 only assay results suggested otherwise. Upon analysis 
of E1 ubiquitination using an alternative method in order to visualise E1~ub complex 
formation, this highlighted that there was no complete inhibition of E1 activity, hence 
why no significant effect was observed in the E2 assays. This may suggest an assay 
 180 
development problem regarding Uba1 inhibition analysis, however, investigation of the 
E1 enzyme inhibitor PYR-41 showed partial inhibition of HECT E3 enzymes, 
suggesting that perhaps these compounds display similar inhibition mechanisms to 
PYR-41 (Yang et al., 2007). This supports the results of the plate assay being a true 
reflection of partial inhibition of E1 but with no significant effect on the next step of the 
ubiquitination cascade. While these results are not ideal for the discovery of selective 
WWP2 inhibitors, it opens up a potential area of future investigation into possible novel 
E1 inhibitors, which remains a relatively unexplored field for drug discovery in cancer 
therapeutics (Itoh and Suzuki, 2018).  
 
Another aspect analysed was the selectivity of the 14 compounds. 4 compounds 
showed significant inhibition of all 3 Nedd4 E3 ligases, with no significant difference in 
% residual activity levels between the 3 proteins. This potentially indicates that these 
compounds bind and inhibit these ligases in a very similar manner. 3 of these 4 small 
molecules have shown HECT binding in ligand-binding analysis, mentioned previously, 
but one was inconclusive. This supports a mechanism of interaction that is shared 
between the HECT domains of the ligases, which considering the similarities between 
HECT domain structures and motions would not be surprising. In contrast with this, 5 
out of 14 hits had a greater effect on WWP2 inhibition in comparison to Nedd4 and 
WWP1. 4 of these also happened to interact with the HECT domain, as mentioned 
above.  This suggests these compounds may be manipulating the differences observed 
between the HECT domains or may just have a better fit or increased affinity when 
interacting with WWP2 compared to WWP1 and Nedd4. Studies into the structures and 
movements of the HECT domains of WWP2, WWP1 and Nedd4 have shown 
differences in the rotational ability and binding sites (Gong et al., 2015; Maspero et al., 
2011; Verdecia et al., 2003). Interestingly, the intramolecular interactions between the 
N- and C-lobes of WWP2 and WWP1 have been found to differ (Gong et al., 2015), 
which may be one of the ways which these compounds are showing increased 
inhibition towards WWP2 over WWP1 despite these proteins being very closely related. 
In contrast, natural product 6 showed greater inhibition of Nedd4 than WWP1 and 
WWP2 while also showing the ability to interact with WWP2 HECT, highlighting that 
the interaction with Nedd4 may be more favourable and could present a possible 
inhibitor for development towards Nedd4 over WWP2. As for the remaining diversity 
set compounds that were tested, both presented increased inhibition of WWP2 and 
Nedd4 compared to WWP1 with one able to bind WWP2 HECT and the other 
inconclusive. It would be interesting to determine whether the binding site resides 
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outside of the HECT domain, as Nedd4 and WWP2 have been shown to share 
substrates which could reveal a potential inhibitor of substrate interactions over 
inhibition of HECT domain activity. Natural product 15 produced similar results with 
even lower inhibition of WWP1 than the other compounds produced, and has not been 
found to bind WWP2 HECT. Lastly, natural product 17 showed inhibition of WWP2 and 
WWP1 to a greater degree than Nedd4, suggesting that this compound manipulates 
the close similarity between these two ligases compared to Nedd4. In order to say more 
conclusively whether these differences between the E3 ligases are due to possible 
alternative binding sites or affinities, more experimental data is required into the binding 
of these compounds with WWP1 and Nedd4. 
 
Auto-ubiquitination self-regulates the activity of HECT E3 ligases and is important for 
the control of substrate concentrations at all times. WWP2 has been shown to interact 
with tumour suppressor protein PTEN (Chen et al., 2016; Maddika et al., 2011), which 
has been implicated in prostate cancer development and progression. Substrate 
ubiquitination using PTEN in the presence of potential inhibitors showed 6 compounds 
prevented poly-ubiquitination of PTEN, however compound 6 still showed some 
generation of high molecular weight PTEN~Ub complexes. This suggests compound 6 
infers greater inhibition on auto-ubiquitination of WWP2, than on PTEN ubiquitination, 
although this would need to be looked at in more detail.  It would be interesting to see 
if similar inhibition is observed for ubiquitination of PTEN by Nedd4, as PTEN is a 
known substrate of Nedd4 as well, although WWP2 is the preferred ligase when PTEN 
is unmodified (Chen et al., 2016). In combination with the results of the selectivity 
assays, compound 6 shows potential for inhibiting Nedd4 over WWP2 in which case 
could also prevent the degradation of PTEN when it is modified. By reducing the ability 
of WWP2 to target PTEN for degradation, the resultant increase in PTEN could 
negatively feedback in the AKT signalling pathway leading to a decrease in cellular 
survival and growth. This has been observed using siRNA against WWP2 and a 
WWP2C838A mutant by Maddika et al. (2011), stabilising PTEN levels and reducing the 
oncogenic potential of cancer cells. Whether this inhibition of substrate ubiquitination 
is mirrored by other proteins targeted by WWP2 remains unanswered and should be 
investigated later. 
 
The wider impact of this research relates to developing novel inhibitors that are effective 
as a treatment for prostate cancer. PC-3 and DU145 cell lines were chosen as they 
lack an androgen response but retain TGF-b sensitivity (Cunningham and You, 2015; 
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Kang et al., 2001; Wu et al., 2013). This ensures that any changes observed are not 
due to the influence of the TGF-b signalling pathway on the AR pathway (Kang et al., 
2001). Furthermore, PTEN expression is absent in PC-3 cells but present in DU145 
(Lee et al., 2004). These factors are important in this research as both PTEN and Smad 
proteins in TGF-b signalling are target substrates of WWP2. Using these 2 cell lines 
provides evidence of compound effects under different molecular backgrounds of 
prostate cancer, however ideally these compounds would be tested in primary tumour 
samples to account for the heterogeneity of prostate cancer (Ciccarese et al., 2017; 
Cunningham and You, 2015). In the absence of TGF-b stimulation, both cell lines 
showed a reduction in migration in the presence of diversity set compound 7, but that 
is where the similarities in response end. PC-3 migration as also reduced by natural 
product 6. Under TGF-b stimulation, only natural product 17 produced a decrease in 
migration of DU145 cells. However, PC-3 cells were slowed by compounds 1, 7, 19 
and natural product 6. Without evidence of the protein and mRNA levels of key 
components in the TGF-b pathway, PTEN and WWP2, and evidence of compound 
uptake, it is difficult to make any conclusions about what might be happening in these 
cell lines on a biochemical viewpoint. However, there is evidence that some of these 
compounds show potential anti-oncogenic effects for advanced prostate cancer. 
 
An important aspect to take into consideration when using biochemical screens for 
small molecular inhibitors is the potential for false positives. This may be caused by the 
aggregation of compounds leading to non-specific inhibition or by pan assay 
interference compounds (PAINS) (Gilberg et al., 2016). Research has gone into the 
generation of computational filters to try and identify potential PAINS in compound 
libraries due to high number of compounds with promiscuous binding properties. 
Analysis of the 5 hits generated in this work from the NCI diversity set V highlighted 
compound 7 (228155) as a known PAIN molecule (Jasial et al., 2017), which could also 
indicate compound 19 (228150) as a potential PAIN molecule and should be taken into 
consideration in further investigations. Furthermore, the quinone groups that make up 
compound 1 (2805) are well-known PAINS therefore 2805 may also be a false-positive 
to be carefully considered in further work. As for the remaining diversity set compounds, 
12 (44750) and 20 (288387), when filtered for potential PAINS, no hits were produced, 
suggesting these are not false-positives and are most likely compounds with true 
activity within these assays. In a similar search on the 2 natural products, no hits were 
produced for natural product 6 (401005), and only 1 hit was generated for natural 
product 17 (169517), in which a derivative called quercetin containing the PAINS 
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catechol group was used in the research (Baell and Holloway, 2010). While natural 
product 17 lacks this catechol PAINS motif, in its place exists a quinone group which is 
also present within natural product 6. This suggests that these compounds could 
potentially have some PAINS-based redox activity, however, as these have not 
specifically been identified as interference compounds, may yet provide a basis for 
further investigations but should be done so with caution. Overall, PAINS analysis 
revealed 2 potential hits that produced no PAINS hits, which in conjunction with having 
low µM IC50 values against WWP2, supports these compounds as potential hits for 
further analysis. 
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6.1. Introduction 
WWP2 is a Nedd4 family HECT E3 ligase that targets substrates with PPxY motifs for 
ubiquitination. Well known substrates of WWP2 include the tumour suppressor proteins 
PTEN and Smad 2, 3 and 7. The overexpression of this E3 ligase has been linked to 
prostate cancer development and progression via the increased degradation of these 
substrates. Therefore, the aims of this work were to build upon current knowledge to 
facilitate the discovery of novel inhibitors against WWP2. Two main approaches were 
used: NMR spectroscopy was carried out the determine the structure of the fourth WW 
domain of WWP2 to enable the design of potential peptidomimetics (Results chapter 
1); and titration analysis was utilised to understand the substrate interactions of the first 
and second WW domains in the hopes of using this to determine the subtle 
characteristics that may further direct peptide design to selectively inhibit substrate 
interaction (Results chapter 2); secondly, compound screening and biochemical 
analysis of potential small molecule inhibitors against WWP2-FL enabled the 
investigation of an activity-based approach with compound inhibitors (Results chapter 
3).  Combined, these approaches can direct selective drug design towards this ligase, 
expanding upon the few that are currently published against other members of the 
Nedd4 family, in order to advance towards a novel therapeutic in the future. 
 
6.2. Structure-based inhibitor discovery 
Structural solution of WW4 in WWP2, discussed in chapter 3, was performed using 
previous data by Lloyd Wahl (2016) and additional experimentation in this research 
with a double-labelled GB1-tagged WW4 construct. The final ensemble consisted of a 
3 stranded b-sheet for WW4, reflective of the common folding pattern of HECT ligase 
WW domains solved to date. Out of the 24 WW domains of the Nedd4 family that have 
currently been structurally solved, the one with the most similarity by RMSD was WW2 
of WWP2 itself (PDB: 5TJ7 – WW2-2,3-linker-HECT; Chen et al., 2017) at a value of 
0.824 Å, calculated using Chimera structure comparison of medoid model 7 for WW4 
and chain B WW2 region. Interestingly, the next most similar WW domain in the Nedd4 
family in the PDB is HECW1 WW2 at 1.043 Å (PDB: 3L4H; Walker et al., 2010). 
Comparison of sequence similarity highlighted that WW2 of HECW1 is actually more 
similar to WW4 than WWP2 WW2 (Figure 6.2.1A). This supports the idea that WW 
domains within the same protein have unique roles to play when it comes to substrate 
selection. Furthermore, the similarity in the primary structure of these WW domains in 
their unbound conformations suggests that their substrate selection preferences may 
occur via subtle changes in specific amino acids. This is likewise supported by 
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preliminary data that the WW domains of WWP2 actually have the ability to bind to the 
same substrates, for example both WW2 and WW4 can bind to Smad 7 substrate, and 
similarly WW1 and WW4 have been shown to interact with Smad 2 and Smad 3 
(Danielle Bourcier, 2018, personal communication; Wahl, 2016; Soond et al., 2013). 
With regards to the three solved structures mentioned above, there are, however, some 
noticeable differences. Both the first and second b-strands are shorter by one amino 
acid in WWP2 WW2 resulting in a longer loop 1 region (Figure 6.2.1B). This variability 
which is also present when compared to HECW1 WW2 may support the reduced role 
this region plays in WW domain function also reflected in the amino acid sequence 
variability of this region. 
 
 
 
Figure 6.2.1 - Structural comparison of WWP2 WW2, WW4 and HECW1 WW2 domains. 
A) Sequence comparison of the WWP2 WW2 and HECW1 WW2 with WWP2 WW4. * 
represents 100 % similarity; : means strongly similar in properties; . refers to weak similarity in 
properties. Green – conserved tryptophan residues, or atypical phenylalanine residue. Blue – 
conserved prolines in the hydrophobic core. Red – residues linked to WW domain class and 
substrate binding. B) Overlaid structures of WWP2 WW2 in blue (PDB: 5TJ7, chain B residues 
335 - 362; Chen et al., 2017), WWP2 WW4 in brown and HECW1 WW2 in pink (PDB: 3L4H, 
residues 1018 – 1056; Walker et al., 2010).  
 
In contrast, however, the residues of the XP pocket in WW4, which are important for 
the binding of the X-P region of the PPxY motif, show both similarity and divergence in 
WWP2 WW2   330 RPLPPGWEKRTDPRGRFYYVDHNTRTTTWQRPTA 363  (34)
WWP2 WW4   444 PALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRP 477  (34)
HECW1 WW2 1018 LELPRGWEIKTDQQGKSFFVDHNSRATTFIDPRI 1051 (34)
** *** :   .*  ::****:*:**:  *  
A
B
C
N
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positioning compared to WWP2 WW2 and HECW1 WW2. Comparison of the 3rd strand 
highlighted that in the WW4 medoid model 7, the rotation of phenylalanine was slightly 
more parallel to tyrosine unlike the WW2 domains of WWP2 and HECW1 which were 
slightly more towards a perpendicular orientation (Figure 6.2.2A). Phenylalanine in 
WW4 models 16 and 20, in which the XP pocket residue is defined as b-strand in 
nature, shows closer similarity in side chain position to the WW2 domains (Figure 
6.2.2B). This could either be the result of a reduced number of distance restraints 
present for the aromatic residue or could be an indication of conformational sampling 
that might be linked to substrate selection. The latter is supported by the research of 
Panwalker and colleagues (2016) who found that with Nedd4 WW3 the 3rd strand 
underwent the most changes in stability and rigidity upon substrate interaction. The 
comparison of published structures of bound conformations supports the potential that 
WW4 models 16 and 20 present a deviation towards that of bound conformations. For 
example, Smurf 1 WW2 second tryptophan when interacting with Smad 7 peptide 
(PDB: 2LTX; Aragon et al., 2012) mirrors the more perpendicular orientation similar to 
models 16 and 20 for WWP2 WW4 (Figure 6.2.2C). Likewise, Smurf 2 WW3 bound to 
Smad 7 peptide (PDB: 2KXQ; Chong et al., 2010) has a more open conformation in a 
more perpendicular fashion (Figure 6.2.2D), however is much further away from the 
tyrosine than WW4 is, suggesting that the rotational flexibility of this residue is important 
for the hydrophobic interaction with proline. It would be interesting to determine the XP 
pocket orientation of WW4 when bound by Smad 7 for comparison to determine 
whether this residue also orientates into the more open conformation upon substrate 
binding. Further research into the dynamics of this region in both unbound and bound 
configurations is required to understand this in detail.   
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Figure 6.2.2 - XP pocket comparison of WWP2 WW4 models with the second WW domains 
of WWP2 and HECW1.  
A) Overlaid structures of medoid models for WWP2 WW4 (brown), WWP2 WW2 (blue) and 
HECW1 WW2 (pink). B) Structure comparison of WWP2 model 16 (green) with WWP2 WW2 
(blue) and HECW1 WW2 (pink). C) Comparison of WWP2 WW4 medoid model 7 (brown) with 
model 16 (green) and Smad 7 bound Smurf 1 WW2 (grey). D) Comparison of WWP2 structures 
as described in C with Smad 7 bound Smurf 2 WW3 (red). All structures show the side chain of 
the XP residues – tyrosine on the 2nd strand and phenylalanine/tryptophan at the end of the 3rd 
strand.  
 
Interestingly, when looking at the other aromatic residue of the XP pocket, tyrosine 461 
(phenylalanine in HECW1 WW2) has a much better-defined orientation across the 
ensemble as well when compared to the same position in WWP2 WW2 and HECW1 
WW2. This could be due to the central nature of the residue in the structure in turn 
having more surrounding connections and a more restrained side chain orientation in 
structural calculations. Alternatively, this may suggest that the orientation of this residue 
in this apparent fixed position is vital for correct binding of substrates. Similarly, valine 
463 which acts as a secondary specificity site for class I substrate interactions (Espanal 
and Sudol, 1999) is also tightly restrained across the WW4 ensemble (Figure 6.2.3A) 
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and is consistent with HECW1 WW2 with a little variation to WWP2 WW2 (Figure 
6.2.3B). Unlike valine 463, at the + 2 position to this residue the histidine (H465) 
previously thought to be involved in substrate specificity has a reduced involvement 
despite being conserved (Kasanov et al., 2001; Wahl, 2016). This is supported within 
the WW4 ensemble where H465 presented increased diversity in the side-chain 
orientations (Figure 6.2.3A), which is also mirrored when compared to WW2 domains 
in WWP2 and HECW1 (Figure 6.2.3B). 
 
 
Figure 6.2.3 - Comparison of residues outside of the XP pocket involved in substrate 
interactions. 
A) Valine 463 and histidine 465 across the refined WW4 ensemble. B) Comparison of valine 
463 and histidine 465 in WW4 medoid model 7 (brown) with the equivalent residues in WWP2 
WW2 (blue) and HECW1 WW2 (pink).  
 
The N and C termini of WW4 both fold underneath the b-sheet away from the curved 
binding site of the domain, stabilising the conformation via hydrophobic interactions. 
Due to the lack of structure for the N-terminal of WWP2 WW2 before the tryptophan 
residue, comparison of the stabilising proline in this region could not be inspected 
(Figure 6.2.4A). Similarly, the ill-defined region of the WW4 domain at the C-terminal 
also prevented confident analysis of these residues therefore little can be said for the 
role of these residues in stabilising the domain other than seeming to come closer in 
the opposing direction of the well-defined core (Figure 6.2.4A). However, the first 
tryptophan at position 450 in WW4 and 336 in WW2 within WWP2 have very different 
side chain positions (Figure 6.2.4B). Within WW4, tryptophan seems to favour a 
direction towards the C-terminal tail of the construct underneath loop II with contacts to 
aspartic acid 464 and asparagine 466, and potentially proline 447 in the N-terminal 
region. In contrast, the equivalent tryptophan in WW2 appears to orientate the other 
way. This may be because the C-terminal tail of WW2 seems to curl under towards the 
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second loop of the structure with arginine 360 extending towards tryptophan 336, unlike 
the WW4 tail which follows a more perpendicular direction away from the b-sheet, 
however with no N-terminal structure it cannot be determined whether contacts here 
may also be involved in this difference. Similar to WW4, tryptophan 1024 in HECW1 
has the same orientation as WWP2 WW4, not WWP2 WW2 but does display the same 
C-terminal tail positioning towards loop II (Figure 6.2.4). However, as to whether there 
is a significant difference in stability between these domains is unknown therefore this 
difference in positioning would require further investigation to determine any role this 
plays in functionality. One other aspect to note regarding WW2 and WW4 of WWP2 is 
the lack of a defined linker between the first and second domains of WWP2 unlike 
between WW3 and WW4 which may affect the positioning of this residue, however 
again this would need further analysis to understand whether this is important or not 
within the full-length protein. 
 
 
 
Figure 6.2.5 - Comparison of the hydrophobic underside of WWP2 WW4 with WWP2 WW2 
and HECW1 WW2. 
A) Alignment of WWP2 WW4 (brown) with WWP2 WW2 (blue) and HECW1 WW2 (pink) with 
focus on the underside of the domains. B) Comparison of the hydrophobic residues of WWP2 
WW4 (brown) and WW2 (blue). C) Overlaid WWP2 WW4 (brown) and HECW1 WW2 (pink) 
showing the hydrophobic residues. 
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The biological function of this structure can be seen in the selective number of known 
substrates that interact with WW4. Interestingly, there was very little difference in the 
binding site residues involved in Smad 2, 3, and 7 interactions with WW4 (Wahl, 2016). 
The residues with the greatest change in environment were threonine 469, 470 and 
471 located to the 3rd b-strand for all three substrates, which supports the evidence by 
Panwalker et al. (2017) with Nedd4 WW3 that this region of the WW domain may be 
the most affected by the binding of a substrate. However, further work is necessary to 
elucidate the bound the structures of this domain with Smad 2, 3 and 7 to identify 
significant conformational changes that may be specific for each substrate and 
underpin the difference in affinities reported by Lloyd Wahl.  
 
Using the conserved residues and those found to be involved in binding (Kasanov et 
al., 2001; Wahl, 2016), the basis for initial peptide design that reflects WW4 would need 
to include:  
xxLPxGWEMK/RxbxxGxxY/FY/FVxHxTR/KTTTFxxPxx 
 
where x represents any aliphatic amino acid and b refers to a polar residue. As yet only 
the isolated WW domains of WWP2 consisting of the naturally occurring primary 
sequence have been analysed in vitro (Yim, 2017). Yim’s preliminary research looked 
at the effect of individual WW domains, as well as tandem domain constructs, on Smad 
3-dependent gene expression. A model by Soond et al. (2013) suggested that cancer 
initiation occurred via a reduction in Smad 3 by activation of WWP2-FL by the shorter 
isoform WWP2-N under TGF-b negative conditions. When TGF-b is then present, as is 
seen in cancerous cells which appear have a higher basal level of TGF-b than non-
cancerous cells, an increase in WWP2-FL and WWP2-C containing the WW4 domain 
then changes substrate preference towards Smad 7 over Smad 3. Considering recent 
titration data, the preference of these isoforms under stimulated conditions would most 
likely have been towards phospho-Smad 7 which has a higher affinity to WW4 than 
unphosphorylated Smad 7 (Wahl, 2016). Using this model as a basis, Tiffany Yim 
(2017) found that expression of WW4 led to no significant difference in unstimulated 
control cells as well as melanoma cell lines. However, when in the presence of TGF-b 
stimulation, there was an increase in Smad 3-dependent gene activity in both the 
control and cancerous cell lines. This increase in Smad 3-dependent activity of the 
pathway may be advantageous in therapeutic terms for the cancer initiation stage by 
stabilising Smad 3 levels, but further investigations into cancer cell migration, 
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proliferation and the biochemical cellular changes upon the addition of this domain is 
required in both non-cancerous cells and at different stages of cancer progression. 
Interestingly, analysis of the effect of tandem domains under the same conditions 
revealed that WW3-4 expression increased Smad 3-dependent activity regardless of 
the stimulation status and cell type. It was thought that this might be due to the presence 
of the 3-4 linker region rather than the domains themselves. Addition of WW3-4 is 
hypothesised to have resulted in sequestration of Smad 3 via interaction with WW3-4, 
and/or potential dimer formation with the same region in WWP2-FL, although evidence 
of WWP2 WW domain dimerization has yet to be uncovered. Furthermore, the 
identification of the 2-3 linker region as a regulator of the auto-inhibition conformation 
of WWP2-FL (Chen et al., 2017) further suggests regulatory roles for these regions and 
that creating a peptide based only on WW4, or even the other domains individually, 
may not be effective in inhibiting the activity of WWP2 but may in fact exacerbate the 
cancerous profile via targeting of regulatory Smad 3 and inhibitory Smad 7 in certain 
conditions. Therefore, further understanding of this switch between substrate choice by 
WW4 is required. Research into the effect these WW domain constructs have on Smad 
2 and other substrates such as PTEN and Oct4 when expressed in mammalian cells 
should also be investigated to determine if changes in expression or signalling activity 
for these substrates are also affected.  
 
Knowledge of the bound structure of WW4 to compare to the unbound reported in this 
thesis and using this for peptidomimetic modelling could reveal novel information about 
substrate selection and further direct successful design of inhibitors for this domain. 
Additionally, the identification of further novel isoforms that contain the WW4 region 
(Yim, 2017) increases the complexity of targeting this domain, especially as knowledge 
of the function of these new isoforms is currently lacking. Also, it is important to note 
that these experiments have only been carried out using melanoma cell lines so far, 
and the same results may not occur in prostate cancer cells, therefore it would be 
interesting to determine the effect of the introduction of these isolated domains to 
prostate cancer cell lines. Also, the design of sequence variations based on these 
domains and linker regions using structural modelling, similar to the medicinal 
chemistry approach to modifications of small compounds, might also be worth 
investigation in the future when more is understood about these domains and their 
substrates.   
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Another aspect to take into consideration is the ability for multiple domains within 
WWP2 to bind to the same substrate, as mentioned earlier. Previously, Soond and 
Chantry (2011) concluded that WW1 within both WWP2-FL and WWP2-N isoforms is 
the main interaction site for Smad 2 and 3, whereas WW4 within WWP2-FL and 
WWP2-C preferred Smad 7. As the interactions of the fourth domain had already been 
investigated, showing capabilities of WW4 in binding to all three Smad proteins of the 
canonical TGF-b pathway, attention was turned to first WW domain and its role in 
WWP2 interactions, especially since WWP2-N was found to be significantly altered in 
prostate cancer. Furthermore, understanding the structure and binding elements of this 
domain could enable multi-domain targeting by novel therapies with WW4 to provide a 
potential combinatorial effect, although as to whether this is effective has yet to be 
tested. As discussed in Chapter 4, structural solution of the first domain was not 
deemed possible due to the unstructured nature of the construct used in this work. 
Jiang et al. (2015) reported having problems expressing this domain for structural 
characterisation experiments using a GST tag, but the use of the GB1 tag in this work 
seemed to increase the levels enough to obtain adequate concentrations for NMR 
spectroscopy. HSQC analysis and backbone assignment identified 30 % of WW1 as 
unassignable, not including proline residues, due to missing peaks. There can be 
several reasons for such a high level of missing peaks in a HSQC spectrum. Firstly, it 
could simply be that the peaks are overlapping in the HSQC which 3D experiments 
would reveal, but only a few extra peaks were present in HNCaCb and CbCaCONH 
that were at chemical shifts of already assigned residue types and these did not 
account for all the missing peaks. Alternatively, these regions of the protein could be in 
intermediate chemical exchange, where the rate at which the population changes 
between different environments is proportional to the NMR time scale, resulting in 
broad peaks as the rate of exchange is close to the frequency separation of the 
environments. One way to overcome this is to alter the temperature used for the NMR 
experiment to either speed up (rate > chemical shift difference) or slow down 
(rate < chemical shift difference) the exchange rate. This can be done in either direction 
dependent on what is wanted from the experiment – an increase in temperature would 
shift the exchange rate towards fast exchange generating an average peak in the 
spectrum, or a decrease in the temperature can be used to shift towards slow exchange 
in which two peaks are present representative of the two chemical environments. 
Previous work in the lab (Danielle Bourcier, 2018, personal communication) using 
WWP2 WW2 domain, where HSQCs were collected over a range of temperatures, 
indicated no significant change in peak number upon a decrease in temperature from 
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298 K, although temperatures higher than this were not tested due to the risk of 
denaturing or degrading the sample. Another aspect could be the buffer or pH of the 
sample. Due to the success of NMR analysis with WWP2 WW4, the same sodium 
phosphate buffer was used for the WW1 samples at pH 6.8. Perhaps further screening 
of a range of buffer types and pHs often used in NMR experiments is worth investigating 
to determine whether there is a more compatible buffer for WW1 and in turn perhaps 
WW2 which also displayed similar problems. Another possibility is that this domain is 
not folded when isolated in this construct or even outside of the cellular environment 
therefore structural determination would not be possible.  
 
The options above mainly focus on the practical aspects of the sample generation and 
NMR experiment conditions. Other reasons which can cause missing peaks include 
dimer formation in which residues of the interface between the two molecules can 
undergo significant changes in environments resulting in intermediate exchange. 
Evidence of WW domain dimerization for Smurf 1 and 2 was reported by Aragon et al. 
(2012), and in conjunction with data supporting interaction between WWP2-FL and 
WWP2-N (Soond and Chantry, 2011a), this suggests that dimerization between WW1 
molecules may be possible. Alternatively, WW1 in its apo state may adopt an unfolded 
flexible conformation that only completely folds upon interaction with substrates. 
Collectively, this suggests that there are even more questions about WW1 that have 
yet to be answered and further work is essential in understanding this domain.  
 
Investigations turned towards substrate interactions and determining the binding site 
residues to see whether this could provide insight into the structure and function of the 
domain, and whether bound conformations could be possible in the future. 
Unfortunately, incomplete saturation of Smad 2 peptide and protein denaturation from 
the presence of high concentrations of TFA in the Smad 3 titration prevented the 
identification of the binding site residues on WW1 for these two substrates. However, 
initial perturbations were detected for residues 322 Asn, 323 Thr and 327 Thr. Changes 
to residues in the predicted loop II region suggests that this may be the result of 
conformational changes in the presence of the peptide rather than direct interaction 
based on the previous identification of key residues in WW domain interactions. 
However, movement of 327 Thr located in the 3rd b-strand may be the result of binding 
by starting to stabilise the domain via interaction with this strand (Panwalker et al., 
2016; Panwalker et al., 2017), although this speculation should be taken lightly given 
the minimal data available. Further investigation into these binding sites is required, 
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and additional experimentation such as the use of ITC may prove interesting in 
determining whether this domain has a preferred substrate like discovered for WW4. 
Another aspect that could be looked at as well is the phosphorylation status of the 
R-Smads, as WW4 presented a higher affinity for phospho-Smad 7. Although initial 
data has shown WW1 as the least folded and most unstable of the four domains of 
WWP2, while binding to substrates as previously described (Soond and Chantry, 
2011a; Soond et al., 2013), the addition of further experiments is essential in 
understanding binding and in turn therapeutic development towards this domain. This 
is of particular importance given the significant association of WWP2-N expression in 
early stages of prostate cancer.  
 
To determine whether the problems faced with WW1 could be overcome by expression 
with the nearby WW2, and to investigate whether these domains act cooperatively, 
potentially altering the binding sites based on the presence and absence of the other 
domain, titration analysis was carried out using the WW1-2 tandem domain. The 
overlap of the end of WW1 and start of WW2 differs from between WW2 and WW3, 
linked to auto-inhibition (Chen et al., 2017) and between WW3 and WW4, thought to 
regulate Smad 3 dependent gene activity (Yim, 2017). The reason for this is unclear, 
however as the other linker regions appear have a role in the regulation of WWP2, 
perhaps the lack of a linker suggests the potential for cross-communication between 
these first two domains, or even a concerted mode of action within WWP2-FL. The 
secondary structure prediction analysis (shown in section 4.3) for the tandem construct 
suggested that WW1 may not fold into the typical 3 stranded b-sheet in the presence 
of WW2 but could create an extended coil region in place of the 3rd strand. However, 
this should be taken lightly as no evidence has yet been uncovered relating to the 
structural solution of this tandem domain. Similar to HSQC analysis of WW1 and WW2 
individually, the number of peaks present for the tandem domain did not correspond to 
the residue number for the construct, suggesting that amide peaks were missing, and 
like discussed earlier could be due to several factors either within the experimental 
design or inherent properties of the protein. Steps towards understanding this region 
as a potential cooperative tandem domain were carried out by investigating the 
interaction of these domains to Smad 2, 3 and 7 peptides. All titrations showed 
chemical shift perturbations indicative of peptide binding and domain folding. Of 
particular interest in these titrations were the changes in the tryptophan side-chains. As 
previously mentioned, the first tryptophan residue of WW domains has been associated 
with domain stability by interacting with proline in the hydrophobic core and the second 
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is part of the XP groove involved in substrate interaction. Within all three titrations with 
GB1-WW1-2, a change in chemical environment was observed for all four tryptophan 
e-amide groups, but not those residing in GB1. This suggests that in the presence of 
Smad 2, 3 and 7 peptides, WW1-2 underwent conformational changes related to both 
stability and binding. There was also a slight difference between the tryptophan side 
chain positions with Smad 7 peptide compared to Smad 2 and 3 which were almost 
identical. This implies a different orientation to the side chains in the presence of 
R-smads and I-smad 7 and may be important in understanding how the binding differs 
between these Smad substrate types. As there is only a two-residue difference 
between the Smad 2 and 3 peptides, it was hypothesised that the binding site would 
be identical, and any differences between these interactions would be subtle. Without 
the assignments, it is difficult to conclude which amino acids in particular are being 
affected within the construct, however the potential appearance of arginine side chains 
suggests participation in hydrogen bonding with the peptide or possibly between 
domains. The majority of the peaks between the two titrations migrate in similar 
directions suggesting that it may be the cellular context that determines whether Smad 
2 or Smad 3 is targeted. However, this is only a hypothesis based upon comparison of 
amide peak positions between the two titrations, and further assignments and analysis 
should uncover the regions and specific residues involved in binding. Furthermore, 
titration analysis of WW2 only with Smad 2 and 3 peptides should also be carried out 
to determine conclusively whether this domain can interact with these substrates as 
well. Understanding the differences between these two R-smads is also important in 
revealing the mechanism of selection between these substrates, although further work 
looking into the timing, rate and cellular context in the regulation of these interactions 
is required.  
 
Interestingly, while research so far has suggested that WW1 and WW1-2 are 
responsible for R-smad binding and ubiquitination (Soond and Chantry, 2011a; Soond 
et al., 2013), work by Tiffany Yim (2017) suggested that WW3 may in fact be the 
predominant interaction site for Smad 2 while WW1 is primarily responsible for Smad 
3 binding. Overexpression of WW1-2 led to increased expression levels of Smad 3 
whereas higher expression levels of Smad 2 were detected when WW3-4 was 
overexpressed. It would be intriguing to determine if there is such a binding preference 
between these domains, as shown for WW4 (Wahl, 2016), however other techniques 
may need to be employed for this such as ITC or fluorescence polarisation. This 
knowledge could then potentially help direct design towards one particular substrate, 
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as it would provide data on the structure-activity relationship (SAR). Often without this 
experimental data, software to predict such affinities are employed for rational peptide 
design which rely on prediction from the construct sequence or use data relating to the 
bound structure (Farhadi and Hashermain, 2018). Again, the latter requires the 
structural solution hence work such as the WW4 solution in chapter 3, and further work 
into solving the other domains, supports using this method for progressing peptide 
design as well as furthering biological understanding via protein structure. Collectively, 
substrate selection by these WW domains appears to be much more complex than 
originally thought, and the binding properties and biological function of these WW 
domains requires further analysis. The idea that these domains may not be easy to 
mimic without fully understanding their roles in both the full-length protein or as shorter 
isoforms and constructs further supports the need for more research.  
 
Another perspective for inhibitor design other than target-based design discussed 
above is to inspect the other interaction partner – the Smad protein substrate – referred 
to as ligand-based peptide design approach. Using the information derived from such 
titrations, and structural data where possible, has shown only one side of the 
interaction. The smad proteins have a very clear PPxY motif required for interactions 
with WW domains, however most of the work in this thesis has looked at the 
protein-protein interactions from the WW domain perspective. While this is important in 
understanding the interaction, additional investigations using both unlabelled and 
isotopically labelled peptide would yield data regarding the specific residues within the 
substrate that contact the WW domain interaction partner, as well as reducing the 
number of potential residues needed to create a peptidomimetic. Unfortunately, efforts 
towards this were hindered by problems purifying Smad 2 and 3 peptides when 
recombinantly expressed thereby preventing such experimentation. However, Smad 7 
purification (Wahl, 2016) and Oct4 peptide purification (Danielle Bourcier, 2018, 
personal communication) has shown that this should be possible but requires further 
design and optimisation. If such problems could be overcome, then smad-based 
peptides could be bacterially expressed in isotopically labelled minimal media and 
purified for use in future NMR experiments such that both unbound and bound 
conformations of the peptide and/or the interaction partner can be determined. One 
downside to this method is the problem obtaining labelled peptides that are 
phosphorylated to reflect such states during pathway activation. This is due to bacteria 
lacking the post-translational machinery required to phosphorylate these proteins. 
Within mammalian cells, phosphorylated Smad 2 and 3 are present by activation and 
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auto-phosphorylation of the TGF-bI receptor by interaction with TGF-bII receptor plus 
ligand binding leading to the activation of the kinase domain (Huse et al., 2001; Xu et 
al., 2012). In addition, for Smad 7 the kinase is currently unknown. Thus, replicating 
this process in bacterial cells is not currently possible. The alternatives for generating 
labelled and modified peptides are costly though as either the peptides require 
chemical synthesis with the addition of the phosphate group carried out after 
production, which in itself has complications in the accuracy of attachment to the correct 
atoms. Alternatively, the phospho-peptides can be made from individually labelled 
amino acids with the phosphate group already attached to the relevant residue(s). 
Support for this ligand-based structural approach in contrast to the target-based 
approach is also seen by the design of peptides using as few as 5 amino acids to cover 
an area of ~ 1600 Å that are able to selectively inhibit protein-protein interactions 
(Sillerud and Larson, 2005). Once the difficulties in modified peptide generation are 
overcome, experiments similar to those carried out in the first two chapters of this thesis 
can be used to look at specific residues of the Smad-based peptides and their 
conformations when interacting with the different WW domains.  
 
NMR is a powerful tool for facilitating structure-based rational design of peptide 
inhibitors as discussed above. However, NMR can also be used in the screening of 
small molecule inhibitors using a SAR-based directive (Skinner and Laurence, 2008). 
Similar to the titration experiments carried out in chapter 4, small ligands can be added 
to a sample in increasing concentrations to determine binding and kinetics. This would 
require a large abundance of isotopically labelled protein to enable the screening of 
many compounds with regards to WWP2, which as yet has proved difficult to obtain for 
these WW domains. As such, another direction was employed for small molecule 
screening.  
 
6.3. Small-molecule based inhibitor discovery 
Biochemical assay analysis of the E3 ligase enzyme activity was used to measure 
inhibition for the discovery of novel compounds against WWP2 activity. Assay 
development showed that the truncated isoform WWP2-C could not be used in the 
plate-assay set-up used here due to no detectable activity, unlike the similar screening 
assay by Rossi et al. (2014) using truncated Itch. One possible explanation for this is 
that WWP2-C may require the presence of substrates or an adaptor protein to activate 
its catalytic activity. Research by Mund and Pelham (2009) showed that WWP2 and 
other Nedd4 E3 ligases had increased auto-ubiquitination levels in the presence of the 
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adaptor protein NDFIP2. The analysis of Itch WW domain presence showed that WW2 
had the most significant effect on NDFIP2-dependent auto-ubiquitination, suggesting 
that WW domain interaction with the PY motif is involved in the regulation of 
auto-ubiquitination. This is further supported by previous work with NDFIP1 where the 
presence of this adaptor protein relieved the WW domain/linker-mediated inhibition of 
Itch, WWP2 and Nedd4 activity (Riling et al., 2015). This supports the activation of 
Nedd4 E3 ligases upon interaction with these adaptors and provides a potential basis 
for the lack of WWP2-C activity detected in this assay. However, this does not eliminate 
the possibility of other mechanisms used within the cellular environment to activate 
WWP2 isoforms. Recent work has suggested that the activation of members of the 
Nedd4 family may also be regulated by membrane interaction and polymerisation of 
substrates (Mund and Pelham, 2018). The evidence showed that upon mutation of key 
residues required for polymerisation in Dishevelled (Dvl), a substrate of WWP2, 
ubiquitination activity was abolished however the addition of a membrane interacting 
sequence to Dvl rescued ubiquitination. This supports these two conditions playing a 
role in WWP2 regulation. Yet, this research only investigated the full-length WWP2 with 
Dvl substrate therefore the application of this as a hypothesis for other isoforms and 
substrates of WWP2 can only be speculated and would require investigation.  
 
The work by Chen and colleagues (2017) as mentioned previously which identified the 
WW2-3 linker as being a regulator of WWP2 activity contradicts the hypothesis that 
WWP2-C activation requires the presence of other proteins. Constructs used by Chen 
and colleagues included HECT only and WW3-WW4-HECT in which both presented 
with detectable auto-ubiquitination activity in western analysis, although the HECT only 
construct presented the highest degree of ubiquitination, potentially indicating 
constitutive activation. These initial experiments were carried out in solution in the 
absence of adaptor proteins or substrates rather than using GST-tag immobilisation of 
the E3 ligase. This comparison suggests that WWP2-C should not require the presence 
of an activator for auto-ubiquitination activity, and that the lack of activity in this assay 
may in fact be a result of the experimental set-up in which WWP2-C was immobilised 
to the plate. This therefore supports the hypothesis that WWP2-C may interact and 
dimerise with itself and/or other WWP2 isoforms to activate auto-ubiquitination. 
Interaction between isoforms has already been identified by Soond and Chantry 
(2011a) where WWP2-N showed interaction and activation of WWP2-FL. However, 
interaction combinations including WWP2-N: WWP2-N, WWP2-C: WWP2-C or 
WWP2-N: WWP2-C were not analysed in this work, thus it is currently unknown 
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whether other combinations of isoform dimerization exist. On the other hand, these 
investigations do not rule out the possibility that substrate presence may lead to 
increased activation of truncated isoforms, which was not tested in this research. 
Understanding more about the regulation of WWP2-C expression and activation in the 
cellular context to facilitate the use of these isoforms has however been difficult. 
Investigations into WWP2-C expression levels in Colo-357 cells by Soond and Chantry 
(2011a), and Tiffany Yim (Yim, 2017) in melanoma cell lines showed that WWP2-C 
expression levels were low or not detected when stimulated with TGF-b. However, 
Soond and Chantry showed that WWP2-C could be detected in ATDC5, a 
chondrogenic cell line derived from testis carcinoma which differentiates upon BMP 
signalling. Additionally, Tiffany Yim (Yim, 2017) also showed that expression of 
WWP2-C could be detected in few melanoma cell lines under BMP stimulation. This 
suggests that WWP2-C isoform activity on Smad 7, a common substrate in both 
pathways, may have a more significant effect in BMP signalling than TGF-b, however 
this requires investigation. Further experiments should include binding assays between 
WWP2 isoforms and the effect overexpression has on the activation and 
auto-ubiquitination of these isoforms to further understand the regulation of these 
proteins. This in turn may reveal information about the cellular contexts in which these 
proteins function to repress or stimulate oncogenesis, as well as facilitate the design of 
novel assays towards selective isoform inhibitor screening. 
 
In contrast to the lack of significant activity by WWP2-C, the use of the full-length 
WWP2 was successful in the screening assay. Use of the full-length protein has the 
advantage of allowing the identification of small-molecules that inhibit activity via the 
binding to any region of WWP2, unlike currently known inhibitors of Nedd4 E3 ligases 
which have shown HECT domain specific inhibition (Kathman et al., 2015; Mund et al., 
2014; Rossi et al., 2014; Quirit et al., 2017).  Full-length WWP2 inhibitor screening may 
facilitate the development of small-molecule inhibitors against other isoforms of WWP2, 
by WW domain or linker binding. Although, given that the HECT domain is the catalytic 
site for ubiquitination by WWP2, it is more likely that inhibitors discovered in this 
screening assay interact with the HECT domain. The inclusion of the auto-inhibitory 
linker between WW2 and WW3 of WWP2 (Chen et al., 2017) did not appear to have 
an effect on WWP2 auto-ubiquitination in these assays. This supports the idea that 
other aspects may be involved in the regulation of this region in inducing the 
auto-inhibitory conformation rather than the absence of substrate or adaptor proteins 
alone. While Nedd4 and WWP1 constructs used in this work for counter E3 ligase 
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screening showed auto-ubiquitination activity, interestingly when Smurf 2 was tested 
no auto-ubiquitination was detected (data not included). When taking into account 
auto-inhibitory conformations which have been reported for most Nedd4 family E3 
ligases, this suggests that Smurf 2 adopts this inactive conformation as a result of 
substrate/adaptor absence. Although, the addition of Smad 7 peptide containing the 
PPxY motif failed to induce activation (data not included) suggesting that the 
auto-inhibition could not be relieved by the presence of the isolated Smad 7 PPxY motif 
region. This implies that adaptors such as NDFIPs may be the necessary factor for the 
activation of Smurf 2, or perhaps membrane association via the C2 domain of Smurf 2 
is required. Although, the use of the full-length Smad 7 in breaking the C2-HECT 
interaction cannot be ruled out which has previously been shown to release this 
interaction (Wiesner et al., 2007). This opens up further questions as to the cellular 
conditions that trigger auto-inhibition over auto-ubiquitination and turnover for different 
members of the Nedd4 family and such knowledge would be useful for further research 
involving selective inhibitor discovery as well as peptidomimetics which could mimic the 
inhibitory regions and block HECT activity. 
 
Using WWP2-FL, plate-based screening of ~2100 compounds revealed 14 potential 
leads presenting IC50 values < 11 µM in dose-dependent analysis. This indicated good 
effectiveness at low concentrations, which is a desired property of drug leads as this is 
thought to result in a reduced number of undesired off-target effects. As these 
compounds have only been tested in in vitro auto-ubiquitination assays using purified 
proteins, it would be interesting to determine whether similar IC50 values would be 
obtained in a cell-based ubiquitination assay. This would have the advantage of 
investigating activity levels of WWP2 in the absence and presence of the compounds 
in the cellular environment. But this may also reveal any problems associated with 
cellular solubility. This aspect has not been tested specifically in this work but is an 
important property for compounds that hope to be successful therapeutics. The 
variation in the structures of the selected hits indicated no obvious characteristic 
important for the inhibition observed in the screening data. Similarity was only observed 
between 228155 and 228150 showing similar indole-based rings with an NO2 side 
group, and 288387 and 3064 with flavin-like structures. Collaboration with Serena 
Monaco and Sam Walpole (Watt et al., 2018; unpublished observations) using 
ligand-based NMR revealed that 6 of the compounds discovered from the Diversity set, 
and 2 natural products, directly bound to the WWP2 HECT domain. Only one of the 
remaining 6 was deemed a non-binder. The others could not be determined possibly 
 202 
due to solubility problems or from the binding of the ligand being too strong for 
detection. The non-binder was 228155, however this compound has previously been 
identified as a PAINS compound (Jasial, et al., 2017), therefore this compound is most 
likely a false-positive result and not worth progressing further. The binding of the similar 
compound 228150 could not be determined, but due to its similarity to 228155 including 
this compound in future work beyond this thesis should be considered carefully.  
 
As for the molecules that have been shown to interact with the HECT domain, further 
analysis has shown for a few examples that binding predominantly resides between 
the N- and C-lobes and has been hypothesised to block the flexible motions required 
for HECT domain function. With the use of STD epitope mapping and the recently 
developed DEEP-STD NMR by Monaco and colleagues (2017), Serena Monaco 
identified the residues within the HECT domain that contact the ligand as well as the 
atoms of the ligand that contact the protein.  Using computational docking of the ligand 
288387 to the WWP2-HECT domain, which was chosen based-on a medium binding 
affinity (IC50 ~2.3 µM), the modelling showed the phenyl ring of the compound resided 
deep inside the pocket between the two HECT lobes and makes contacts with 
hydrophobic leucine and proline residues (Watt et al., 2018). The end of the flavin-like 
ring group is more solvent-exposed with contacts to valine and arginine by the opening 
of the pocket. It would be interesting to determine whether the similar compound 3064 
makes the same or similar pattern on contacts that reflect binding between the lobes 
of the HECT domain as this has yet to be analysed. Using this approach for the other 
hits may be difficult though therefore for compounds unsuitable for NMR analysis, 
another method is required for binding site identification such as co-crystallisation as 
the unbound HECT domain has already been structurally solved. Despite some of the 
compounds may be potential PAINS and therefore should be used with caution, this is 
the first set of data for WWP2 inhibitors that shows low micromolar IC50 values, 
selectivity to the E3 ligases of the Nedd4 family, and has enabled the 3D mapping of 
the binding to the WWP2 HECT domain using a novel NMR approach. Binding analysis 
with other potential hits from this research may uncover further support for these 
compounds as potential inhibitors. Additionally, perhaps using other Nedd4 family 
HECT domains could reveal similarities and differences in binding that could be 
manipulated in further compound modification to increase the selectivity towards 
WWP2. Briefly mentioned in chapter 5, the differences in intramolecular interactions 
and sequences of the HECT domains may explain the different mechanisms revealed 
so far with other HECT domain inhibitors, and the variance in potency. Experimentation 
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to support the binding site between the lobes by either mutation of these key residues, 
or of other important sites within the HECT domain, for example the E2 binding site or 
the non-catalytic ubiquitin ‘exocite’ (Kamadurai et al., 2009; Kim et al., 2011; Maspero 
et al., 2011) would help conclude that this region between the lobes is the predominant 
interaction site. This binding site between the lobes of the HECT domain has been 
speculated for the anti-depressant clomipramine that has been identified as an inhibitor 
of ubiquitin thiolation for the Nedd4 E3 ligase Itch by Rossi et al. (2014). In contrast to 
this, the Pelham lab (Mund et al., 2014) published another HECT E3 ligase inhibitor 
called heclin that acted by oxidising the catalytic cysteine residue in the C-lobe although 
a lower degree of binding was detected to the hinge and N-lobe. This suggests that the 
binding sites for these compounds may be common between Nedd4 E3 ligases 
therefore modifications are required to increase selectivity. Interestingly, the difference 
between compounds I, II and III (heclin) (Mund et al., 2014) was a methyl/ethyl group 
attached to the furan ring that seemed to increase the potency, however the variation 
in effect between the ligases tested reduced upon modification. This highlights the 
difficulties faced when modifying side groups that may result in an improvement of 
certain qualities but also reduce others. Despite the analogues of clomipramine 
showing varying effects on Itch, the effect the modifications had on other Nedd4 E3 
ligases was not published therefore whether any of the modifications were able to 
increase potency and selectivity is unknown. One way to potentially increase specificity 
while maintaining or enhancing potency may be look into linking compounds that 
interact with different but nearby sites in the proteins with one providing higher 
selectivity and the other relaying the inhibitory effect or by linking E3 ligase selective 
inhibitory peptides to a compound for both potent inhibition and increased targeting of 
a particular ligase. This latter option has yet to be designed and tested however, but 
when taking into account he potential for inhibitory peptides generated based on Smad 
proteins as previously discussed, this may open up another area of research and 
potential drug design. Furthermore, knowledge of the mechanisms of action will also 
aid this directed design approach by providing information about whether the inhibitor 
is physically blocking, chemically changing the environment and/or acting upon another 
functional aspect of the protein.  
 
For these compounds to progress into potential leads for therapeutic applications, their 
activity on the ubiquitination pathway had to be tested. As discussed in chapter 1, three 
enzymes are involved in the canonical ubiquitination pathway. In order to analyse the 
specificity of the compounds discovered in the initial screening towards the final E3 
 204 
enzyme, counter assays using Uba1 (E1) and UbcH7 (E2) were carried out. 
Interestingly, as mentioned in chapter 5, no significant effect was observed in the E2 
assay, but all compounds presented an inhibitory effect on E1 activity in the plate assay 
format experiment. The counter assay results suggest that these compounds do not 
affect the overall function of E1 and E2 steps in the ubiquitination cascade via the E2 
assay results, however the partial inhibition observed in the E1 assay cannot be 
ignored. Further quantitative investigations into whether this is the result of the 
experimental conditions or if the compounds are having an inhibitory effect on E1 
activity is required. The second assay used to observe E1 ubiquitin charging in the 
absence and presence of compound provided a method of visualising whether E1~Ub 
complexes formed in the samples after incubation with the test compounds. The 
presence of this complex in all samples suggested that none of the compounds were 
capable of complete inhibition but does not rule out a reduction in E1 activity as 
quantification of this method of counter screening was not carried out. Therefore, the 
results of the plate assay may be true, but require further work to determine this. In 
support of the latter possibility however, work using the E1 inhibitor PYR-41 showed 
partial inhibition of HECT E3 ligase activity in vitro (Yang et al., 2007), suggesting that 
the plate assay results may reflect a similar partial inhibition mechanism as PYR-41, 
which blocks the E1 cysteine residue, between E1 and E3 enzymes. Furthermore, this 
may also suggest that these compounds have the potential to be modified such that 
they could become either E1 or E3 inhibitors. Further investigation into the binding sites 
and mechanism of action for the inhibitors screened here is required to determine 
whether this may be possible. Although, the direction of this work towards inhibitors 
against the E3 ligase WWP2 was of focus rather than E1 inhibitors. This is due to the 
increased selectivity of E3 ligases in targeting particular pathways, unlike E1 in which 
only 1 of 2 currently discovered in humans acts within the ubiquitination pathway.   
 
When considering substrate ubiquitination, WWP2 has been found to target tumour 
suppressor proteins such as Smad 2, 3 and 7 within both the TGF-b signalling pathway 
and PTEN, a negative regulator of PI3K/AKT signalling, as outlined in chapter 1. WWP2 
acts to ligate ubiquitin to the target lysine residues within these proteins in order for 
them to be recognised either for degradation or other cellular consequences (Chen et 
al., 2016; Soond and Chantry, 2011b). The small molecule screening utilised 
auto-ubiquitination as a readout, and while this is adequate for initial discovery, the 
compounds required testing to establish if they could also inhibit substrate 
ubiquitination by WWP2. Results showed that the 7 compounds presenting IC50 values 
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of 3 µM or lower all inhibited the ubiquitination of PTEN in vitro. This highlights that 
these compounds are functionally active against the activity of WWP2 towards this 
substrate. It is hypothesised that by inhibiting WWP2-mediated ubiquitination of PTEN 
using these hit compounds, this could result in the rescue of the PTEN steady state 
levels and in turn reduce AKT signalling by lowering the levels of phosphorylated AKT. 
These consequences are supported by work by Maddika et al. (2011) where WWP2 
knockdown by siRNA in DU145 cells resulted in increased PTEN levels, reduction in 
phospho-AKT and increased sensitivity to stress-induced cell death. In contrast, 
overexpression of WWP2 resulted in the opposite occurring and cells developed 
resistance to apoptosis. The stabilisation of PTEN levels has also been reported in 
WWP2 knockout mice tissues (Li et al., 2018). While the transcription levels of PTEN 
were not affected by WWP2 knockout, the evidence supports the role of WWP2 
inhibition on a protein level at reducing the cancer profile facilitated by WWP2-mediated 
PTEN degradation. Interestingly, WWP2 knockout/knockdown did not affect the 
localisation of PTEN in both reports further supporting the role of WWP2 as a regulator 
of PTEN turnover. As PTEN insufficiency is a mediator of prostate cancer development, 
and WWP2 is commonly overexpressed in prostate cancer, inhibition of WWP2 using 
compounds identified here as a basis for further inhibitor optimisation, makes WWP2 a 
very promising druggable target. However, it is important to note that these potential 
inhibitors should also be tested for ubiquitination inhibition of other substrates to further 
validate these compounds and rule out non-specific activity or false-positives.  
 
The overall aim of this work was to facilitate the development of novel inhibitors against 
WWP2 for potential use as an advanced or potentially earlier stage prostate cancer 
therapeutic. Current chemical treatment options, briefly mentioned in chapter 1, such 
as abiraterone, docetaxel and/or enzalutamide chemotherapy and hormone 
treatments, are limited to advanced cancer stages (Schweizer and Antonarakis, 2012), 
in which tumours either return, are no longer localised or are non-responsive to earlier 
therapies. This supports the requirement for further research and development of novel 
therapeutics. Initial experiments into the effect of the compounds with IC50 values 
below 3 µM was carried out in metastatic prostate cancer cell lines to establish whether 
these initial compounds had any effect on growth/migration. Preliminary findings 
showed that the presence of natural product 6 (401005) resulted in reduced 
growth/migration in both conditions in PC-3 cells but not DU145 cells. While compound 
7 (228155) had an effect in this study, the PAINS identity of this compound suggests 
this is most likely non-specific, but it is still interesting that there is an effect on the PCa 
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cells by this compound and perhaps modifications may be able to overcome the PAIN 
compound aspects. While both cells lines are not responsive to androgens, PC-3 cells 
are highly metastatic compared to the moderately metastatic DU145 cells (ATCC CRL-
1435TM; ATCC HTB-81TM). This suggests that natural product 6 may be showing more 
of an effect in more advanced prostate cancer. Other compounds seemed to present a 
TGF-b dependent effect in PC-3 cells. As to the cellular context of this result, no 
conclusions can be accurately drawn as this requires further experimentation. 
Furthermore, the ability for the compounds to penetrate the cellular membrane has not 
been tested, therefore the presence and concentration of the compounds within these 
cells is unknown. Further investigations into these compounds in cell-based 
experiments are necessary to further advance these molecules towards potential lead 
therapeutics.  
 
6.4. Future work 
• Obtain bound WW4 structures using isotopically labelled WW4 and labelled 
peptides to provide information relevant to understanding the interaction and 
enable interruption of the contacts. Docking studies could also be used to model 
peptide binding using the unbound refined structure. 
• Design WW domain-based peptides and test alongside natural WW domains in 
auto-ubiquitination assays as well as non-cancerous and cancer cell-based 
assays, including the use of luciferase reporter assays to determine effect on 
TGF-B mediated transcription and signalling. Further experiments to investigate 
the effect of the compounds on PI3K/AKT signalling should also be considered 
• Assign tandem domain HSQC peaks to determine residues important to 
interactions; collect Smad 2/3 titrations with WW2 to determine any differences 
between tandem WW1-2 and WW2 interactions and potentially reveal whether 
bound structures may be possible. 
• Continue analysis, modification and optimisation of current compound hits and 
begin testing ADME; determine cellular effects of compounds in non-cancerous 
and cancerous conditions. 
• Investigate the development of proteolysis-targeting chimera molecules 
(PROTACs) in which a WWP2 specific binding ligand is connected via a linker 
to another ligand either against another E3 ligase which is overexpressed in 
order to reduce the protein levels, or another oncogenic protein that is currently 
difficult to target using small molecule inhibition.  
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